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CHAPTER 1- GENERAL INTRODUCTION AND GENERAL HYPOTHESIS
Prostanoid Discovery and Biosynthesis
In 1935, the initial discovery of prostaglandins was made by Swedish physiologist
Ulf Von Euler [2]. Additionally, prostaglandins were independently described by Goldblatt
around the same time [3]. Prostanoids is the name given to a bioactive lipid subset of
eicosanoids that contains the prostaglandins and thromboxanes; prostaglandin (PG) E 2
(PGE2), prostaglandin D2 (PGD2), prostaglandin F2⍺ (PGF2⍺), prostacyclin (PGI2), and
thromboxane (TxA2) [4]. Prostaglandin production is based on the activity of prostaglandin
endoperoxide H synthases 1 and 2 (PGHS-1 and PGHS-2) also known as
cyclooxygenase 1 (COX-1) and 2 (COX-2) [5]. In general, prostaglandin production
occurs step-wise; membrane-bound phospholipids release the major prostanoid
precursor Arachidonic acid (20:4 ɷ-6) by the actions of an enzyme termed phospholipase
A2. Phospholipase A2 can be either secretory (sPLA2) or cytoplasmic (cPLA2) [6].
Arachidonate is then oxygenated by the prostaglandin synthases (COX-1 or COX-2)
yielding PGG2, an unstable intermediate that is quickly converted to PGH2. Lastly, this
intermediate is converted to the biologically active end prostanoid end products via tissue
specific synthases [4, 5].
Different cell types possess different downstream synthases producing the various
prostanoid products. Furthermore, some cells can express multiple isomerases at once.
It has been shown that COX-1 typically couples with thromboxane synthase and PGF2α
synthase. COX-2 is associated with prostacyclin synthase and microsomal PGE2
synthase-1 [7-9]. Thromboxane synthase is constitutively expressed in platelets and
causes platelet aggregation [10]. PGI2 classically antagonizes thromboxane and is largely
produced by cells of the vasculature and acts to reduce platelet aggregation [11]. In
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addition, PGD2 is synthesized in mast cells, basophils, and in T helper cells by the actions
of PGD synthases [12]. PGF2α is produced by the cells of the uterus in response to
oxytocin [13]. PGE2 is ubiquitously distributed throughout the mammalian body. Its
actions are the most diverse out of all the prostanoids with actions in the reproductive
system, vasculature, kidney, brain, and cardiovascular system.

Figure 1: Scheme Depicting the Biosynthesis Pathway of the Prostaglandins and
Thromboxane [14].
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The cyclooxygenase enzymes have been important in medical drug discovery.
COX-1 is constitutively expressed, while COX-2 is the inducible isozyme [4]. COX-1 and
COX-2 are very similar in regard to active site structure, products, kinetics, etc. However,
there are two major differences. First of all, the active site of COX-2 is larger which has
allowed for the production of drugs (selective COX-2 inhibitors; rofecoxib, valdecoxib,
celecoxib, etc.) that are selective for COX-2. Secondly, differences in allosteric regulation
allows COX-2 to compete more efficiently for newly released arachidonic acid [5].
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a class of drugs that reduce
inflammatory pain. NSAIDs such as ibuprofen or aspirin inhibit both COX-1 and COX-2
enzymes. In contrast to ibuprofen, aspirin irreversibly inhibits cyclooxygenase. It has been
shown that low dose aspirin preferentially and irreversibly inhibits thromboxane synthesis
in platelets while only having a minor inhibition of PGI2 production [15]. Platelets only
express the COX-1 isoform and constitutively produce thromboxane, thus promoting
platelet aggregation. Furthermore, platelets do not contain a nucleus and therefore cannot
synthesize new cyclooxygenase until there is platelet turnover after 8-12 days [16]. In the
vascular endothelium, prostacyclin is constitutively produced and counteracts the prothrombotic actions of thromboxane. In contrast to platelets, endothelial cells have nuclei
and normal rates of protein synthesis; therefore low-dose aspirin selectively inhibits
thromboxane synthesis as opposed to prostacyclin. In contrast to NSAIDs, selective
COX-2 inhibitors target the COX-2 isoform and therefore affect prostacyclin production
rather than thromboxane synthesis [17]. NSAIDs have been used for decades to treat
pain and inflammation. In addition to treatment of pain, daily low dose aspirin has become
a popular regiment for reducing cardiovascular events. There are side effects, however,
to chronic NSAID use. By inhibiting prostaglandin synthesis, NSAIDs have
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gastrointestinal, cardiovascular, and renal side effects [18]. In the kidneys, adverse
effects of NSAID use include reductions in sodium excretion, potassium excretion, and
renal perfusion [19, 20]. Among the cardiovascular side effects, increased risk for MI has
been studied in depth. The reduction in prostacyclin synthesis as a result of selective
COX-2 inhibition has been linked to increased myocardial infarction by tipping the balance
of prostacyclin/thromboxane in favor of pro-thrombotic thromboxane production [21, 22].

Figure 2: Scheme Depicting the Action of NSAIDs vs. Selective COX-2 Inhibitors [17]
Prostanoid Function
Prostanoids play an important role in sustaining homeostatic function, like blood
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pressure, while also mediating pathogenic mechanisms (i.e. inflammatory response). For
example, TXA2 is a potent vasoconstrictor and causes platelet aggregation, while PGI 2
has important vasodilator effects and promotes sodium excretion by the kidneys [23].
Furthermore, the ability of prostanoids to exert both pro-and-anti- inflammatory effects
relies upon which receptor is activated and which cell type it is activated in.

The

prostanoid receptor family consists of eight G-protein coupled receptors (GPCRs); the
PGD receptor (DP), the PGF2α receptor (FP), the PGI receptor (IP), the thromboxane
receptor (TP), and the four known subtypes of the PGE receptor (EP1, EP2, EP3, and
EP4) [24]. The IP, DP, EP2 and EP4 receptors all signal through G s to stimulate cAMP
production in the cell (relaxant response). On the other hand, TP, FP, and EP1 induce a
calcium increase in the cell (contractile response). The EP3 receptor signals through G i
to reduce cAMP levels (inhibitory), however, the function and signaling of these receptors
can change depending on ligand concentration as well as alternative splicing of certain
receptors. For the purpose of this dissertation, only the role of PGE2 will be discussed as
this is the most relevant prostanoid to the project.
The four signs of acute inflammation rubor (red), calor (heat), tumor (swelling), and
dolor (pain) are characteristics of an inflammatory response. COX-2 derived PGE2 is
known to play a major role in inflammation. COX-2 has been shown in numerous studies
to be increased in the site of inflammation [25]. It has also been shown in rodent models
of inflammation, such as lambda carrageenan injection, COX-2 levels were increased
substantially in the spinal cord [26-30], while the levels of COX-1 remained relatively
unchanged [26]. In fact, inhibition of COX-2 is the mechanism by which non-steroidal
anti-inflammatory drugs reduce PGE2 and the above symptoms of inflammation. Early in
inflammation, the vasodilation and increased vascular permeability are thought to be
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attributed to COX-2 mediated PGE2 [31]. At the site of inflammation, PGE2 via its EP2 and
EP4 receptors has been shown to increase local vasodilation and subsequent vascular
permeability [32-35]. In contrast, PGE2 acting via its EP3 receptor suppresses vascular
leakage [35]. PGE2 has also been implicated in promoting the pain associated with
inflammation and it was reported that mice lacking mPGES-1

-/-

had reduced pain and

inflammation in a mouse model of collagen induced arthritis [36, 37].
Angiotensin II
Angiotensin II (Ang II) is a vasoconstrictor peptide produced from the renin
angiotensin system (Figure 3). In the classical renin-angiotensin system pathway, renin

Figure 3: Scheme Depicting the Classical Renin-angiotensin System and Production of
Angiotensin II. Angiotensin II can be further metabolized to Angiotensin III, Angiotensin
IV, and Ang II (1-7) [1]. ACE-Angiotensin converting enzyme, NEP- Neutral
endopeptidase.
produced from the kidney juxtaglomerular cells cleaves angiotensinogen (liver derived)
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into angiotensin I. This is then converted by angiotensin-converting enzyme (ACE) in the
lungs to form the active Ang II peptide [38-40]. Ang II is further processed by
aminopeptidases to form Ang III, Ang IV, and Ang (1-7) [1]. Ang III promotes similar
physiological responses as Ang II [41]. Ang IV is produced from cleavage of Ang III and
has effects on blood flow, learning, and neuronal development [42]. Ang (1-7) is formed
via the actions of the enzyme ACE2 on Ang II and is shown to be antagonistic to the
actions of Ang II via its AT1 receptor [43, 44].

Figure 4: Scheme Depicting the Physiological Actions of Angiotensin II.
In addition to the classical renin-angiotensin pathway, local generation of Ang II
has been well documented [45-47]. Aside from vasoconstriction and blood pressure
regulation, Ang II also plays an important role in myocardial remodeling after MI and in
vascular remodeling during chronic hypertension [1, 48-56]. Ang II mediates its effects
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through two plasma membrane receptors AT1 and AT2. The AT1 receptor is a G proteincoupled receptor that signals through Gq to activate phospholipase C [57, 58]. Literature
suggests that most of the functions mediated by Ang II appear to be through the AT 1
receptor, especially in the vasculature [59]. AT1 is expressed abundantly in the smooth
muscle cells, with much lower levels in the adventitia and is virtually undetectable in the
media [60, 61]. The AT2 receptor is also a G protein-coupled receptor, although the exact
signaling mechanism is still unknown. It is thought however, to antagonize the actions of
AT1. The AT2 receptor is expressed at high levels in fetal tissue and then decreases after
birth. Also, AT2 expression in adults is detectable in the pancreas, kidney, adrenals, brain,
vasculature (adventitia and media only), and the heart [62, 63]. The expression of both
receptor subtypes can change with injury. For example, hypertension has been shown to
cause overexpression of AT1 in the kidney and brain, while overexpression of AT 2 has
been shown in the mesenteric arteries and endothelium [64].
Chemokines and Cytokines in Cardiac Repair and Remodeling
One significant end point of chronic inflammation, chronic hypertension, or
myocardial infarction (MI), is myocardial repair. After myocardial injury, chemokines such
as CCL2 and cytokines including IL-6 and TNF-⍺ are released and regulate myocyte
survival by recruiting inflammatory cells (i.e., neutrophils and macrophages) to the site of
injury to clear up debris and dead cells [65-67]. Chemokines are small 8-12 kDa proteins
that activate and mediate the immune cell responses during an inflammatory event. There
are four classes of chemokines, C, CC, CXC, and CX3C. They are so named for the
location of the first two cysteines. For example, in the CC family the two cysteines are
adjacent, while in the CXC family, they are separated by any amino acid. Both the CC
and CXC chemokines are significantly increased in the infarcted heart [65]. In general,
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Figure 5: Scheme Depicting the Four Families of Chemokines, their Receptors, and the
Cell Type that they Recruit [74].
the chemokines bind their respective receptors on the surface of the leukocytes. The
chemokine contact with its receptor induces integrin activation and promotes a closer
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interaction between the rolling leukocyte and the endothelium wall. This leads to
infiltration of the leukocyte into the inflamed tissue [68, 69]. CCL2, or monocyte
chemoattractant protein (MCP)-1, is rapidly increased in the infarcted heart and mediates
monocyte recruitment to clear the myocardium of debris from apoptotic/necrotic cells [70].
Additionally, activated by the CC family of chemokines, CCR1, CCR2, and CCR5
receptors have been shown to be most important for leukocyte recruitment during an
inflammatory cascade [71]. One particular chemokine, CCL12 (MCP-5), is the mouse
analogue to human MCP-1. MCP-5 is a potent chemoattractant for monocytes via the
CCR2 receptor subtype. Additionally, MCP-5 was shown to be produced by activated
macrophages [72]. Thus MCP-5 is important in inflammatory processes such as cardiac
remodeling and a previous study from our laboratory showed that MCP-5 was
upregulated in the hearts of adult EP4 KO mice that are in heart failure [73].
Expression of pro-inflammatory cytokines IL-6, TNF-α, and IL-1β is increased in
MI [75, 76]. Evidence suggests that initially, cytokine gene expression is increased by
myocardial cells in response to the ischemic insult. By 24 hours, cytokine gene expression
was shown to return to normal baseline levels. However, by 7 days there was a second
wave of cytokine expression, largely produced by infiltrating macrophages [76]. These
cytokines are not typically expressed in the normal heart and only released during an
innate stress response [77]. This biphasic response in ischemic conditions is typically
regulated by the size of the infarct. For example, if the infarct is small, cytokines can be
upregulated in the infarct zone up to 50-fold but will quickly return to baseline levels [78,
79]. If the infarct is large, however, this cytokine upregulation can be prolonged and
promote a second wave of remodeling (the chronic phase) extending into the remote zone
and eventually, the entire myocardium [79, 80]. The release of cytokines during injury is
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actually favorable, leading to cardiac healing and improved cardiac function. However,
persistent inflammation can lead to heart failure through chronic remodeling [81]. Acutely,
the increase in cytokines has 4 major effects on cardiomyocytes that contribute to cardiac
remodeling; myocyte apoptosis [82, 83], hypertrophy [84], reduced contractility [85], and
inflammatory signaling [67]. Chronically, cytokines such as TNF-a, IL-1β, and IL-6, have
effects on integrins, vasculature, and the extracellular matrix [79, 86]. Mechanistically,
myocardial stress is potentially sensed by mechanosensors (integrins, sarcolemmal
proteins, and cytoskeleton) and leads to activation of MAPK, STAT, and calcineurindependent signaling. These pathways ultimately lead to downstream activation of proinflammatory transcription factors such as NF-κB and AP-1 [87].
Cardiac Inflammation and Remodeling
Myocardial Infarction
The pathological process of heart failure following myocardial infarction consists
of a cardiac remodeling process. The adult heart has essentially no capacity to regenerate
its tissue and therefore the process of remodeling the infarcted myocardium consists of
an inflammatory response and repair of the heart via collagen deposition and formation
of a scar [67, 88]. The normal heart contains a small population of immune cells, although
the majority of resident immune cells have been shown to be macrophages [89-91]. This
small population expands in the event of an infarct to start the repair process. The
reparative response following an ischemic event is typically divided into three phases: the
inflammatory phase, the proliferative phase, and the resolution/maturation phase [92].
During the inflammatory phase, ischemic cardiomyocytes release danger signals
(DAMPs) that activate the Toll-Like receptor signaling in various cell types present in the
heart (macrophages, cardiomyocytes, vascular cells, fibroblasts, infiltrating leukocytes,
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etc.) [93]. Some examples of DAMPs include extracellular RNA [94], mitochondrial DNA
[95, 96], Hyaluronan [97-99], HSP60 [100, 101], and IL-1β [102]. The signaling induced
by these DAMPs promotes production of chemokines and cytokines and the subsequent
recruitment of neutrophils (early), monocytes, and lymphocytes into the infarcted
myocardium. The activated phagocytes clear the infarcted region of dead cells and debris.
This clearance of debris is a transitionary event and is the beginning of the proliferative
phase [88].

Figure 6: Scheme of the Monocyte Response in the Post-MI Mouse Heart. PMN:
neutrophil, MΦ: macrophage, ECM: extracellular matrix [116].
During the proliferative phase, there is substantial expansion and activation of the
cardiac fibroblasts and induction of angiogenesis [103, 104]. Fibroblasts within the infarct
zone acquire an activated phenotype (myofibroblast) and are responsible for production
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of extracellular matrix proteins and collagen within the infarct [105]. Fibroblasts are suited
for this role because they are less susceptible to ischemic injury, are widely distributed
throughout the heart, and have a close anatomical relationship with the myocytes [106].
The potential of the fibroblasts to initiate an inflammatory response has also been well
documented [107-109]. Unfortunately, the role of cardiac fibroblasts as inflammatory cells
is still not fully understood for multiple reasons. First, there are other cell types in the heart
like endothelial cells and resident cardiac mast cells, both of which have been implicated
in triggering inflammation post-MI [110, 111]. Secondly, there are no commercially
available markers for cardiac fibroblasts that are reliable so investigating the fibroblastspecific inflammatory response has been challenging [112]. However, data from our lab
suggests that in response to stimuli such as Lipopolysaccharide (LPS), isolated adult
mouse cardiac fibroblasts produce a substantial amount of chemokines, including MCP5.
Lastly, during the maturation phase, the newly synthesized extracellular matrix
undergoes cross-linking and the collagen scar is reinforced. Without reinforcement of the
scar, cardiac rupture can occur, although incidence in humans is low. Furthermore, the
proliferation of the fibroblasts is inhibited to prevent further extracellular matrix deposition
[113]. The cellular effectors important in the maturation of the scar are still unknown,
however macrophages have been implicated in this process [88]. A normal, properly
healed infarct contains extracellular matrix that matrix that can make up to 80% of the
infarct area [114], presumably with little fibrosis in the remote area of the heart. Thickness
of the scar has been correlated with improved LV function [115].
If the collagen deposition process becomes dysregulated, deposition can also
occur in the interstitium promoting ventricular stiffness and cardiac dysfunction. Over time
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this interstitial fibrosis leads to adverse remodeling of the ventricle and reduction of
function [117]. Further contributing to fibrosis is the local production of Angiotensin II
(discussed in greater detail in later sections). Ang II is produced in the heart by activated
macrophages, cardiomyocytes, and the myofibroblasts and stimulates production of TGFβ1, and subsequently increased production of collagen by the myofibroblasts [118]. The
persistent expression of Ang II, its AT1 receptor (discussed later), and TGF-β1 have all
been observed months following MI in rodents [118].
Excessive extracellular matrix turnover contributes to high morbidity and mortality
in human patients [119]. This is in part due to the activity of matrix metalloproteinase
enzymes (MMPs). There are 25 known MMPs, of which about half have been measured
in the left ventricle post MI [120]. After MI, MMPs degrade the extracellular matrix and
promote further recruitment of immune cells to phagocytize dead cells/debris. Long term
stimulation of MMPs results in activation of the tissue inhibitor of metalloproteinases
(TIMPs). This leads to long-term remodeling by reducing the MMP/TIMP ratio [121, 122].
The use of MMP inhibitors post MI is still being investigated [123]. However, several
current therapies for MI and heart failure act as indirect inhibitors for MMPs (ACE
inhibitors, Angiotensin receptor blockers (ARBs), beta-blockers) [119]. The indirect
inhibition of MMPs by ACE inhibitors has been well documented and shown to improve
cardiac outcomes post MI in human patients [124]. In addition, there is strong evidence
for the use of ARBs post MI [125]. Rats that were treated with an ARB, losartan, had
reduced expression of MMP-8, -13, TIMP-1, -2, and collagen in the heart post MI [125].
Moreover, deletion of the AT1 receptor in mice reduced LV remodeling and improved
survival of rats after MI [126].
A major complication of adverse cardiac remodeling is the development of heart

15
failure [127]. Infarct size is a major predictor of future heart failure [128]. Furthermore, the
combination of the loss of ventricular muscle with the adverse cardiac remodeling that
occurs during and after MI contributes to the development of heart failure. In addition,
there are several geometric changes that occur in the heart that can lead to systolic and
diastolic function such as ventricular wall thinning, chamber dilatation, and expansion of
the infarct [129, 130]. At first, left ventricular enlargement is a compensatory mechanism
in response to loss of ventricular muscle, to maintain stroke volume. However, this is a
balance between chamber dilatation and increased heart volume. Over time, this can lead
to further cardiac dysfunction and failure.
Chronic Hypertension
Chronic hypertension is the single most significant risk factor for developing heart
failure globally [131]. A major consequence of chronic hypertension is the development
of left ventricular hypertrophy (LVH) [132]. One of the major differences between
hypertensive heart disease and other forms of heart failure is in the way the LV remodels.
Hypertensive heart disease is a chronic disorder thus patients with hypertensive heart
disease frequently present with LVH, but preserved systolic function, depending upon the
stage of the disease. Patients with heart failure caused by ischemia, however, present
with dilated LV chambers and frequently right ventricle enlargement as well, along with
systolic dysfunction [133-135]. Hypertrophy of the left ventricle in the presence of
hypertension is a powerful predictor of negative cardiovascular outcomes such as
coronary heart disease, stroke, sudden cardiac death, and heart failure [136-140]. LVH
is an adaptation to the increased workload in the heart in order to normalize wall tension
and preserve cardiac function. However, persistent LVH leads to cardiac dysfunction in
the form of ischemia, arrhythmias, heart failure, and/or sudden death [141]. In humans,
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the occurrence of LVH is directly associated with the level of systolic blood pressure [142146]. Blood pressure itself is not the only contributing factor in the development of LVH
[147]. Other factors include sex, age, race, and body mass index (BMI). For example, the
left ventricle mass of hypertensive women was reportedly higher than that of hypertensive
men (57 % vs. 31 %, respectively) [136]. The frequency of LVH also increases with age
and this effect is greater in women compared to men. African Americans have a 2-3 fold
higher risk of LVH than whites with the same elevation of systolic blood pressure [148].
Obesity is also a major risk factor for LVH. It was reported that a 2 Kg/m 2 increase in BMI
correlated with a 50 % risk of increased left ventricle mass in elderly men and women
[149].
Mechanical stress inducing myocyte hypertrophy is one component contributing to
LVH. However, hypertrophy of the myocytes without fibrosis does not appear to have
negative implications. Samples taken from patients with LVH and hypertensive heart
disease have increased collagen and fibrosis compared to normal hearts [150]. The profibrotic process is controlled by a variety of hormones and cytokines such as Ang II,
aldosterone, TGF-β. In contrast, breakdown of collagen is regulated by substances such
as bradykinin, nitric oxide, and glucocorticoids [151]. Fibrosis in hypertensive heart
disease is typically more widespread than in other causes of heart failure. It is found in
the anterior, posterior, lateral walls of the left ventricle, interventricular septum, and right
ventricle [135]. Changes in the collagen content in the hypertensive heart can impair
systolic and diastolic function [152]. Normal collagen turnover by the fibroblasts is slow
(80-120 days) [153]. In pathological conditions, the collagen turnover is determined by
myofibroblasts and regulated by autocrine and paracrine factors. Animal models have
provided insight into three potential mechanisms for the transition from LVH to heart
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failure by degradation of the collagen network [152]. The first mechanism involves an
interrupted collagen network, resulting in loss of support, geometric alignment, and
coordination of cardiomyocyte contraction. The second mechanism involves loss of
interaction between laminin and collagen with their receptors. The third mechanism
involves loss of the number of muscular layers in the ventricular wall and LV dilation [135].
The MMPs and TIMPs also play a role in hypertensive heart disease, although the
role of these molecules is not fully elucidated. In hypertensive Dahl salt-sensitive rats,
MMP2, TIMP1, and TIMP2 expression increased in parallel with LVH [154]. Likewise, in
spontaneously hypertensive rats, MMP2 activity is increased [155]. In patients with
hypertension and LVH, there are increased TIMP1 levels, but reduced MMP1 and
collagen type I telopeptide (a breakdown product of collagen) [156]. Patients with
hypertension and LVH were also shown to have reduced levels of MMP2 and MMP13,
but increased levels of MMP9 [157].
Cytokines are suggested to play a major role in the pathogenesis of hypertension.
For example, TGF-β was suggested to play a role in hypertensive disease by regulating
cell growth/differentiation and extracellular matrix/repair [158, 159]. Furthermore,
polymorphisms within the TGF-β1 gene have been associated with increased risk of
hypertension [160]. The role of inflammation in hypertensive end organ damage has
become evident in the past several years. There is little data on immune cell infiltration in
human organs but this has been investigated in several animal models. For example,
mice lacking RAG1 lack all lymphocytes and had a blunted hypertensive response to Ang
II, deoxycorticosterone acetate (DOCA)-salt, and norepinephrine challenges [161-163].
Likewise, deletion of this gene in Dahl salt-sensitive rats attenuates their hypertensive
response after salt feeding [164] .
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Polarization of Macrophages in Cardiac Inflammation and Remodeling
Macrophages exist in all tissues of the body, even in steady-state conditions [165].
These tissue resident macrophages contribute to homeostatic functions by removing
dead or senescent cells and preventing infection [166]. Interestingly, macrophages can
have tissue-specific functions. For example, macrophages in adipose tissue can produce
catecholamines to maintain thermogenesis and promote insulin resistance [167]. Also,
peritoneal macrophages promote migration of B cells to the intestines, thereby
orchestrating their early response to pathogens and production of antibodies [168]. After
an injury or during inflammation, circulating monocytes are recruited to the site of
inflammation where they differentiate into macrophages. Furthermore, during the
inflammatory phase of cardiac remodeling, the majority of the macrophages present are
derived from these circulating monocytes [169].
The macrophages play a key role in response to MI [170, 171]. After MI, circulating
monocytes infiltrate the infarct and border regions and differentiate into macrophages
[116]. Within 7 days of MI, these cells have become the majority of the macrophages in
the infarct [172]. Macrophages can phagocytize dead/dying cells, secrete proinflammatory or anti-inflammatory factors, and can interact with other cell types to assist
in the reparative response [173, 174]. The ability of macrophages to have such diverse
functions could be attributed to the different phenotypes and their polarization status.
Macrophages can express different genes and possess different functions in response to
environmental signals. Early after MI, macrophages have a proinflammatory M1
phenotype, while displaying an anti-inflammatory M2 phenotype in the later phase [175,
176].
Cardiac macrophages have been shown to be of the M2 phenotype in steady-state

19
conditions [169, 177]. Various markers for identification of monocytes and macrophages
currently exist, such as CD68, CCR2, CD11b, CD163, F4/80, and MHCII [166, 178-186].
Additionally, the Ly6C/Gr-1 marker is used extensively and is unique to rodent models as
it is not expressed in human macrophages. Cardiac macrophages have been shown to
be heterogeneous in their origins and four populations have been identified in the mouse
heart [187].
One population, Ly6C-CCR2-, comprises the vast majority of cardiac macrophages
and are derived from the yolk sac. This population contains both MHCIIhigh and MHCIIlow
subsets and is further subdivided into the second population based on Ly6C -CCR2+
(second population). The third population Ly6C+CCR2- and the fourth population
Ly6C+CCR2+, originate from hematopoiesis [179, 187, 188]. The roles for these different
macrophage populations within the heart are not fully understood. It has been shown that
MHCIIhigh macrophages present antigens to T cells more efficiently, while the MHCII low
macrophages have more phagocytic capabilities [179]. Within the circulating pool of
monocytes in mice, there are 2 subsets of Ly6C expression. Ly6Chi are proinflammatory
and express high amounts of CCR2. In contrast, the second subset, Ly6Clow, express low
levels of CCR2 [175].
Macrophages demonstrate high adaptability and heterogeneity, making an exact
classification of their phenotype difficult. However, early after MI (days 1-3), the M1
macrophage phenotype dominates, whereas the predominant macrophage phenotype at
days 5-7 is the M2 [189]. In the heart, the pro-inflammatory M1 macrophages secrete
chemokines, cytokines, and other growth factors to cause phagocytosis of debris and
extracellular matrix [176]. In contrast, the M2 macrophages are reparative and produce
anti-inflammatory factors such as IL-10, and TGF-β1 [176]. The transition from the M1 to
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M2 phenotype post MI has been shown to be crucial in promoting repair following MI in
mice [190-193]. Furthermore it was shown in rodents that MMP-28, IL-10, and deletion of
MMP-9 affect cardiac remodeling post MI by shifting the M1/M2 balance to the M2
phenotype [194-196].
The M1 and M2 macrophage phenotypes were originally based on data showing
that treatment of macrophages with lipopolysaccharide and IFN-γ causes macrophages
to produce pro-inflammatory molecules, such as IL-1β, IL-6, and TNF-α and was named
M1. On the other hand, IL-4 promotes macrophage production of anti-inflammatory
molecules, such as Arginase1, Fizz1, and Ym1 and was named M2 [194]. Unfortunately,
in vivo, there is complex diversity in the macrophage population and trying to define
macrophages as M1/M2 based on only one or a few markers is difficult. Additionally, the
mechanism of macrophage polarization remains poorly understood. One hypothesis,
presented by Nahrendof et al. states that early recruitment of Ly6Chigh cells relies on
CCR2 signaling and that these cells can differentiate into Ly6C low during the reparative
phase [197]. In contrast, they show that later Ly6Clow recruitment depends on CX3CR1.
Furthermore, the same authors showed that the Ly6Chigh cells were proinflammatory and
phagocytic, while the Ly6Clow cells were anti-inflammatory and pro-reparative. This
hypothesis agrees with others [189, 198, 199], although it fails to recognize the role of the
local infarct environment on macrophage polarization. Further studies are necessary to
identify distinct pathways that are involved in coordinating macrophage polarization.
PGE2 has been shown to play a role in macrophage polarization by inducing the
M2 phenotype through up-regulation of the CREB pathway. Furthermore, PGE2
attenuates pro-inflammatory M1 macrophage gene expression by inducing IL-10
expression via cAMP-PKA-CREB signaling [200-202]. The EP receptor responsible for
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these effects was not examined in the aforementioned studies; however, one can
presume it is via the EP2/EP4 receptor axis due to increases in cAMP-PKA signaling.
The Role of T Cells in Cardiac Inflammation and Remodeling
T Cells in Myocardial Infarction
Several studies have implicated T cells in the cardiac remodeling process following
MI, however their role is not fully understood and is controversial [203]. One major
question in the field is whether or not the T cells are responding to tissue specific damage
signals or systemic auto-antigens [204]. In contrast to the rapid response by cells of the
innate immunity (i.e., monocytes/macrophages), cells of the adaptive immune response
(e.g., T cells) respond much more slowly in response to injury. In general, T cells reside
in the lymph node until stimulated [205]. Differentiated T cells leave the lymph node and
migrate to inflammatory sites where they employ their unique functions. At steady state,
there are less than 10,000 lymphocytes per milligram of tissue in the heart. After MI, the
levels increase 5-10 fold due to an influx of recruited cells, peaking around day 7 [189].
One subset of T cell, CD4+, are further classified into Th1, Th2, Th17, and Treg. Tregs
are unique specialized cells that act to suppress inflammation [206, 207]. After MI, CD4+
cells in the infarcted area are mainly Th1 cells and produce mainly IFN-γ [189]. It has also
been shown that T cells regulate the infiltration of proinflammatory monocytes. The
absence of CD4+ T cells resulted in an increase in Ly6Chigh monocytes and subsequently
increased collagen deposition and impaired cardiac remodeling by reducing capillary
density 7 days post MI [208]. This mechanism still remains to be elucidated. Furthermore,
depletion of CD4+ cells resulted in a predominantly M1 phenotype in myocardial
macrophages suggesting cross talk or interactions between the two cell populations [193].

22
T Cells in Chronic Hypertension
In recent years there have been numerous studies examining the contribution of
inflammation and immunity to the development of hypertension. One study by Itani et al.
employed a unique bone/liver/thymus humanized mouse to address the role of T cell
activation in hypertension. Two weeks of Ang II infusion resulted in an increase in T cell
(CD4+ and CD8+) infiltration in the kidneys, aorta, and lymph nodes. When blood pressure
was normalized with diuretics (hydralazine and hydrochlorothiazide) the infiltration of T
cells in the various tissues was abrogated, suggesting that Ang II does not directly activate
T cells. The authors confirmed this by treating cultured T cells with Ang II and analyzing
a panel of cytokines [209]. Other studies have suggested that T cells can increase
reactive oxygen species as a result of their natural host defense activity, thereby
promoting hypertension in response to hypertensive stimuli, such as Ang II [161, 210,
211].
To date, the effects on blood pressure and end organ damage via T cell activation
remains to be elucidated. It is complicated by the fact that different T cell populations, T
cell localization, activity of other immune cells, and the model used are all important
variables in the T cell response observed.
Prostaglandin E2 and Its Signaling
PGE2 is produced from PGH2 by the tissue specific synthases cPGES-1 (cytosolic
form), mPGES-1 and mPGES-2 (microsomal forms). PGE2 is one of the most abundant
prostaglandins produced in the body and exerts a variety of biological effects.
Additionally, PGE2 is the most abundant PG produced in left ventricle myocytes [212].
Prostaglandin E2 plays an important role in the cardiovascular system such as regulating
vascular tone [213-215] and cardiac remodeling [73, 212, 216-219].
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PGE2 has four known receptor subtypes, EP1-EP4. EP1 couples to Gq [220, 221]
and increases intracellular Ca2+ via activation of PLC and has many functions throughout
the body, depending on where it is expressed. The highest expression of EP1 is recorded
in the collecting duct of the kidneys [222]. The literature also describes expression of EP1
in the glomerulus, podocytes, and in the proximal tubules [223-226]. Furthermore, EP1
knockout mice have a reduced pressor response to angiotensin II infusion [227]. EP1 in
the heart has been shown to increase the beating rate of neonatal rat cardiomyocytes
[228] and in neonatal ventricular fibroblasts, activation of EP1 and/or EP3 in this cell type
promotes fibroblast cell growth and proliferation, perhaps implicating this mechanism in
increased cardiac fibrosis [229]. In general, research around the EP1 receptor has mostly
focused on cancer, pain, inflammation, and stress responses [230].

Figure 7: Scheme Depicting PGE2 Biosynthesis, its Four Receptor Subtypes, and their
Signaling Pathways [231].

24
The EP2 and EP4 receptors both couple to Gαs, however EP4 has been shown to
have additional signaling through the ERK and PI3K pathways. This has been implicated
in cancer and inflammatory disorders [232]. Both receptors stimulate adenylate cyclase,
increase cAMP production, and activate PKA. PKA activation has been shown to
phosphorylate CREB and increase the activity of Tcf/lef-induced genes. EP2 and EP4
have various roles depending on where they are expressed although both typically induce
smooth muscle relaxation [233]. The EP4 receptor has been heavily studied in the context
of cancer research, but also has been shown to have cardioprotective effects in in vitro
and in vivo models [234]. EP2 knockout mice have been shown to have an attenuated
cardiac function after myocardial infarction, suggesting a protective role of this receptor
in the heart.
In contrast to EP2/EP4 signaling, the EP3 receptor signals through Gi, to inhibit
adenylate cyclase production. In the mouse, EP3 has 3 isoforms due to alternative
splicing of the c-terminal tail [235]. It has been reported that these splice variants have
differences in function, differences in signaling, different sensitivities to agonists, different
trafficking patterns, and different internalization patterns [236-238]. Some EP3 isoforms
can activate RhoA through Gα12 signaling [239]. Like the other receptor subtypes, EP3
has various functions throughout the body. In adult mouse cardiomyocytes and in a
working Langendorff preparation, EP3 receptor activation was shown to directly reduce
cardiac contractility, presumably via reductions in phosphorylated phospholamban [217].
The Role of Prostaglandin E2 in Blood Pressure Regulation and Hypertension
In general, PGE2 is a potent vasodilator, natriuretic [240], and diuretic. The
vasodilatory effects of PGE2 been demonstrated in several different tissues including
hamster uterus, rabbit ductus arteriosus, human pulmonary vein, rabbit ear artery, and
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rabbit saphenous vein [241-247]. Furthermore, a vasodilatory role for PGE2 has been also
been observed in resistance vessels; pig pial arterioles [248] and in canine renal
juxtamedullary arterioles [249]. In contrast, vasoconstrictor actions of PGE2 have been
reported; in rings of human internal mammary arteries (via EP3 receptor) [250] and rat
mesenteric arteries [251]. These different effects of PGE2 are most likely to the different
receptors that are being activated in that tissue bed. Consistent with vasoconstriction,
activation of the EP1 receptor is coupled with increases in intracellular calcium. In
spontaneously hypertensive rats, EP1 antagonism reduced blood pressure as well as
attenuated the pressor response of Sulprostone, an EP1/EP3 agonist [227]. It was shown
in normal Sprague Dawley rats that the aorta and mesenteric arteries express EP3 and
an EP3 agonist enhanced contraction of these vessels [215]. Another component of the
variable response to PGE2 is the genetic background of the rodent model being used. For
example, studies using mPGES1 knockout (mPGES-1

-/-)

mice on a mixed genetic

background had an accelerated hypertensive response to Ang II [252], whereas mice on
a pure C57Bl/6 background achieved similar levels of systolic blood pressure after 8
weeks of Ang II infusion [218].
The Role of Prostaglandin E2 in Inflammation
In contrast to the classical, pro-inflammatory notion of PGE2, studies have shown
an anti-inflammatory role for PGE2 signaling via its EP4 receptor in a variety of different
cell types [253-258]. Several studies also suggest that PGE2 can modulate the
inflammatory cell (i.e., monocytes, macrophages) response at the site of the
injury/inflammation [256, 259-261]. EP4 activation reduces the production of chemokines,
like MCP-1 and MIP-1⍺ in human macrophages [256, 262] and reduced expression of
adhesion molecules in human monocytes [263], however the exact mechanism is not fully
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understood. A study by Ngoc and colleagues showed that PGE 2-EP4 signaling inhibits Tcell proliferation in a rat model of experimental autoimmune myocarditis. Furthermore,
activation of the EP4 receptor lead to improvements in cardiac function, reduction of heart
size, and reduced circulating MCP-1 levels [259].
Macrophages express the EP4 receptor more than any other of the EP receptor
subtypes. It has been reported that PGE2 can suppress the chemokines produced in
LPS-stimulated human macrophages, presumably through EP4 receptor activation [256].
Also, it has been documented that PGE2 can promote the anti-inflammatory M2
macrophage phenotype via activation of PKA and phosphorylation of CREB [200, 201].
In a study by Luan et al., bone marrow derived macrophages exposed to IL-4 and PGE2
promoted induction of M2 macrophage markers, which was antagonized in CREB mutant
cells [200]. Another study conducted by Sanin et al. confirmed these findings [264]. A
separate study by Tang et al. examined the effect of the EP3 receptor on two separate
populations of macrophages, Ly6Chigh (pro-inflammatory, M1 type) and Ly6Clow (antiinflammatory/reparative, M2 type). They found that deletion of the EP3 receptor impaired
the expression of the chemokine receptor CX3CR1, suppressed TGFβ1 signaling, and
therefore reduced infiltration of the Ly6Clow, M2 macrophage in mouse hearts after MI
[265].
The Role of PGE2 in Cardiac Remodeling
The

role

of

PGE2

has

been

well

characterized

in

the

context

of

ischemia/reperfusion (I/R) injury in the heart and in the MI model. Myocardial injury
resulting from I/R is the cause of oxygen free radical production and the inflammatory
response, leading to death of the cardiomyocytes and ventricular remodeling (i.e.,
interstitial fibrosis). It has been shown that EP4 receptor activation protects the heart from

27
I/R in a rat model, by reducing the number of inflammatory cells and suppressing the
production of MCP-1 [266]. Moreover, our laboratory previously demonstrated that mice
with cardiac specific knockout of the EP4 receptor have reduced cardiac function after
MI, as well as a phenotype of dilated cardiomyopathy with age [73, 267]. In contrast to
the EP4 receptor, Martin and colleagues report that in mice with cardiac overexpression
of the EP3 receptor, I/R injury is attenuated by reducing ischemic contracture. However,
these mice are also described as having moderately reduced ejection fractions and
increased end systolic volume at baseline [268]. Other studies have shown that activation
of the EP3 receptor confers cardio protection in I/R injury as well [269-271].
Angiotensin II and Hypertension
Ang II plays a critical role in the development of hypertension due to its direct
effects on vascular cells leading to vasoconstriction, by promoting increased sodium
reabsorption in the kidneys, and by increasing production of aldosterone, which further
promotes sodium and water retention (Figure 4). When Ang II binds to its receptor(s) on
the vascular cell surface it induces a variety of effects comprising immediate, early and
late effects. Activation of phospholipase C and Src occur within seconds leading to
increases in free [Ca2+] and increased mobilization of Ca2+ [272-275]. Activation of
phospholipase A2, phospholipase D, and MAPKs occurs within minutes and leads to
regulation of vascular smooth muscle function (i.e., growth, migration, and production of
growth factors) [276].
Recently, Rho-kinase signaling has been recognized as an important mediator in
inducing vasoconstriction by Ang II. One member of the Rho family, RhoA, is expressed
in vascular smooth muscle cells and sensitizes contractile proteins to Ca2+ and promotes
phosphorylation of myosin light chain, causing increased contraction in response to Ang
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II [277-279]. In a rat model of hypertension induced by Ang II infusion, protein levels of
RhoA were increased in the aorta [280]. It was also shown in cell culture that the activity
of RhoA/Rho-kinase signaling pathway is increased after Ang II treatment [281, 282]. The
role of other Rho family members such as RhoB in hypertension is still not understood.
TNF-α was shown to induce RhoB expression in endothelial cells [283]. Another group
was able to reproduce these findings and showed that stimulation with TNF-α for 16 hours
upregulated RhoB expression and activation, whereas levels for RhoA remain unchanged
[284]. Therefore in contrast to RhoA, RhoB appears to be inducible and may be an
important, novel mediator in inflammatory signaling in response to cytokines like TNF-α.
Ang II can also stimulate phospholipase A2 activity which leads to production of
prostaglandins, like PGE2 that can exert pro- or anti-hypertensive effects [285, 286]. Long
term generation of oxidative stress and protein synthesis occurs in the order of hours or
days and contributes to the late effects. Ang II has been shown to increase O2- and H2O2
production in cardiac, endothelial, vascular smooth muscle, and mesangial cells [287291]. H2O2 dissociates into O2- and water and the production of these radical ions is
important for the pathogenesis of hypertension. The literature suggests the underlying
mechanism of Ang II-induced radical ion production is via p38 MAPK [291] and AKT/PKB
[292] signaling. This evidence suggests that Ang II is critical in maintaining the
vasculature integrity, thus playing a key role in cardiovascular disease and hypertension.
Furthermore, clinical trials using ACE inhibitors and angiotensin receptor blockers (ARBs)
improved morbidity and mortality in hypertension, congestive heart failure, and MI [293,
294]. Mainly this was by lowering blood pressure and improving cardiac remodeling [295301].
Ang II also regulates blood pressure by its actions in the kidneys, primarily by
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regulating salt and water balance. Dysregulation of this system can lead to hypertension
and is believed to be a key player in the development and maintenance of essential
hypertension [302]. Ang II has direct effects on renal vascular smooth muscle cells,
causing vasoconstriction of both the efferent and afferent arterioles. This reduces renal
blood flow, which favors sodium reabsorption [56]. Ang II can also act in the nephron
directly, stimulating salt and water reabsorption [303]. Deletion of the AT1 receptor from
the proximal tubule lowers blood pressure and reduces Ang II-dependent hypertension
[304]. In this dissertation, however, the kidneys will not be studied.
Angiotensin II in Inflammation and Cardiac Remodeling
Early studies suggested that in hypertension, Ang II increased vascular
permeability by indirect pressure-mediated injury to the endothelium [53, 305-307]. It was
later shown, however, that Ang II could influence endothelial permeability independent of
any changes in hemodynamics. Prostaglandins (e.g., PGE2) and growth factors (e.g.,
VEGF) were considered potential players in this effect. In rats, AT 1 blockade with losartan
prevented a prostanoid-dependent increase in vascular permeability [308]. Furthermore,
in humans, ACE inhibitors increase vasodilation in the pulmonary circulation which can
be blocked with cyclooxygenase inhibitors, suggesting an influential role of prostaglandins
on Ang II signaling [309, 310].
A key characteristic of inflammation in cardiovascular disease is infiltration of
monocytes/macrophages [51, 311]. In patients with cardiovascular disease, elevated
levels of circulating MCP-1 were reduced with ACE inhibitor treatment as well as AT 1
antagonist treatment [312, 313]. Inflammatory cells themselves have been shown to be
equipped with the RAS machinery and can produce Ang II locally [314-318] and Ang II
can directly increase the phagocytic activity of macrophages [319, 320]. The expression
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of several genes involved in inflammation can be regulated by nuclear transcription
factors AP-1 and NF-κB [321, 322] and evidence suggests that NF-κB in particular may
be a mediator of Ang II-induced inflammation [323, 324].
Studies have shown that Ang II has an important role in the processes involved in
myocardial remodeling [49, 325, 326] and in left ventricular hypertrophy as a result of
hypertension [327]. A chronic increase in blood pressure leads to left ventricular
hypertrophy that can eventually lead to heart failure. Recent evidence suggests that Ang
II can act both independently or synergistically with increased blood pressure to promote
cardiac hypertrophy [49, 328].
Ang II can directly induce cardiac inflammation [52, 326, 329, 330] which in turn
leads to cardiac remodeling. Furthermore, Ang II has been shown to have direct effects
on cardiomyocytes, inducing hypertrophy, inflammation, and production of extracellular
matrix [151, 331-333]. However, the direct effect of Ang II on cardiomyocytes in vivo is
controversial [334]. The induction of cardiac hypertrophy via Ang II has been linked to
ERK 1/2, NFAT, and CAMKII/MEF2 signaling cascades [335, 336]. It is thought that the
action of Ang II in the cardiomyocytes in vivo is amplified by an activation of the immune
system and inflammatory cascades [337-339]. This involves stimulation of proinflammatory factors, such as IL-18, IFN-𝛾, NF-κB, and reactive oxygen species (ROS)
production via Nox2 and Nox4 [56]. Relevant molecules discussed in this dissertation are
NF-κB and Nox2. Ang II promotes expression of an enhancer molecule, connection to
IKK and SAPK/JNK (CIKS), leading to activation of NF-κB or AP-1 transcription factors
and an upregulation of pro-inflammatory cytokines/chemokines [340]. Another study
determined that Ang II infusion increases activated monocyte levels, enhances iNOS
expression, and uncouples eNOS, promoting more oxidative stress [341]. Additionally,
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ROS produced from NADPH oxidase stimulates MCP-1 expression through Toll-Like
Receptor (TLR)-4 [56]. Moreover, TLR-4 is well characterized and associated with chronic
inflammation and cardiovascular disease [342]. Recent evidence suggests that aside
from its classical activation of AT1, Ang II can also activate TLR-4 and its downstream
signaling pathway [343], although this precise mechanism is unknown. Other evidence
has shown that mice deficient in TLR-4 attenuated Ang II-induced cardiac hypertrophy,
infiltration of macrophages/monocytes, and cardiac dysfunction. Importantly, this was in
the absence of any difference in blood pressure [344].
Cardiac fibrosis induced by Ang II infusion has been shown to be dependent upon
the infiltration of macrophages originating from the bone marrow [345]. The levels of
macrophage infiltration into the myocardiumalso appears to be dose dependent [345,
346]. Furthermore, accumulation of the macrophages appears to be controlled by MCP1 [347].
Animal Models Used in This Study/General Hypothesis
Myocardial Infarction Model
MI is induced by permanent ligation of the left anterior descending coronary artery
(LAD), resulting in in ischemia [348, 349]. This model is applicable to the human
conditions since MI can be caused by blockade of the coronary vessels due to a disrupted
atherosclerotic plaque. This is typically accompanied by ST-segment elevation,
determined by electrocardiogram (ST-elevated MI, STEMI) [350]. For many STEMI
patients (15-25 %), there is no reperfusion therapy for various reasons. For example,
current guidelines state that if the patient is hemodynamically stable for more than 12
hours after onset of symptoms, reperfusion is not recommended [351]. Thus, permanent
LAD ligation in mice resembles this scenario. Following LAD ligation, the mice develop
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heart failure characterized by left ventricular dilation, cardiac dysfunction, and infarct wall
thinning. These heart failure characteristics are observed in human patients as well and
are typically diagnosed as heart failure with reduced ejection fraction (HFrEF) [351, 352].
In mice, HFrEF is observed after 24 hours and worsens over time [353, 354]. In the mouse
MI model, the left ventricle is often divided into three distinct regions following LAD ligation
and ischemia: infarct, border, and remote zones. Generally, the inflammation and fibrosis
are most abundant in the infarct zone [355]. This model allows us to examine the role of
PGE2 and its receptors on these inflammatory processes and on cardiac function 2 weeks
after MI when the scar is fully formed and cardiac function is reduced.
Chronic Angiotensin II Infusion Model
Hypertension induced by chronic administration of Ang II in mice has been shown
to mimic the chronic hypertension and neurohumoral effects observed in patients [350].
Ang II infusion causes cardiac injury and remodeling by both cardiac pressure overload
and direct effects of Ang II and/or aldosterone on the heart [356]. Depending on the dose
of Ang II used in the study, mice can display cardiac remodeling in the presence (pressor
dose) [357] or absence (sub-pressor dose) [358] of hypertension. The degree of
hypertension that is achieved is also dose dependent. Gomolak et al. reported that a low
dose Ang II (0.1 mg-1 x kg-1 x day-1) does not induce hypertension, whereas an
intermediate dose (0.5 mg-1 x kg-1 x day-1) increases blood pressure chronically, and a
high dose (1.4 mg-1 x kg-1 x day-1) causes a severe and immediate increase in blood
pressure and hypertension after only 3 days [346]. Other studies implement a
substantially high dose of Ang II such as 3 mg-1 x kg-1 x day-1 [359]. This dose is used to
cause increased end-organ damage, however it is not physiological or pathologically
relevant. Our study implements the high pressor dose of Ang II (1.4 mg-1kg-1day-1) to
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achieve severe hypertension and subsequent cardiac end organ damage. In contrast to
the ischemic MI model where the injury is localized and defined, the cardiac remodeling
that takes place with Ang II infusion is less defined and more diffuse. For example,
pressure overload induced by hypertension increases stretch of the cardiomyocytes and
subsequent inflammatory cascades [360]. Pressure overload also may induce cell death
and subsequent release of DAMPs promoting inflammation. Lastly, there are the
concomitant effects of Ang II on blood pressure and direct effects of Ang II on the cardiac
cells.
General Hypothesis
The purpose of this dissertation is to examine how the relative abundance of EP3
and EP4 receptors in the heart alters cardiac inflammation/remodeling after MI or Ang II
infusion. We hypothesize that the EP3 receptor mediates the deleterious effects of PGE 2
in the heart, while the EP4 receptor is cardioprotective. To test our hypothesis, we will
use two well-known models of heart failure: myocardial infarction and Ang II-induced
hypertension.
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CHAPTER 2 – OVEREXPRESSION OF PROSTAGLANDIN E2 EP4 RECEPTOR
IMPROVES CARDIAC FUNCTION AFTER MYOCARDIAL INFARCTION
(This Chapter contains previously published material. See Appendix B)
Introduction
Prostaglandin E2 (PGE2) signals through 4 separate G-protein coupled receptor
sub-types (EP1, EP2, EP3 and EP4) to elicit a variety of physiological and
pathophysiologic effects. EP2 and EP4 increase cAMP levels in the cell via adenylate
cyclase activation, whereas EP3 inhibits cAMP production, and EP1 increases Ca2+ levels
in the cell, although the cardiac effects of the receptors have not been studied in depth.
Our laboratory has studied the role of PGE2 via its EP4 receptor over the last decade and
reported that the EP4 receptor causes hypertrophy of cardiomyocytes in vitro; that
deletion of the EP4 receptor only in the cardiac myocyte worsens cardiac function after
myocardial infarction (MI), and that male mice with cardiomyocyte deletion of the EP4
receptor develop a dilated cardiomyopathy with age that is characterized by reduced
ejection fraction, left ventricle dilation, thinning of the posterior wall, and an increased
interstitial cellular infiltrate [73, 218, 267]. Moreover, we recently reported that PGE2 via
its EP3 receptor could reduce contractility of preparations ranging from isolated myocytes
to the whole heart by mechanisms that appeared to involve decreased phosphorylation
of phospholamban (PLN) [217]. Presumably, this would lead to an inhibitory effect on
SERCA, thereby decreasing contraction. Additionally, we reported that the EP3 receptor
is upregulated after MI and although the EP4 receptor is also upregulated, it does not
appear to be to a similar extent. We thus hypothesized that an imbalance in the EP3/EP4
ratio favoring expression of EP3 would explain some of the reduced contractility observed
after MI and that over-expression of EP4 in the same model would improve cardiac
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function. This was tested in the present study using a mouse model of MI with the use of
AAV9-EP4 driven by the myosin heavy chain promoter to overexpress EP4 in the left
ventricle.
Methods
Animal Use
10-12 week old male C57Bl/6 mice used for the MI studies and in vitro studies
were from Jackson labs. The mouse model of MI using permanent ligation of the left
anterior descending coronary artery was previously described by us [73] and is shown in
Figure 8. All studies involving the use of animals were approved by the animal care and
use committee (IACUC) at Henry Ford Hospital, in accordance with federal guidelines.

Figure 8: Demonstration of LAD Ligation and AAV9-EP4 Injection. Left Image adapted
from Redgrave et al. [361] depicting a mouse heart 24 hours after permanent ligation of
the left anterior descending branch of the coronary artery. Note the pale infarcted region.
Right Cartoon depicting the 3 AAV9 injections into the left ventricle free wall. Importantly,
the left ventricle cavity is not punctured.
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AAV-9 EP4 Transduction of the Mouse Heart
Our viral constructs consisted of adeno-associated virus serotype 2/9 with EP4
(hereafter termed AAV9-EP4) and the control virus AAV2/9-CMV luciferase (hereafter
termed AAV9-luc). AAV9-EP4 driven by the myosin heavy chain promoter and AAV9CMV luciferase under control of the CMV promoter, were obtained from Vector BioLabs
(Malvern, PA) and both were administered at the same viral load. To first determine the
localization of AAV9-EP4, we performed intracardiac injections of AAV9-EP4 containing
a hemagglutinin (HA) tag on the N-terminus (hereafter termed AAV9-EP4-HA; AAV9aMHCp-HA-mPTGER4-WPRE; Vector BioLabs), with the same viral titer as AAV9EP4/AAV9-luc. In the other experiments, we performed either sham operation or ligation
of the coronary artery and just before the ligation we administered 30 μL (3 separate 10
μL injections) of either AAV9-EP4 or AAV9-luc for a total of 1 x 1012 viral particles. These
injections were given into three different areas of the left ventricle free wall, but not in the
predicted infarct zone (Figure 8). Two weeks after injection we performed
immunohistochemistry with antibodies against the HA tag to visualize expression of the
construct. We also performed confocal microscopy to examine localization of the
construct in animals that received AAV9-luc or AAV9-EP4 virus.
Echocardiography
Echocardiography was performed on conscious animals at 2 weeks after sham or
MI surgery. The cardiac function of all mice was assessed by echocardiography using an
Acuson 256 system (Mountain View, CA) with a 15-MHz linear transducer, as reported
previously [219]. Diastolic measurements were made at the maximum left ventricle cavity
dimension, whereas systolic parameters were measured during maximum anterior motion
of the posterior wall. All echocardiography was performed by the same investigator who
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was blinded to the experimental groups.
Histology: Measurement of Myocyte Cross Sectional Area (MCSA), Picrosirius Red
Staining, and Infarct Size
Histological assessment of myocyte cross sectional area (MCSA) was performed
as previously described after 2 weeks of MI [362]. Briefly, mouse hearts were harvested
and sectioned transversely into three slices from apex to base (sections A-C). The
sections were frozen in Optimal cutting temperature (OCT) media pre-chilled in
isopentane and stored at –80°C for determination of MCSA. All three sections of the heart
were stained with fluorescein-labeled peanut agglutinin to delineate the myocytes. Four
radially oriented microscope fields were selected from each section and photographed
under the 20x objective. However, we did not analyze the scar itself as there are no visible
cardiomyocytes in that region. MCSA was measured by computer-based planimetry (NIH
Image J) and averaged across all 4 fields of the sections. The mean cardiomyocyte area
was then calculated for each animal.

All assessments were performed by blind

observers. Infarct size was determined using the method described by Takagawa et al.
for the mouse [363]. Briefly, using Metamorph software, infarct area was digitally traced
and calculated as [(epicardial infarct ratio + endocardial infarct ratio) /2] ×100 for all
sections and the average of the three sections was taken. To analyze collagen fraction,
picrosirius red staining was performed using frozen sections of left ventricles and a
method previously published [364]. Briefly, sections were postfixed in Bouin’s fluid and
they were then stained with 0.1% picrosirius red for 1 hour and washed twice with 0.5%
acetic acid. Images of collagen staining were obtained under 2X objective and analyzed
using Nikon Elements software.
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Immunohistochemistry for Macrophages, T cells, and HA Tag-Ep4
The number of macrophages was assessed using CD68+ staining (rat anti-CD68+
antibody, BioRad) on frozen heart sections as we previously described [362]. T cells were
visualized using CD3+ staining (rabbit-anti CD3+ antibody, Abcam). EP4 containing the
HA tag was visualized using anti-HA Tag staining (mouse anti-HA, Cell Signaling).
Briefly, frozen sections were fixed in acetone for 10 minutes, followed by incubation with
fresh 0.3% hydrogen peroxide for 30 minutes.

Sections were then blocked in 5%

centrifuged milk in TBS (Tris- buffered saline) blocking buffer and incubated with either
anti-CD68+ (1:200 in blocking buffer), anti-CD3+ (1:100 in blocking buffer), or anti-HA tag
(1:100 in blocking buffer) overnight at 4oC. Biotinylated secondary antibodies (1:200
dilution of anti-mouse IgG for CD68+ and HA Tag staining, 1:200 dilution of goat antirabbit IgG for CD3+ staining) were placed onto sections for 1 hour at room temperature.
Sections were then incubated with horseradish peroxidase reagent for 40 minutes at room
temperature and then visualized by AEC single solution (Vector laboratories; Burlingame,
CA). After a rinse in water, slides were counterstained with Harris’ hematoxylin solution
for 1 min, then rinsed again in tap water and mounted onto slides using Aquamount
(Lerner laboratories). Negative controls consisted of sections incubated in the absence
of primary antibody. Photographs of five randomly-chosen fields per CD68+ stained
section were taken under the 20X objective and the number of positively stained cells
was counted by a blinded observer. For CD3+ staining, four randomly-chosen fields were
taken under the 20X, 40X, and 100 X oil-immersion objectives. The number of cells per
mm2 was measured by a blinded observer using Image J software. For HA tag staining,
photographs of the negative control were taken under 20X and positive slides were taken
under the 20X, 40X, and 100X oil-immersion objective.
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Co-localization of HA-EP4 Using Double Immunofluorescence
Frozen left ventricle sections were allowed to warm to room temperature followed
by fixation with ice-cold acetone for 15 minutes. Slides were rinsed twice in ice-cold TBS
followed by permeabilization with TritonX-100 (0.1 % in TBS; pH 7.6) for 5 minutes at
room temperature. Slides were then blocked for 1 hr. at room temperature in a humidified
chamber in 2% bovine serum albumin (BSA; pH 7.6). Slides were incubated with primary
antibodies sequentially at room temperature in a humidified chamber. First, slides were
incubated with biotinylated anti-HA tag (BAM0601; R&D Systems) for 2 hours, followed
by three washes with TBS. These slides were then incubated with Streptavidin conjugated
to Northern LightsTM 557 (NL999; R&D Systems) for 1 hour in the dark. Slides were then
washed 5 times with TBS, 5 minutes each, followed by incubation with either rat antiCD31 (557355; BD BioSciences), the endothelial cell marker or rabbit anti-α-Sarcomeric
Actinin (ab137346; Abcam), the cardiomyocyte marker, for 2 hours. Slides were washed
as before followed by secondary antibody detection with either goat anti-rat FITC or goat
anti-rabbit FITC for 1 hour in the dark. Slides were washed 5 times with TBS, followed by
incubation with DAPI nuclear stain (1: 18,000 in TBS) for 10 minutes. Slides were then
mounted using AquaMount (Lerner laboratories). Control sections were cryosections from
animals that received AAV9-Luc virus and thus do not express HA-EP4. Slides were
imaged using confocal microscopy.
Confocal Microscopy
Fixed and labeled left ventricle tissue slices were imaged by confocal microscopy
using an Olympus FV1200 confocal microscope. Images were acquired using a 40X
objective and an optical zoom function was used to acquire images at 200X. DAPI was
excited with a 405 nm diode laser and fluorescence acquired between 420 and 490 nm.
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FITC labeled CD31 or α sarcomeric actinin was excited at 489 nm and fluorescence
acquired between 495 and 555 nm. Northern Lights

TM

was excited at 557 nm and

fluorescence acquired between 570 and 700 nm. No cross-bleed between channels was
observed under these conditions. Images on the three channels were acquired
simultaneously.
Western Blot
Phospholamban (PLN), phosphorylated PLN (p-PLN), and HA-EP4 expression
were measured by Western Blot using homogenized left ventricles from sham and MI
mice who received either AAV9-EP4 or AAV9-Luc, as we have previously described
[217]. The p-PLN antibody is from Cell Signaling (Danvers, MA) and recognizes
phosphorylation at Ser16/Thr17. After detection of p-PLN, the blot was stripped and a
total phospholamban antibody (Cell signaling, Danvers, MA) was applied at a 1:1000
dilution. The p-PLN signal was corrected to total PLN. Expression of HA-EP4 was
measured using antibodies raised against the HA tag (mouse anti-HA; Cell signaling, Cat
No.2367) at a 1:1000 dilution. GAPDH was used to control for the amount of protein
loaded.
In Situ Zymography
To assess MMP activity, we performed in situ zymography on frozen sections as
previously described [365]. Fluorescein conjugated, dye-quenched gelatin from pig skin
(DQ™-gelatin) was obtained from Molecular Probes (Invitrogen, Basel, Switzerland). A 1
mg/ml stock solution of DQ-gelatin was prepared in gelatinase reaction buffer (150 mM
NaCl, 5 mM CaCl2, 0.2 mM NaN3, 50 mM Tris-HCl, pH 7.6) and stored at 4°C. The working
solution for in situ zymography was made by directly diluting DQ-gelatin stock solution in
reaction buffer to a final concentration of 20 µg/ml. Unfixed cryosections were thawed,
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rounded with a wax pen, overlaid with 25 µl DQ-gelatin working solution and incubated at
37°C in a humidified dark chamber for 5 hours and pictures were immediately taken under
the microscope. Control sections were incubated in the presence of 20 mM EDTA which
inhibits gelatinase activity. Photographs of four randomly-selected fields were taken under
the 20X objective and a threshold was set using Nikon elements that encompassed only
the bright green fluorescence indicative of gelatinase activity. The percent area of
gelatinase activity was calculated for each animal per field and the mean calculated for
each group.
Real Time RT-PCR
Measurement of β-myosin heavy chain (β-MHC), brain natriuretic peptide (BNP),
tumor necrosis factor α (TNFα), inducible nitric oxide synthase (iNOS), Secreted protein,
acidic and rich in cysteines (SPARC), matrix metalloproteinase 2 (MMP2), EP1, EP2,
EP3, and EP4 mRNA expression was performed by quantitative real-time RT-PCR using
a SYBR green method. Real time RT-PCR was performed as follows: 1 μg of DNAsetreated total RNA sample was reverse transcribed using random primers and Omniscript
reverse transcriptase (Qiagen, Valencia, CA) in a total volume of 20 µl for 1 hr. at 37 °C
followed by an inactivation step of 95 °C for 5 min. 2 µl of the reverse transcription
reaction was then amplified in a Roche version 2.0 lightcycler PCR instrument (Roche,
Indianapolis, IN) using SYBR green dye (SA Biosciences, Frederick, MD) and specific
primers. Reactions were set up in a final volume of 20 μl, which contained 2 μl of sample,
1 μM each of both the primers and 10 μl of 2x SYBR green PCR mix. After an initial “hot
start” at 95oC for 10 min, amplification occurred by denaturation at 95 oC for 15 s, then
annealing at 58-60oC for 40 s for a total of 30-40 cycles, followed by extension at 72oC
for 40 s. At the end of PCR cycling, melting curve analyses were performed. For all
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Qiagen primers, extension and annealing were performed together in one step at 60 oC
for 1 minute. A relative quantitation method (ΔΔCt) [366] was used to evaluate expression
of each gene relative to control. Real time RT-PCR of GAPDH was used for normalization
of all data. Primer sequences are shown in Table 1.
Table 1: Primer Sequences.

Gene
Sense
Anti-Sense
β-MHC 5ʹ-acaggaagaacctactgcgrc-3ʹ
5ʹ-agcttgttgacctgggact-3ʹ
BNP
5ʹcccaaaaagagtccttcggt-3ʹ
5ʹcctacaacaacttcagtgcgtt-3
iNOS
5ʹcccttcaatggttggtacatgg-3ʹ
5ʹacattgatctccgtgacagcc-3ʹ
MMP2 5ʹ-ataccccaagccactgacca-3ʹ 5ʹ-ccaggagtctgcgatgagct-3ʹ
GAPDH 5ʹ-caaggtcatcccagagctg-3ʹ
5ʹ-tgtcatcatacttggcaggtt-3ʹ
Qiagen, NM_013693.3
TNF-α
EP1
Qiagen, NM_013641.2
Qiagen, NM_008964
EP2
Qiagen, NM_011196
EP3
Qiagen, NM_009242
SPARC
Primers from Qiagen are proprietary and only the RefSeq number for the mRNA sequence is provided.

Cytokine/Chemokine Multiplex ELISArray
To identify changes in expression of major cytokines/chemokines after MI with
injection of either control AAV9-Luc virus or AAV9-EP4 virus, we performed a multiplex
Enzyme-Linked ImmunoSorbent Assay (ELISA) using a commercially available kit from
Qiagen (Cat No. MEM-005A). Following the manufacturer’s instructions, we
homogenized 20 mg of left ventricle tissue in sample buffer provided in the kit with the
addition of a protease inhibitor (Cat No. 4693132001, Roche). The 96-well plate was
analyzed at 450 nm and 570 nm using a plate reader. The absorbance at 570 was to
account for auto-fluorescence of the plate and was subtracted from final readings per the
manufacturer’s instructions. After being corrected, absorbance values were corrected for
amount of protein in each well of the assay plate.
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Statistical Analysis
All statistical analysis was performed by a statistician in the Department of Public
Health Sciences of Henry Ford Hospital using the statistical package SAS Version 9.4.
All data are shown as mean ± standard error of the mean (SEM). Data were analyzed
using multiple two-sample Wilcoxon tests for unequal variances along with a Hochberg’s
correction for multiple comparisons. This procedure provides a series of adjusted cutoff
values for significance for 4 comparisons (cutoff p values are 0.05, 0.025, 0.017, and
0.013).
Results
Effect of AAV9-EP4 Injection on EP4 mRNA Expression
To determine the extent of EP4 expression after viral injection, we performed real
time RT-PCR for EP4. After 14 days, sham-operated animals receiving AAV9-EP4 had
a 2.86-fold increase in EP4 mRNA expression compared with control (1.08 ± 0.25 vs.
3.09 ± 0.73 in Sham + AAV9-EP4; p=0.05). The expression levels of EP1 (1.25 ± 0.10 vs.
1.11 ± 0.11 in Sham + AAV9-EP4), EP2 (1.02 ± 0.15 vs. 0.71 ± 0.16 in Sham + AAV9EP4), and EP3 (1.13 ± 0.33 vs. 2.23 ± 1.01 in Sham + AAV9-EP4), were not significantly
changed following administration of AAV9-EP4.
AAV9-EP4-HA Overexpression Level and Localization
To assess the level of AAV9-EP4 expression and localization after injection, we
performed intracardiac injections as described in the methods in sham animals with an
AAV9-EP4-HA construct. After two weeks, we performed immunohistochemistry with
antibodies against the HA tag. Figure 9 A shows representative images of positive
staining under different magnifications and of the negative control (bottom right panel).
We observed intense positive staining throughout the left ventricle with staining around
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cardiomyocyte nuclei and on the cell membrane. This expression was confirmed by
western blot.

Figure 9 A: Representative EP4-HA Immunohistochemistry. Images showing anti-HA
staining using the 20X objective (top left), a portion of this staining at 40X (top right), and
100X (bottom left). Bottom right panel shows a section incubated in the absence of
primary antibody for a negative control. Positive staining is indicated by the black arrows.
Also note that the interstitial region, indicated by the white arrow is devoid of staining.

Figure 9 B shows that HA-EP4 expression in the left ventricles of mice injected
with AAV9-EP4 is highly abundant two weeks post MI, and is negative in animals that
received AAV9-Luc.
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Figure 9 B: Representative EP4-HA Western Blot. Western blot for HA expression in
homogenized left ventricles from MI animals that received injections of either CMVLuciferase or AAV9-EP4.
Localization of HA-EP4 in the Left Ventricle
To determine localization of overexpressed EP4 within the heart, we performed
double labeled immunofluorescence using the HA tag as a surrogate of EP4 expression.
As a control we used cryosections from animals that received AAV9-Luc virus and
therefore do not express the HA tag. Figure 9 C clearly shows that the HA tag is
expressed only in those animals that received AAV9-EP4 virus, and not in animals that
received the control virus AAV9-Luc. We next used confocal microscopy to determine
whether the HA tag co-localized with either the endothelial cells (CD31) or within the
myocytes (α-Sarcomeric Actinin) (Figure 9 D). The top panel clearly shows no association
between the HA tag (red) and the endothelial cells (green). However, the HA-tag does
co-localize

with

cardiomyocytes.
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Figure 9 C: Representative EP4-HA Immunofluorescence. Images showing expression
of the HA tag in the left ventricle of a mouse that received AAV9-Luc virus (left panel) vs.
a mouse that received AAV9-EP4 (right panel). Images were taken under the same
exposure.

Figure 9 D: Confocal Microscopy of EP4-HA in the Cardiomyocytes. Images showing
double immunofluorescence labeling of the HA tag with the endothelial cell marker CD31
(top right panel merged; 40X) and the cardiomyocyte marker α-Sarcomeric Actinin
(bottom right panel merged; 200X). Note that the HA tag does not co-localize with the
positive green CD31 signal outlining capillaries and vessels.
Effect of EP4 Overexpression on Cardiac Function
Representative echocardiography images (Figure 10 A) and data (Figure 10 B and
Table 2) are presented. As expected, animals with MI exhibited a lower ejection fraction
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(EF) than sham operated animals (37.8 ± 2.2 % for MI+AAV9-luc vs. 76.9 ± 2.1 % for
sham + AAV9-luc, p =0.0001). The administration of AAV9-EP4 to MI animals resulted in
a significant improvement in EF (to 47.7 ± 2.4 %, p=0.0025 compared to animals receiving
AAV9-luc) whereas it had no effect in sham-operated mice. In addition to increased EF,
our data show an improvement in shortening fraction (SF; p=0.0003) coupled with less
ventricle dilatation at systole (LVDs; p=0.0013) and a tendency for reduced chamber
dimension at diastole (LVDd) also (p = 0.028 NS). Altogether, the data suggest that
expression of EP4 improves cardiac function and alters ventricular remodeling.
Furthermore, the effects on cardiac function appear to be independent of infarct size since
there was no difference between MI + AAV9-luc vs. MI + AAV9-EP4 (33.53 ± 4.39%
versus 31.29 ± 3.32%, respectively).

A

Figure 10 A: Representative M-mode of Echocardiography. Images from each of the four
groups used for analysis.
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Figure 10 B: Quantitative
Analysis of Echocardiography
Data. EF-ejection fraction, SFshortening fraction, LVDs – left
ventricle dimension at systole,
LVDd - left ventricle dimension
at diastole. N = 9 for Sham +
AAV9-luc, N=10 for Sham +
AAV9-EP4, N=16 for MI +
AAV9-luc, N=17 for MI +
AAV9-EP4.
*
denotes
statistical significance vs.
respective sham group, +
denotes statistical significance
vs. MI+AAV9-Luc.
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Table 2: Echocardiography Data of EP4 Overexpression Mice

Data presented as mean ± SEM. * represents a significant difference vs. Sham + AAV9-Luc, + BWbody weight, LV- left ventricle, HR- heart rate, CO- cardiac output, EF- ejection fraction, SF- shortening
fraction, LVD – left ventricle dimension.* represents significant difference vs. MI + AAV9-Luc, and ‡
represents a significant difference vs. Sham + AAV9-EP4. N = 9 for Sham + AAV9-Luc, N=10 for Sham
+ AAV9-EP4, N=16 for MI + AAV9-Luc, N=17 for MI + AAV9-EP4.

With respect to survival, 20-30% of mice typically die of cardiac rupture in the first
week following MI after ligation of the LAD. However, in our experiments, we did not
observe any differences in mortality between mice receiving control virus (17.6%) and
those receiving AAV9-EP4 (19.0%).
Effect of EP4 Overexpression on Collagen Fraction (Picrosirius Red Staining)
As expected, MI increased the collagen content in all three regions of the left
ventricle examined (infarct, peri-infarct, and remote; Figure 11 B left, middle, and right
panels respectively) by picrosirius red staining (PSR). In the infarcted region, animals that
received MI and control AAV9-Luc virus showed an increase in collagen to 18.78 ± 2.58
% vs. 8.62 ± 1.13 % in sham operated animals. In animals that received MI and AAV9EP4 virus, positive PSR staining was increased even further to 29.96 ± 2.94 %. In the
peri-infarct region, animals given MI and AAV9-Luc virus had a similar significant increase
in collagen content (25.10 ± 2.00 % vs. 7.13 ± 0.91 % in sham operated animals). In
contrast to the infarcted region, collagen content in the peri-infarct was reduced after MI
with injection of AAV9-EP4 to 17.12 ± 2.24 %. As anticipated, there was a small, but
significant increase in collagen in the remote region of the heart (6.72 ± 1.14 % vs. 2.68
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± 0.38 % in sham operated animals). This increase was also reduced to 3.62 ± 0.91 % in
animals that received MI with AAV9-EP4 injection. Representative images of the staining
from the peri-infarct zone are shown in Figure 11 A.

Figure 11 A: Representative Picrosirius Red Staining. Images captured under 2X
objective from each treatment group taken from the peri-infarct zone.

Figure 11 B: Quantification of Picrosirius Red Staining. Performed from the infarcted
region (left panel), peri-infarct region (middle panel), and remote region (right panel) of
frozen left ventricle sections. Data is presented as mean ± SEM. *** p<0.001 compared
to respective sham group. + p<0.05, +++ p<0.005 compared to MI + AAV9-Luc. (Left
panel) N=6 for Sham + AAV9-Luc, Sham + AAV9-EP4, and MI + AAV9-Luc, N=14 for MI
+ AAV9-EP4. For middle and right panels N=6/group.
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Effect of EP4 Overexpression on Myocyte Cross-Sectional Area (MCSA)
As anticipated, MI increased MCSA but this increase was smaller in mice receiving
AAV9-EP4 (Figure 11 C: 259.4 ± 4.0 µm2 vs. 296.6 ± 6.0 µm2, p < 0.01). The
administration of AAV9-EP4 did not affect MCSA in sham-operated animals (202.3 ± 5.2
µm2 for sham-operated receiving AAV9-luc vs. 231.4 ± 18.5 µm2 for mice receiving AAV9EP4, NS).

Figure 11 C: Myocyte Cross Sectional Area Analysis. Analyzed using NIH Image J
software. MCSA is presented as mean ± SEM. *** p< 0.005 vs. Sham + AAV9-Luc, ++
p<0.01 vs. MI + AAV9-Luc. N=5 for Sham + AAV9-Luc, N=5 for Sham + AAV9-EP4, N=7
for MI + AAV9-Luc, N=11 for MI + AAV9-EP4.

Effect of EP4 Overexpression on Gene Markers of Cardiac Hypertrophy
Since treatment with AAV9-EP4 reduced MCSA in response to MI, we also
measured expression of β-myosin heavy chain (β-MHC) and BNP, gene markers of
hypertrophy, using real time RT-PCR, corrected to GAPDH. As shown in Figure 11 D,
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both β-MHC and BNP were increased after MI and these increases were attenuated after
treatment with AAV9-EP4; consistent with the MCSA data. After MI, β-MHC mRNA
expression (Figure 11 D, left panel) was significantly increased 5-fold compared with
sham animals (6.64 ± 1.9 vs. 1.31 ± 0.43, p < 0.001). Animals treated with AAV9-EP4
virus had a significant increase in β-MHC mRNA expression after MI, although this
increase was only 2.2-fold that of sham animals (3.76 ± 1.2 vs. 1.75 ± 8.7, p < 0.05).
Similarly, BNP mRNA expression (Figure 11 D, right panel) significantly increased after
MI (3.46 ± 1.0 vs. 1.11 ± 0.17, p < 0.001). However, there was no difference in BNP
mRNA expression after MI in animals who first received AAV9-EP4 treatment (1.65 ± 0.34
vs. 1.03 ± 0.11).

Figure 11 D: β-MHC and BNP mRNA Expression. β-myosin heavy chain (β-MHC)
mRNA expression and Brain natriuretic peptide (BNP) mRNA expression. For both βMHC and BNP data was corrected to GAPDH and presented as fold of Sham + AAV9Luc control group. N = 10 for Sham + AAV9-Luc, N=9 for Sham + AAV9-EP4, N=14 for
MI + AAV9-Luc, N=12 for MI + AAV9-EP4. ***p<0.005 vs. Sham + AAV9-Luc, + p < 0.05
vs. Sham + AAV9-EP4.
Effect of EP4 Overexpression on MMP-2 mRNA
Matrix metalloproteinases (MMPs) play an important role in extracellular matrix
remodeling in various pathological conditions, including myocardial infarction [367-369].
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Specifically, MMP-2 has been shown to play an important role in LV remodeling [368,
370]. For this reason, we determined the effect of EP4 overexpression on MMP-2 mRNA
expression (Figure 12, left panel). There was a significant increase in MMP-2 expression
in MI animals receiving control AAV9-Luc virus (2.91 ± 0.62 vs. 1.00 ± 0.06 in Sham +
AAV9-Luc, p<0.05). However, in animals receiving AAV9-EP4, there was no change in
expression of MMP-2 after MI (1.68 ± 0.65 vs. 1.47 ± 0.31 in Sham + AAV9- EP4, p=0.85).
Since mRNA levels do not always reflect activity, we also performed in situ zymography
to
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shown
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Figure 12: MMP-2 mRNA and Gelatinase Activity Assay. (Left panel): MMP-2 mRNA
expression from left ventricles. Data is presented as mean ± SEM. N=3 for Sham +
AAV9-Luc, N=4 for Sham + AAV9-EP4, N=8 for MI + AAV9-Luc, and N=6 for MI + AAV9EP4. *p < 0.05 vs. Sham + AAV9-Luc. (Right panel): In situ zymography to assess
gelatinase activity in infarct zone. Data is presented as mean % area positive.
N=3/group, + p< 0.05 vs. Sham + AAV9-Luc.

right panel. As expected, gelatinase activity was increased in the infarct zone after MI in
animals that received control virus (10.47 ± 3.71 RFU vs. 2.35 ± 0.60 RFU in sham
animals that received the same virus; p=0.07). Surprisingly, treatment of sham-operated
mice with AAV9-EP4 increased MMP activity (2.35 ± 0.60 RFU for sham-operated AAV9luc vs. 7.23 ± 1.75 RFU, p < 0.05 for sham animals receiving AAV9-EP4). There was no
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further increase in MMP activity after MI in animals that received AAV9-EP4 virus (7.15 ±
1.60 RFU vs. 7.23 ± 1.75 RFU in sham + AAV9-EP4 group).
In the remote region of the heart, a similar increase in MMP activity was noted after
MI in mice receiving control virus (0.42 ± 0.16 RFU in sham + AAV9-Luc vs. 5.67 ± 1.59
RFU in MI + AAV9-Luc, p < 0.05). Similar to results noted in the infarct zone,
administration of AAV9-EP4 to sham-operated animals tended to increase MMP activity
although the change failed to achieve statistical significance (0.42 ± 0.16 RFU in sham +
AAV9-Luc vs 2.75 ± 1.20 RFU in sham + AAV9-EP4, p = 0.104). After MI, there was no
statistically significant change in MMP activity for animals that received AAV9-EP4 (2.75
± 1.20 RFU for sham + AAV9-EP4 vs 5.31 ± 1.51 RFU for MI + AAV9-EP4). Secreted
protein, acidic and rich in Cysteines (SPARC) is a glycoprotein that plays an important
role in activation and production of MMPs. We measured the expression of SPARC
mRNA by real time RT-PCR and we found that SPARC was significantly increased after
MI in animals that received control virus, compared to sham animals (3.57 ± 0.69 vs. 1.02
± 0.14 in sham animals; p=0.001). SPARC expression was not changed in sham-operated
animals overexpressing EP4 (1.02 ± 0.14 for AAV9-luc vs 0.83 ± 0.25 for AAV9-EP4) and
neither was it altered in mice subject to MI (3.37 ± 0.63 in MI+AAV9-EP4; p=0.787).
Effect of EP4 Overexpression on Macrophage Migration and Polarization
A representative image of macrophage migration in all four groups is presented in
Figure 13 A.

Figure 13 B shows a representative image of the CD68 + staining
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Figure 13 A: Representative CD68+ Staining (20X). Images from all four groups showing
CD68+ staining for macrophages in the infarct / peri-infarct region of frozen left ventricle
sections.

Figure 13 B: Representative CD68+ Staining (2, 10, and 20X). Images of CD68+
staining from the infarct zone under 2X (left panel), 10X (middle panel) and 20X (right).

observed in the infarct/peri-infarct zone after 2 weeks of MI under different magnifications.
As expected, after 2 weeks of MI, the number of macrophages in the infarct/peri-infarct
region was increased 2.2-fold (Figure 13 C, left panel), from a value of 181.79 ± 10.2
cells/mm2 in sham-operated animals receiving AAV9-luc to 401.65 ± 58.6 cells/mm2 in MI
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+ AAV9-luc injected hearts (p < 0.001). Treatment with AAV9-EP4 substantially reduced
the number of infiltrating macrophages in the MI heart to a value of 281.77 ± 28.2
cells/mm2 (p=0.09). In the remote zone of the heart (Figure 13 C, right panel), the number
of CD68+ cells was unchanged after MI (102.02 ± 22.04 cells/mm2 vs. 98.10 ± 15.51
cells/mm2

in

sham-operated

animals),

however,

injection

of

AAV9-

Figure 13 C: Quantification of CD68+ staining. In the infarct / peri-infarct region (left
panel) and in the remote region (right panel) of the left ventricle. Data are presented as
means ± SEM. N=12 per group. ** p<0.01, ***p<0.005 vs. respective sham group,
++p<0.01 vs. MI + AAV9-Luc
EP4 resulted in a significant increase in CD68+ cells in sham animals (176.30 ± 13.41
cells/mm2 vs. 98.10 ± 15.51 cells/mm2) and this was further increased after MI to 194.80
± 27.48 cells/mm2. We also performed real time RT-PCR for inducible nitric oxide
synthase (iNOS), one established marker of the M1 macrophage phenotype. As shown
in Figure 13 D, the expression of iNOS (corrected to GAPDH) in the left ventricles was
significantly increased in MI mice receiving control virus (2.04 ± 0.31; p<0.01). However,
there was no increase in iNOS mRNA expression after MI in mice that received AAV9EP4.
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Figure 13 D: iNOS mRNA Expression. Inducible nitric oxide synthase (iNOS) mRNA
expression; data are corrected to GAPDH control and are presented as mean ± SEM fold
of Sham + AAV9-Luc. ** p<0.05 vs. Sham + AAV9-Luc. N = 3 for Sham + AAV9-Luc,
N=4 for Sham + AAV9-EP4, N=8 for MI + AAV9-Luc, N=6 for MI + AAV9-EP4.
Effect of EP4 Overexpression on T cells
Figure 13 E displays representative images of CD3+ staining for each of the four
groups and Figure 13 F shows a representative image of the CD3+ staining observed in
the infarct/peri-infarct zone after 2 weeks of MI under different magnifications. Figure 13
G (left panel) shows that two weeks post MI there was a 2.26-fold increase in positive T
cell staining in the infarct region of mice that received AAV9-luc compared to shamoperated mice that received the same control virus (504.39 ± 46.80 cells/mm 2 vs. 222.61
± 18.27 cells/mm2 respectively, p<0.001). Furthermore, the increase in T cells was
prevented when MI mice were treated with AAV9-EP4 (329.71 ± 33.53 cells/mm2 vs.
504.39 ± 46.80 cells/mm2 MI + AAV9-Luc mice). CD3+ cell staining was not different
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between groups when the remote zone was analyzed (Figure 13 G, right panel).

Figure 13 E: Representative of CD3+ Staining (20X). Images showing CD3+ staining for
T lymphocytes in the peri-infarct zone in frozen left ventricle sections taken under 20X
objective.

Figure 13 F: Representative CD3+ Staining (2, 10, and 20X). Images of CD3+ staining
taken under 2X (left panel), 10X (middle panel) and 20X (right panel). Arrows depict
regions of positive staining.
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Figure 13 G: Quantification of CD3+ Staining. In the infarct + peri-infarct zones (left
panel), and in the remote zone of the left ventricle (right panel); data are presented as
means ± SEM. N = 12/group for Sham + AAV9-Luc, Sham + AAV9-EP4, and MI + AAV9Luc. N=16 for MI + AAV9-EP4. * p<0.05, *** p< 0.005 vs. respective sham group. ++
p<0.01 vs. MI + AAV-Luc.
Effect of EP4 Overexpression on Cytokines
It is well known that cytokines like TNFα play an important role in the
pathophysiology of heart failure. Since increased expression of TNFα has been correlated
with an increased severity of heart failure, we determined if treatment with AAV9-EP4
would prevent its expression. Figure 14 A shows that TNFα mRNA expression (corrected
to GAPDH) significantly increased after MI in mice receiving control virus (2.65 ± 0.63 vs.
1.05 ± 0.23 in sham animals, p = 0.002). However, TNFα mRNA did not increase after
MI in mice receiving AAV9-EP4 (1.74 ± 0.24 vs. 1.17 ± 0.39; NS). We next performed a
multiplex ELISA on left ventricle homogenates to identify key cytokines/chemokines that
might be changing in MI with overexpression of EP4 (Figure 14 B). Using the array kit,
we identified a significant reduction in MCP-1 expression (left panel) in mice receiving
AAV9-EP4 (0.254 ± 0.0146 vs. 0.167 ± 0.0187 in MI + AAV9- EP4; p< 0.01) and an
increase in IL-10 (0.025 ± 0.0061 vs. 0.044 ± 0.0121 in MI + AAV9-EP4; p=0.172),
although this did not reach statistical significance (right panel). In isolated cardiomyocytes
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from MI mice that received either control virus or AAV9-EP4, levels of these
cytokines/chemokines were below the levels of detection. However, these data indicate
that overexpression of EP4 may reduce the expression of pro-inflammatory
chemokines/cytokines (MCP-1) while increasing expression of anti-inflammatory
cytokines (IL-10).

Figure 14. TNFα mRNA Expression and Cytokine ELISarray. Panel A: Tumor necrosis
factor α (TNF α) mRNA expression. Data was corrected to GAPDH and all data are
presented as mean ± SEM as fold of Sham + AAV9-Luc. N = 3 for Sham + AAV9-Luc,
N=4 for Sham + AAV9-EP4, N=8 for MI + AAV9-Luc, N=6 for MI + AAV9-EP4. *** p<0.001
vs. Sham + AAV9-Luc. Panel B: Cytokine/chemokine multiplex ELISA data. Left panel
shows protein expression of the chemokine MCP-1 and the right panel shows protein
expression of the cytokine IL-10. Data presented is optical density (O.D.) corrected for µg
of protein in each well x 1000. Data are presented as mean ± SEM. Panel A: N = 4 for MI
+ AAV9-Luc, N=5 for AAV9-EP4. Panel B: N = 6 for MI + AAV9-Luc, N=5 for AAV9-EP4.
** p < 0.01 vs. MI + AAV9-Luc.
Effect of EP4 Overexpression on Phosphorylation of Phospholamban
Since phosphorylation of phospholamban is important in regulating the
sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) and therefore contractility, we
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performed western blot analysis of p-PLN and total PLN expression (Figure 15). There
was a significant increase in expression of p-PLN, corrected to total PLN, in sham animals
who received AAV9-EP4 compared with sham animals that received the control AAV9Luc virus (1.01 ± 0.16 vs. 0.35 ± 0.09; p<0.05). In animals subject to MI with injection of
AAV9-EP4, the expression of p-PLN was already elevated and thus there was no further
increase.

Figure 15. Western Blot
for the Expression of
Phosphorylated
Phospholamban. p-PLN
in left ventricles of mice
that received either sham
or MI operation with
injection of either AAV9Luc or AAV9-EP4. Total
phospholamban (t-PLN)
served as a loading
control. Top panel shows
a representative blot,
while the bottom panel
shows the quantification.
Data is presented as
mean ± SEM. *p< 0.05
compared
to
Sham+AAV9-Luc.
N=5
per group

Discussion
The results of this study show, for the first time, that administration of AAV9-EP4
into the left ventricle of mice with MI is beneficial in improving cardiac function. We have
previously reported that male mice lacking the EP4 receptor in cardiomyocytes (EP4-KO)
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have worsened cardiac function after MI and develop dilated cardiomyopathy with age
[73, 267]. More recently we also reported that PGE2 via its EP3 receptor reduced
contractility whereas stimulation of EP4 had the opposite effect. These effects appeared
to involve changes in the phosphorylation of phospholamban. Moreover, we also reported
that after MI, expression of the EP3 receptor subtype in the left ventricle was increased
to a greater extent than EP4 [217]. We therefore hypothesized that overexpression of
EP4 in the heart would improve cardiac function after MI. Thus, in our experiments
described here, we used an adeno-associated viral vector driven by the alpha myosin
heavy chain promoter to increase the expression of the EP4 receptor in the
cardiomyocytes rather than increase the activation of receptors already present. The
results support our hypothesis, with significant improvements in ejection fraction and
shortening fraction noted, coupled with reductions in left ventricular dimension after MI
without affecting infarct size.
Overexpression of EP4 also significantly reduced hypertrophy and fibrosis after MI
as evidenced by a smaller MCSA and reduced picrosirius red staining in the peri-infarct
and remote zone, and the former was confirmed by reductions in β-MHC and BNP mRNA
expression. Previously, other studies have shown a protective role for the EP4 receptor
in ischemia-reperfusion injury. Xiao et al [371] reported that global EP4 KO mice had
larger infarcts after reperfusion injury while administration of an EP4 agonist had the
opposite effect. A study by Hishikari et al [266], using a rat model described similar
findings but also indicated that treatment with an EP4 agonist could reduce cytokine
secretion stimulated by the ischemia/reperfusion. Our data using the permanent coronary
ligation model with EP4 overexpression agrees with the aforementioned findings except
that we did not observe a change in infarct size at the end of the study. Whether this
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relates to the different models or different time points remains unknown. Since we also
recently reported that PGE2 via its EP3 receptor reduced contractility of the heart via
mechanism(s) that appeared to involve decreased phospholamban phosphorylation; we
examined phosphorylation of phospholamban in these studies. Sham-operated mice who
received AAV9-EP4 exhibited a significant increase in phosphorylated phospholamban,
consistent with our in vitro data using the EP4 agonist in isolated cardiomyocytes [217].
A similar trend was observed in animals with MI, although the data did not achieve
statistical significance. We therefore speculate that the increased EP3 receptor
abundance after MI could account, in part, for the decreased contractility observed. The
role of the EP3 receptor in cardiac function is controversial. Martin et al [268] reported
that cardiac overexpression of the EP3 receptor attenuated ischemia-induced myocardial
injury. However, that paper used an isolated heart perfusion method and curiously, EP3
transgenic animals exhibited a reduced ejection fraction as measured in vivo using MRI.
In subsequent studies, we think it will be necessary to identify the impact of EP3 receptor
inhibition with simultaneous EP4 overexpression on cardiac function.
Treatment with AAV9-EP4 also improved aspects of adverse cardiac remodeling.
The increased collagen deposition noted in the peri-infarct and remote zone after MI was
substantially attenuated by use of AAV9-EP4 and there were significant reductions in the
number of macrophages and T cells infiltrating the left ventricle. Although the beneficial
role of the EP4 receptor in heart failure has not been fully explored, our data agree with
several other studies suggesting an anti-inflammatory role for the PGE2 EP4 receptor
subtype. Our data agree with the beneficial role of the EP4 receptor reported in other cell
types. In a rat model of autoimmune myocarditis, Ngoc et al. [259] reported that treatment
with an EP4 agonist reduced immune cell infiltration, heart size, and area of fibrosis. More
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recently, a publication by Wang et al. [372] demonstrated that an EP4 receptor agonist
could prevent cardiac dysfunction and cardiac fibrosis in a pressure overload, transaortic
constriction mouse model.
In human samples, Haywood et al. [373] showed that iNOS was undetectable in
control heart samples but could be detected in 36 of 51 patients with heart failure. Our
data show that iNOS expression in the left ventricle is increased after MI and can be
attenuated by treatment with AAV9-EP4, consistent with a cardioprotective effect. iNOS
is also one marker for the M1 macrophage phenotype but it is unclear from our data
obtained from left ventricle samples whether the iNOS originates from resident/infiltrating
macrophages or another cell type such as cardiomyocytes. If the former, then the
reduction noted in iNOS may relate simply to a reduction in the number of infiltrating
macrophages observed after AAV9-EP4 treatment. Alternatively, PGE2 has been shown
to have anti-inflammatory effects in macrophages by reducing TNFα expression and
increasing Interleukin 10 expression via the EP4/cAMP/protein kinase A (PKA) pathway,
which promotes macrophage M2 polarization [374-376]. It remains to be elucidated if
overexpression of EP4 in the left ventricle mediates macrophage polarization towards an
anti-inflammatory M2 phenotype and our data using a limited number of markers do not
allow us to draw any complete conclusions.
Another aspect of cardiac remodeling involves the matrix metalloproteinases
(MMPs) family of proteins and other molecules that play a role in collagen deposition.
Specifically, MMP-2 has been implicated in LV remodeling and furthermore, MMP-2 KO
mice are reported to have lower incidences of cardiac rupture after MI [377, 378], although
the mechanism of how MMP-2 contributes to cardiac rupture is not well understood. Also,
reports show that broad inhibition of MMPs contributes to attenuation of LV dilatation [379,

65
380]. Several MMPs are involved in this process, although MMP-2 may play a key role.
Matsumura et al. [369] reported that deletion of MMP-2 in mice profoundly improved
survival rates after MI. Moreover, they reported that deletion of MMP-2 completely
reduced macrophage migration after MI. Our data using in situ zymography which
measures gelatinase activity (MMP-2 and MMP-9) is interesting but rather perplexing in
that we observe increased MMP activity in sham-operated animals treated with AAV9EP4 that is not significantly increased further after MI. Overall, our data indicate that
treatment with AAV9-EP4 alters the cardiac remodeling process after MI and changes in
MMP activity may be an important player in the mechanism of reduced macrophage
migration and the subsequent prevention of LV dilatation we observed with
overexpression of EP4. The secreted protein, acidic and rich in cysteines (SPARC) was
also shown to affect remodeling after MI. Schellings et al [381] reported that deletion of
SPARC increased rupture following MI and a role for this molecule in macrophage
clearance has also been postulated [382]. Our data show no effect of EP4 overexpression
on this molecule, consistent with its high expression in fibroblasts and endothelial cells
but low expression in myocytes [383].
Previously, we have described increased expression of both cytokine and
chemokine mRNA (e.g. MCP-5 and fractalkine) in the left ventricle of male EP4-KO mice
with dilated cardiomyopathy [73]. Takayama et al. [256] have shown that PGE2 potently
inhibits cytokine/chemokine secretion (MCP-1, interleukin 8, macrophage inflammatory
protein, and CxCL10) in human macrophages. Thus, inhibition of chemokine or cytokine
release may be a significant mechanism to explain how treatment with AAV9-EP4
reduces macrophage infiltration. Treatment with AAV9-EP4 also significantly prevented
increases in TNFα mRNA after MI. TNFα is a major cytokine implicated in heart failure
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and increases in TNFα have been correlated with the severity of cardiac disease although
anti-TNFα therapies have met with little clinical success [384, 385].

In addition to

alterations in TNFα, our results also show that overexpression of EP4 affects other
chemokines/cytokines. Using a mouse cytokine/chemokine array we detected a
significant reduction in MCP-1 protein levels in the left ventricle and increases in IL-10,
an anti-inflammatory cytokine, after treatment of MI hearts with AAV9-EP4.
Unfortunately, protein levels of these cytokines/chemokines were below the limits of
detection in isolated mouse cardiomyocytes treated with AAV9-EP4 or control virus, even
after stimulation with LPS. Thus, we cannot be certain if overexpression of EP4 affects
production of these factors from cardiomyocytes or if it has paracrine effects. However,
our data show that reduction of pro-inflammatory cytokines/chemokines may be one
mechanism by which over-expression of the EP4 prevents the deleterious effects of MI.
One limitation of the study is that the viral package was administered at the same
time as MI and would have better clinical relevance if it was administered post-MI.
However, this would require multiple major open-chest surgeries. Furthermore, it would
take at least 48 hours for the viral DNA to insert itself into the host genome and to
transcribe the EP4. We believe this is key to the model’s success. If EP4 is overexpressed
too early, the reduced inflammation may result in poor scar formation and result in
increased rates of cardiac rupture. Our timing is ideal in that we reduce persistent
inflammation during the inflammatory phase of cardiac remodeling and promote a
resolving, healing phase in the heart.
Conclusion
We have demonstrated for the first time that overexpression of the EP4 receptor
is protective in a mouse MI model. We have also shown that overexpression of the EP4
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receptor may prevent inflammation involved in cardiac remodeling post MI, thus
contributing to the preserved cardiac function. If our results can be applied to the human
condition, our data support therapeutic interventions that increase EP4 expression.
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CHAPTER 3 - PROSTAGLANDIN E2 AND AN EP4 RECEPTOR AGONIST INHIBIT
LPS-INDUCED MONOCYTE CHEMOTACTIC PROTEIN 5 PRODUCTION AND
SECRETION IN MOUSE CARDIAC FIBROBLASTS VIA AKT AND NF-κB
SIGNALING
(This Chapter contains previously published material. See Appendix B)
Introduction
Chemokines are a group of small (8-14 kDa) chemoattractant molecules that
regulate the trafficking of various leukocytes, mainly neutrophils, monocytes,
lymphocytes, and eosinophils to various tissues [386]. Chemokines bind to about 20
different receptors, all of which belong to the seven transmembrane G-protein-coupled
class of receptors [387]. One particular chemokine, monocyte chemoattractant protein-5
(MCP-5), is the mouse analogue to human MCP-1, and is a potent chemoattractant for
monocytes and macrophages [72]. Several studies have implicated MCP-1 in diseases
characterized by infiltrating monocytes, especially myocardial ischemia [388-390]. Far
less is known about the murine MCP-5, however.
Prostaglandin E2 (PGE2) signals through 4 distinct receptor subtypes (EP1, EP2,
EP3, and EP4) to elicit a variety of effects. EP2 and EP4 both increase cAMP levels in
the cell via adenylate cyclase activation, whereas EP3 inhibits cAMP production. EP1
increases Ca2+ levels in the cell [391, 392]. The differences in signaling of these receptors
in cardiac tissue have still not been studied in depth. Previously, our lab developed a
mouse line in which the EP4 receptor is deleted specifically in the cardiomyocytes. These
mice develop a phenotype of dilated cardiomyopathy with reduced ejection fraction with
age, as well as pockets of interstitial infiltrate within the left ventricle. Gene array data
showed that these mice have increased production of chemokine/cytokines in their left
ventricles, including CCL12 (MCP-5) [73]. Very recently, we reported that overexpression
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of the EP4 receptor improves cardiac function in a myocardial infarction (MI) model
(chapter 2). Moreover, we showed that overexpression of the EP4 receptor was
associated with an anti-inflammatory effect shown by reduced levels of MCP-1 with
increased IL-10 in the left ventricle [216]. Precisely how PGE2 exerts its anti-inflammatory
effects in the heart has not been elucidated. PGE2 signaling through its EP4 receptor,
however, has been shown to have anti-inflammatory effects in organ systems and cell
types other than the heart [256, 259, 393-396]. Specifically, PGE2-EP4 signaling has been
shown to inhibit bacterial lipopolysaccharide (LPS) signaling [396], but this result has not
been reported for isolated adult mouse cardiac fibroblasts.
Damage-associated molecular patterns (DAMPs), such as LPS, activate pattern
recognition receptors (PRRs) of the toll-like receptor (TLR) family, particularly TLR-2 and
4 [397]. Activation of TLRs characteristically leads to the transcriptional activation of
genes which encode pro-inflammatory cytokines and other mediators of inflammation by
transcription factors such as nuclear factor κB (NF-κB). Both TLR-2 and TLR-4 have
been shown to be expressed in cardiomyocytes and fibroblasts [398]. Cardiac fibroblasts
play a particularly important role in cardiac injury due to their ability to maintain the
integrity of the extracellular network. Furthermore, cardiac fibroblasts play an important
role in secreting and responding to cytokines/chemokines in response to injury [399].
In this current study, we take an in vitro approach to examine whether treatment
of cardiac fibroblasts with exogenous PGE2 affects chemokine production. We
hypothesized that PGE2 inhibits LPS-induced MCP-5 secretion in adult mouse cardiac
fibroblasts via its EP4 receptor.
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Methods
Animal Use
Male 16-20 wks. old C57Bl/6 mice used for cardiac cell isolation were from
Jackson labs. The isolation of adult ventricular fibroblasts (AVF) was previously described
by us [73]. All studies involving the use of animals were approved by the institutional
review committee at Henry Ford Hospital, in accordance with federal guidelines.
Chemicals
EP1 antagonist (SC-51089), EP2 agonist (Butaprost), EP2 antagonist (TG4-155),
EP4 agonist (CAY10598), EP4 antagonist (GW627368X), and prostaglandin E 2 were
from Cayman Chemical (Ann Arbor, MI). EP3 antagonist (L798, 106) and cardamonin
were obtained from Tocris (Minneapolis, MN). IKK inhibitor III was from Millipore Sigma
(Burlington, MA). Tri-reagent was obtained from Molecular Research Center (Cincinnati,
OH). All other drugs were obtained from Sigma Aldrich.
Treatment of Isolated Cardiac Fibroblasts
For all AVF experiments, the cells were passaged to p3 followed by serum
starvation for at least 16 hours. Time Course Experiment; cells were pre-treated with
vehicle (ethanol), PGE2 (1 μM), or the EP4 agonist (CAY10598; 1 μM) for 1 hour. After 1
hour, cells were treated with lipopolysaccharide (LPS; 10 μg/ml) for 1, 2, 4, and 24 hours.
Media were collected and snap-frozen in liquid nitrogen for ELISA analysis. Cells were
scraped in 1 ml of Tri-reagent and snap frozen for future RNA isolation and real time RTPCR. EP receptor antagonist experiment; In another set of experiments, the cells were
first pre-treated with the EP1 antagonist SC-51089 (1 µM), EP2 antagonist TG4-155 (0.5
µM), EP3 antagonist L798, 106 (1 µM), or an EP4 antagonist GW627368X (1 µM) prior
to treatment as described above for 24 hrs. In separate experiments at shorter time points
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(0, 5, 15, 30 mins), protein lysate was collected for Western blot analysis by scraping the
cells on ice with lysis buffer containing protease and phosphatase inhibitors (Roche).
Dibutyryl cAMP (db cAMP); cells were pre-treated with vehicle (DMSO), Dibutyryl cAMP
(100 μM), or the EP4 agonist (1 μM) for 1 hour. After 1 hour, cells were treated with LPS
(10 μg/ml) for 24 hours. Media were collected and snap-frozen for ELISA analysis. PI3K
Inhibitor (wortmannin and LY290042); cells were pre-treated with vehicle (DMSO and
ethanol), PGE2 (1 μM), or Wortmannin (1 μM) or LY290042 (10 µM) for 1 hour. After 1
hour, cells were treated with LPS (10 μg/ml) for 24 hours. Media were collected and snapfrozen for ELISA analysis. NF-κB inhibition (cardamonin and IKK inhibitor III); cells were
pre-treated with vehicle (ethanol), cardamonin (10 μM), or IKK inhibitor III (10 μM), for 1
hour. After 1 hour, LPS (10 μg/ml) was added to the appropriate wells for 24 hours. Media
were collected and snap-frozen for ELISA analysis and protein lysates were collected for
western blot analysis. JNK inhibitor (SP600125); cells were pre-treated with vehicle
(ethanol), or SP600125 (10 μM) for 1 hour. After 1 hour, the cells were treated with vehicle
(ethanol and DMSO), PGE2 (1 μM), or the EP4 agonist (1 μM) for 1 hour. After 1 hour,
cells were treated with LPS (10 μg/ml) for 24 hours. Media were collected and snapfrozen in liquid nitrogen for ELISA analysis. Protein lysates were collected for western
blot analysis.
MCP-5 Secretion Analyses
MCP-5 ELISA analysis of media samples was performed according to the
manufacturer’s instructions (Ray BioTech; Catalog No. ELM-MCP5). For all ELISA
experiments, data was collected as pg/ml, corrected for the amount of protein in each
sample and then presented as fold of vehicle. This kit is specific for MCP-5 and shows no
cross reactivity with a number of different cytokines/chemokines, including MCP-1. The
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limit of detection for this kit is 0.5 pg/ml.
Polymerase Chain Reaction
Measurement of MCP-5 mRNA expression was performed by real-time RT-PCR
using a SYBR green method as follows. 1 µg of DNase I-treated RNA sample was reverse
transcribed using random primers and Omniscript reverse transcriptase kit (Qiagen;
Valencia, CA). 2 µL of the reverse transcription reaction was amplified in a Roche version
2.0 lightcycler PCR machine (Roche; Indianapolis, IN) using SYBR green dye and specific
primers against MCP-5, EP1, EP2, EP3, and EP4. Primers were purchased from TIB
MolBiol (Adelphia, NJ) and Qiagen (Germantown, MD). It has been reported that
stimulation with LPS in other cell types can affect GAPDH expression [400]. In our hands,
the average GAPDH crossing points did not change with LPS stimulation, thus GAPDH
was used as a control (17.00 ± 0.22 for vehicle treated mice vs. 17.37 ± 0.38 for LPS
treated mice. p=0.796). To determine the mRNA expression of EP1, EP2, EP3, and EP4
in the fibroblasts, 2 µg of RNA was reverse transcribed in the same manner described
above. 2 µl of the reverse transcription reaction was amplified in a Bio-Rad PTC-100
thermal cycler using Taq polymerase. PCR conditions were: 94°C for 30 s, 58–62°C for
30 s, 72°C for 90 s and a final extension at 72°C for 5 min. Sequences for all primers
used are shown in Table 3.
Table 3: Primer Sequences

Gene
Sense
Anti-Sense
MCP5 5’-caagagratcaccagcagcagg-3’
5’- tgcttgaggtggttgtggaa-3’
GAPDH
5’-caaggtcatcccagagctg-3’
5’-tgtcatcatacttggcaggtt-3’
EP1
5’- atcatggtggtktcgtgcatct-3’
5’-catgggtccaggatctggtt-3’
EP2
5’-tatgctccytgcctttcac-3’
5’-ctcagtgaagtccgacaacag-3’
Qiagen, NM_011196.2
EP3
EP4
5’-gtgcagagatccagatggtca-3’
5’-atcygggtttctgctgatgtc-3’
Primers from Qiagen are proprietary and only the RefSeq number for the mRNA sequence is provided.
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MCP-5 mRNA Stability
Measurement of MCP-5 mRNA stability was determined using real time RT-PCR
(see methods 2.5). AVF were pre-treated with PGE2, EP4 agonist, or vehicle for 1 hour.
After a 1-hour pre-treatment, cells were treated with LPS (10 μg/ml) for 2 hours. Previous
experiments in our lab have determined that 2 hours is adequate to stimulate MCP-5
mRNA.

After

LPS

treatment,

AVF

were

treated

with

5,6-Dichloro-1-β-D-

ribofuranosylbenzimidazole (DRB) for 0 and 30 minutes to block transcription. The cells
were harvested in Tri-reagent and stored at -80oC for further PCR analysis.
Western Blot Analysis
Phosphorylated IκBα (p-IκBα; 1:1000), phosphorylated Akt (T308, p-Akt; 1:1000),
phosphorylated JNK (p-JNK; 1:1000), phosphorylated p44/42 (p-p44/42; 1:1000) and
phosphorylated p38 (p-p38; 1:1000) were measured by western blot using a method
previously described by us [217]. Phosphorylated IκBα, p-Akt, p-JNK, p-p44/42, and pp38 were corrected to total IκBα, Akt, JNK, p44/42 and p38 respectively. All antibodies
were from Cell Signaling (Danvers, MA). Western blot was quantified using NIH Image J
software (Bethesda, MD). Phosphorylated protein was corrected to total and then
corrected to vehicle. LPS stimulation at 15 minutes was set to 100% and the effect of
PGE2 and the EP4 agonist are presented as the percentage of LPS stimulation.
Statistical Analysis
Statistical analysis was performed by a statistician in the Department of Public
Health Sciences of Henry Ford Hospital using the statistical package SAS Version 9.4.
For all tests, a two-sample Wilcoxon test with the Fligner-Policello correction for unequal
variances was used. We also used a Hochberg’s method for multiple testing. For the
western blot analysis, a paired T-test was used. A p-value < 0.05 was considered as
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evidence of a statistically significant difference for experimental data with the p values
being two-sided.
Results
All EP Receptors are Expressed in Adult Mouse Cardiac Fibroblasts
Figure 16 shows the expression profile of the EP receptors in cultured adult mouse
cardiac fibroblasts. The mRNAs for all four of the EP receptors are expressed and this
experiment was repeated on two separate occasions using different preparations with the
same result.

Figure 16. Representative EP Receptor mRNA Expression. 2 % Agarose gel of PCR
products; product sizes (in bp) are as follows: EP1; 142, EP2; 186, EP3; 134, EP4; 139.
PGE2 and an EP4 Receptor Agonist Inhibit MCP-5 Secretion after LPS-Stimulation
To first determine the effect of PGE2 and the EP4 agonist on LPS-stimulation of
MCP-5 secretion, we performed a time-course experiment, analyzing the concentration
of MCP-5 in media at 1, 2, 4, and 24 hours after treatment with LPS (10 µg/ml). Cells
were pre-treated with PGE2 or the EP4 agonist for 1 hr prior to stimulation. On average,
the baseline MCP-5 concentration in the media was 61.23 ± 19.51 pg/ml and this rose to
1470.51 ± 163.21 pg /ml after 24 hrs of LPS treatment. All data were corrected for total
protein in the sample and presented as fold of vehicle control. After 1 or 2 hours of LPS
stimulation, there was no detectable increase in MCP-5 in the media compared with
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vehicle treated cells (0.95 ± 0.14 vs. 1.00 ± 0.0 in vehicle treated cells; p=0.423) and (1.38
± 0.23 vs. 1.00 ± 0.0 in vehicle treated cells; p=0.240), respectively. After 4 hours of LPS
treatment however, there was a significant increase in MCP-5 in the media (2.27 ± 0.42
fold vs. 1.00 ± 0.0 in vehicle treated cells; p=0.012). PGE 2 significantly reduced LPSstimulated MCP-5 (1.23 ± 0.18 vs. 2.27 ± 0.42 in LPS treated cells; p=0.005). There was
also a tendency for a decrease in LPS-stimulated MCP-5 when cells were pre-treated
with the EP4 agonist, although this data did not reach statistical significance (1.77 ± 0.24
vs. 2.27 ± 0.42 in LPS treated cells; p=0.36). Figure 17 A shows that by 24 hours, LPS
stimulation of MCP-5 remained significantly elevated (3.38 ± 0.36 vs. 1.00 ± 0.0 in vehicle
treated cells; p=0.005). At this time point, both PGE 2 and the EP4 agonist significantly
reduced MCP-5 production after LPS stimulation (1.18 ± 0.12 in PGE2 pre-treated cells
vs. 3.38 ± 0.36 in LPS treated cells; p=0.009 and 1.53 ± 0.20 in EP4 agonist pre-treated
cells vs. 3.38 ± 0.36 in LPS treated cells; p=0.009). Since PGE 2 and the EP4 agonist both

Figure 17 A: 24 Hour LPS
Stimulation of MCP-5 ELISA. AVF
were pre-treated for 1 hour with
PGE2 (1 µM) or the EP4 agonist
(EP4 ag; 1 µM) followed by
treatment with LPS (10 µg/ml) for 24
hours. All results were obtained as
pg/ml and corrected for the amount
of protein in each well. Data is
presented as fold of vehicle
treatment (set to 1.0) ± SEM. **
p<0.01 vs. vehicle, ++ p< 0.01 vs.
LPS. N=5
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reduce MCP-5 production after LPS stimulation, it suggests that the effect of PGE 2 is
mediated via the EP4 receptor. To test this, we pre-treated the cells with an EP4
antagonist (GW627368X) prior to treatment with PGE2 or the EP4 agonist and LPS for 24
hours (Figure 17 B).
Figure 17 B: MCP-5 ELISA
Analysis with GW627368X. AVF
were pre-treated for 1 hour with
the EP4 antagonist GW627368X
(GW; 1 µM). Cells were then
treated with or without PGE2 (1
µM) for 1 hour, followed by
treatment with LPS (10 µg/ml) for
24 hours.
All results were
obtained as pg/ml and corrected
for the amount of protein in each
well. Data are presented as fold
of vehicle treatment (set to 1.0) ±
SEM. *p<0.05 vs. vehicle, +
p<0.05 vs. LPS. N=6-9

Surprisingly, GW627368X did not reverse the inhibitory effect of PGE2 suggesting
some of the effects of PGE2 are through a mechanism other than the EP4 receptor
signaling pathway. However, the inhibitory effect of the EP4 agonist was significantly
attenuated with GW627368X (Figure 17 C), suggesting that the EP4 agonist is specific
and its inhibitory effects are indeed through the EP4 receptor (3.80 ± 0.22 in LPS treated
vs. 1.36 ± 0.15 in LPS + CAY10598 treated; p<0.005 and 2.97 ± 0.16 in LPS + CAY10598
+ GW627368X treated vs. 1.36 ± 0.15 in LPS + CAY10598 treated; p=0.000009).
Additionally, we pretreated the AVF with antagonists to either EP1, EP2, or EP3
receptors. Antagonism of these receptors had no effect on the ability of PGE 2 to reduce
LPS-stimulated MCP-5 secretion suggesting they are not responsible for the inhibition of
LPS-stimulated MCP-5 by PGE2 (EP1: 0.89 ± 0.08 in LPS + PGE2 vs. 0.73 ± 0.06 in LPS
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+ SC-51089 + PGE2; EP2: 0.89 ± 0.08 in LPS + PGE2 vs. 1.04 ± 0.08 in LPS + TG4-155
+ PGE2; EP3: 0.89 ± 0.08 in LPS + PGE2 vs. 0.55 ± 0.06 in LPS + L798, 106 + PGE 2).
None of the EP receptor antagonists alone affected basal MCP-5 secretion.
Figure 17 C: GW627368X Reverses EP4
Agonist. AVF were pre-treated for 1 hour
with the EP4 antagonist GW627368X (GW;
1 µM). Cells were then treated with the EP4
agonist (1 µM) for 1 hour, followed by
treatment with LPS (10 µg/ml) for 24 hours.
All results were obtained as pg/ml and
corrected for the amount of protein in each
well. Data is presented as fold of vehicle
treatment (set to 1.0) ± SEM. ***p<0.005
vs. vehicle, +++ p<0.005 vs. LPS, $$$
p<0.005 vs. LPS + EP4 agonist. N=6.

PGE2 and an EP4 Agonist Reduce LPS-Stimulated MCP-5 mRNA
Both LPS-stimulation of MCP-5 secretion and its inhibition by PGE2 and the EP4
agonist appears to take at least 4 hours to be detectable, suggesting that PGE 2 and EP4
signaling may regulate MCP-5 transcription as well as its secretion. To test this, we
performed a time-course experiment examining MCP-5 mRNA levels after 1, 2, 4, and 24
hours post LPS stimulation. We also examined the effects of PGE 2 and its EP4 receptor
agonist at these time points. Figure 17 D shows that after 1 hour of LPS stimulation,
MCP-5 mRNA increased over 4-fold compared to vehicle (4.49 ± 0.71 vs. 1.00 in vehicle
treated cells; p=0.005). Treatment with the EP4 agonist significantly blunted the response
to LPS (2.09 ± 0.82 vs. 4.49 ± 0.71 in LPS-treated cells; p=0.004). Similarly, at the same
time point, PGE2 treatment attenuated MCP-5 levels after LPS stimulation, although this
failed to reach statistical significance (2.68 ± 1.04 vs. 4.49 ± 0.71 in LPS-treated cells;
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Figure 17 D: Real Time RT-PCR of
MCP-5
mRNA
after
LPS
Stimulation. AVF were pre-treated
for 1 hour with PGE2 (1 µM) or the
EP4 agonist (1 µM) followed by
treatment with LPS (10 µg/ml) for 1
hour. All results were obtained as
fold induction and corrected to the
housekeeping gene GAPDH. Data
are presented as fold of vehicle
treatment, means ± SEM.
**
p<0.01 vs. vehicle. +++p<0.005 vs.
LPS. N=5.

p=0.186). LPS stimulation resulted in a significant elevation in MCP-5 mRNA levels
throughout all time points; however, there was no significant effect of either PGE2 or the
EP4 agonist at any other time points after 1 hr. These data suggest that EP4 receptor
activation leads to downstream signaling that quickly downregulates MCP-5 mRNA. Since
previous reports have suggested that LPS can directly affect the stability of proinflammatory chemokine/cytokine mRNA transcripts [401-403], we performed an
Figure 17 E: MCP-5 mRNA Stability.
Real time RT-PCR analysis for MCP5 mRNA stability. AVF were pretreated with PGE2 (1 µM) for 1 hour,
followed by treatment with LPS (10
µg/ml) for 2 hours. After 2 hours,
transcription was blocked using DRB
(60 µM) and the decay of MCP-5
mRNA was assessed after 30
minutes. Data are presented as fold
of LPS-stimulated MCP-5. N=6.
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experiment using the transcriptional inhibitor DRB (60 μM). Figure 17 E shows that after
30 minutes of DRB treatment, there was no effect of PGE 2 on LPS-stimulated MCP-5
mRNA (1.10 ± 0.18 vs. 1.02 ± 0.23 in LPS-stimulated cells; ns). These data suggest that
the inhibition of LPS-stimulated MCP-5 is not due to an effect on MCP-5 mRNA stability.
Inhibition of NF-κB Abolishes LPS-induced Secretion of MCP-5
It is well known that NF-κB is an important transcription factor in regulating cytokine
production [404-406]. Typically, the IκB complex sequesters NF-κB in the cytoplasm.
Upon phosphorylation by IκB Kinase (IKK), IκBα is targeted for degradation allowing NFκB p65 subunit to translocate into the nucleus to regulate transcription [404]. Therefore,
we used p-IκBα as a surrogate of NF-κB activation. To determine if NF-κB is involved in
regulating transcription of MCP-5, we pre-treated AVF with the NF-κB inhibitor,
cardamonin. Figure 18 A shows that, as expected, 24 hours of LPS stimulation
significantly increased MCP-5 production compared with vehicle treatment (9.11 ± 3.09
vs. 1.00 ± 0.0 in vehicle treated cells; p=0.003). Pre-treatment with cardamonin greatly
reduced the MCP-5 produced after LPS treatment (1.71 ± 0.41 vs. 9.11 ± 3.09 in LPS
treated cells; p=0.001). Furthermore, we confirmed the specificity of this inhibitor by
examining phosphorylation of IκBα. The western blot in Figure 18 B clearly shows that
after 24 hours of LPS + cardamonin treatment, p-IκBα is reduced compared to LPS alone.
To confirm our findings, we repeated these experiments using an IKK inhibitor (IKKi).
Similar to cardamonin, pre-treatment with the IKK inhibitor significantly reduced LPSstimulation of MCP-5, (3.49 ± 0.34 in LPS vs. 1.02 ± 0.16 in LPS + IKKi; p=0.00000001).
Together, these data suggest that NF-κB plays a major role in regulating the production
of MCP-5 in LPS-stimulated cardiac fibroblasts.
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Figure 18 A: MCP-5 ELISA Analysis
with Cardamonin.
Mouse MCP-5
ELISA analysis: AVF were pre-treated
with the NF-κB inhibitor, cardamonin
(10 µM) for 1 hour, followed by
treatment with LPS (10 µg/ml) for 24
hours. Data were obtained as pg/ml of
MCP-5, corrected to the amount of
protein in each well and presented as
fold of vehicle ± SEM. *** p<0.005 vs.
vehicle. +++ p< 0.005 vs. LPS. N=6.

Figure 18 B: Western Blot Analysis for Phosphorylated IκB with Cardamonin.
Phosphorylated IκBα and total IκBα used as a loading control.
PGE2 and an EP4 Agonist Reduce LPS Stimulation of MCP-5 by Inhibiting NF-κB
Signaling
NF-κB appears to be a major factor in regulating MCP-5 production after LPS
challenge. Furthermore, the attenuation of MCP-5 production by PGE2 and the EP4
receptor agonist only occur under LPS stimulation and not under basal conditions.
Therefore, we sought to determine at which point in the inflammatory signaling cascade
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PGE2 and/or EP4 signaling is eliciting its effects. The western blot analysis in Figure 19
shows that after 15 minutes of LPS treatment, p-IκBα was reduced with PGE2 and the

Figure 19: Western Blot Analysis of Phosphorylated IκB with PGE2 and an EP4 Agonist.
Top panel: Representative western blot analysis using antibodies against phosphorylated
IκBα. AVF were pre-treated with PGE2 (1 µM) and the EP4 agonist (1 µM) for 1 hour,
followed by treatment with LPS (10 µg/ml) for 15 minutes. Data obtained were corrected
to total IκBα. Bottom panel: LPS stimulation at 15 minutes was set to 100% and data was
calculated as a percentage of the LPS stimulation. *p<0.05, ** p<0.01 vs. LPS. N=6.
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EP4 agonist. Pretreatment of AVF with PGE2 resulted in a 45% decrease in LPSstimulated p-IκBα (55.2 ± 12.0 % vs. 100 ± 0.0 % in LPS treated cells; p<0.005). Likewise,
when the cells were pretreated with the EP4 agonist, there was a 32% decrease in LPSstimulated p-IκBα (68.5 ± 10.6 % vs. 100 ± 0.0 % in LPS treated cells; p<0.05). By 30
minutes p-IκBα remains greatly elevated with LPS treatment, however there was no
significant reduction when cells were pretreated with PGE2 or the EP4 agonist, suggesting
that their inhibition on NF-κB signaling may be a rapid signaling event, climaxing at 15
minutes (415.91 % ± 157.5 vs. 100 % ± 0.0 at 15 minutes; p=0.07).
Inhibition of MCP-5 via PGE2 and an EP4 Agonist is independent of the JNK, p38,
and p44/42 Signaling Pathways
Since LPS treatment can stimulate c-Jun N-terminal kinase (JNK) signaling,
p44/42 and p38 MAPK pathways in other cell types leading to cytokine production [407],
we examined whether these pathways played a role in AVF. Figure 20 A shows that LPS
treatment stimulates p-JNK. We observed an inhibitory effect of LPS-stimulated
phosphorylation of JNK with PGE2 and EP4 agonist treatment, although these data did
not reach statistical significance (27.3 % reduction; 72.71 ± 17.9 % in PGE2 treated vs.
100 ± 0.0 % in LPS treated cells and a 20 % reduction; 80.11 ± 22.7 % in EP4 agonist
treated vs. 100 ± 0.0 % in LPS treated cells, respectively). The stimulation of p-JNK
persisted for at least 30 minutes (141.2 ± 57.8 in LPS treated cells vs. 100 ± 0.0 % in LPS
treated cells at 15 minutes). Similarly, PGE2 and the EP4 agonist each had a 30 %
reduction on the LPS-stimulation of p-JNK with values of 70.2 ± 11.2 % and 71.32 ± 12.3
%, respectively. To examine whether the reduction in p-JNK with PGE2 and the EP4
agonist after LPS stimulation affects MCP-5 production/secretion, we treated AVF with
the JNK inhibitor, SP600125. Treatment with PGE2 and the EP4 agonist reduced LPS-
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stimulated MCP-5 production as expected (1.4 ± 0.21 in PGE 2 treated vs. 4.7 ± 0.15 in
LPS treated cells; p<0.005 and 2.2 ± 0.21 in EP4 agonist treated vs. 4.7 ± 0.15 in LPS;
p<0.005).

Figure 20 A: Representative JNK Western Blot Analysis. Top panel. Representative
western blot for phosphorylated JNK. AVF were pre-treated with PGE2 (1 µM) and the
EP4 agonist (1 µM) for 1 hour, followed by treatment with LPS (10 µg/ml) for 15 and 30
minutes. Bottom panel. LPS stimulation at 15 mins was set to 100% and data were
calculated as a percentage of the LPS stimulation at 15 mins. N=4.
However, as shown in Figure 20 B, when cells were pretreated with the JNK
inhibitor (SP600125), there was an additional inhibitory effect, greater than the effect of
PGE2 or the EP4 agonist alone (0.6 ± 0.03 in LPS + PGE 2 + SP600125 vs. 1.4 ± 0.21 in
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LPS + PGE2; p<0.005 and 0.9 ± 0.04 in LPS + EP4 + SP600125 vs. 2.2 ± 0.21 in LPS +
EP4; p<0.005). Furthermore, Figure 20 C shows that after LPS stimulation (3.6 ± 0.47 vs.
1.0 ± 0.03 in vehicle; p< 0.005), there was a slight reduction in MCP-5 production with the
JNK inhibitor alone, however these data did not reach statistical significance (2.7 ± 0.32
vs. 3.6 ± 0.47 in LPS treated cells; p=0.12). Together these data suggest that JNK
signaling may play a small role in LPS signaling. However, both PGE2 and EP4 signaling
appear to be acting through a pathway separate of JNK signaling to reduce MCP-5
production/secretion. Additionally, phosphorylation of p44/42 and p38 also increased
after LPS treatment but neither PGE2 nor the EP4 agonist had any effect (Figures 20 D
and 20 E, respectively).

Figure 20 B: MCP-5 ELISA
Analysis with JNK Inhibitor.
AVF were pre-treated with the
JNK inhibitor, SP600125 (10
µM), PGE2 (1 μM), and/or the
EP4 agonist (1 μM) for 1 hour,
followed by treatment with
LPS (10 µg/ml) for 24 hours.
Data were obtained as pg/ml
of MCP-5, corrected to the
amount of protein in each
sample and presented as fold
of vehicle ± SEM. *** p<0.005
vs. vehicle. +++ p< 0.005 vs.
LPS, $$$ p< 0.005 vs. LPS +
PGE2, &&& p< 0.005 vs. LPS
+ EP4 ag. B, N=4-6.
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Figure 20 C: MCP-5 ELISA Analysis with
JNK Inhibitor. AVF were pre-treated with
the JNK inhibitor, SP600125 (10 µM) for 1
hour, followed by treatment with LPS (10
µg/ml) for 24 hours. Data were obtained
as pg/ml of MCP-5, corrected to the
amount of protein in each sample and
presented as fold of vehicle ± SEM. ***
p<0.005 vs. vehicle. N=12-14

Figure 20 D: Representative p44/42
Western Blot Analysis. Top panel.
Representative western blot analysis
using
antibodies
against
phosphorylated p44/42. AVF were
pre-treated with PGE2 (1 µM) and the
EP4 agonist (1 µM) for 1 hour,
followed by treatment with LPS (10
µg/ml) for 15 and 30 minutes. Data
obtained were corrected to total
p44/42.
bottom
panel.
LPS
stimulation at 15 mins was set to
100% and data were calculated as a
percentage of the LPS stimulation.
N=4.
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Figure 20 E: Representative p38 Western Blot Analysis. Top panel. Representative
western blot analysis using antibodies against phosphorylated p38. AVF were pre-treated
with PGE2 (1 µM) and the EP4 agonist (1 µM) for 1 hour, followed by treatment with LPS
(10 µg/ml) for 15 and 30 minutes. Data obtained were corrected to total p38. Bottom
panel. LPS stimulation at 15 mins was set to 100% and data was calculated as a
percentage of the LPS stimulation. N=4.
Inhibition of MCP-5 via PGE2 and the EP4 Agonist is Independent of cAMP
One of the major downstream signaling pathways of the EP4 receptor is activation
of adenylate cyclase and increased cAMP production. We sought to determine if PGE2
or the EP4 agonist contributes to the reduction of LPS-induced MCP-5 production via this
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pathway. Using ELISA, we found that LPS stimulation for 24 hours increased MCP-5
secretion (Figure 21 A). Importantly, when cells were pre-treated with dibutyryl cAMP (db
cAMP), the cell permeable analogue of cAMP, there was no reduction of LPS-stimulated
MCP-5 secretion (1.95 ± 0.17 in LPS + db cAMP vs. 2.29 ± 0.20 in LPS treated cells;
p=0.190). Interestingly, db cAMP alone increased MCP-5 secretion (2.55 ± 0.35 vs. 1.00
± 0.0 in vehicle treated cells; p=0.001). These data suggest that the inhibitory effect of
the EP4 agonist is not occurring through cAMP production. Activation of the EP2 receptor
is also linked to cAMP [408]. However, Figure 21 B shows that when we treated AVF with
the EP2 agonist butaprost (500 nM), we observed no change in LPS-stimulated MCP-5
(2.89 ± 0.43 in LPS treated cells vs. 2.04 ± 0.18 in LPS + butaprost treated cells; ns). This
data suggests that the inhibitory effect of PGE2 is independent of EP2 signaling.

Figure 21 A: MCP-5 ELISA
Analysis with Dibutyryl cAMP.
AVF were pre-treated for 1 hour
with the EP4 agonist (1 µM), or
dibutyryl cAMP (db CAMP; 100
µM) followed by treatment with
LPS (10 µg/ml) for 24 hours. All
results were obtained as pg/ml
and corrected for the amount of
protein in each well. Data is
presented as fold of vehicle
treatment ± SEM. *** p<0.005 vs.
vehicle. +++ p< 0.005 vs. LPS.
N=10.
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Figure 21 B: MCP-5 ELISA Analysis with Butaprost. AVF were pre-treated for 1 hour with
the EP2 agonist butaprost (0.5 µM) followed by treatment with LPS (10 µg/ml) for 24
hours. All results were obtained as pg/ml and corrected for the amount of protein in each
well. Data is presented as fold of vehicle treatment ± SEM. *** p<0.005 vs. vehicle. N=68.
Inhibition of MCP-5 via PGE2 and an EP4 Agonist is Partly Dependent on the PI3K
Pathway
PGE2 via EP4 signaling can also activate the PI3K-Akt pathway [254]. We
therefore investigated the effects of the PI3K inhibitor wortmannin on LPS-stimulated
MCP-5 production. As expected, LPS increased MCP-5 secretion after 24 hours (Figure
22 A; 4.04 ± 0.98 in LPS treated cells vs. 1.00 ± 0.0 in vehicle treated cells; p=0.037), but
pretreatment with wortmannin did not affect the ability of either PGE 2 or the EP4 agonist
to reduce the LPS-stimulation of MCP-5 (0.96 ± 0.22 in LPS + PGE2 + wortmannin vs.
4.04 ± 0.98 in LPS treated cells; p=0.050 and 1.74 ± 0.51 in LPS + EP4+ wortmannin vs.
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4.04 ± 0.98 in LPS treated cells; p=0.019). In a separate experiment (Figure 22 B), we
show that under basal conditions wortmannin had significant effect on MCP-5 secretion
itself (0.60 ± 0.17 in wortmannin vs. 1.00 ± 0.0 in vehicle treated cells; p=0.043).
Furthermore, the treatment with wortmannin significantly reduced MCP-5 secretion after
LPS stimulation suggesting that the PI3K-Akt pathway itself plays a role in the
inflammatory response to LPS (1.45 ± 0.19 in LPS + Wortmannin vs. 2.44 ± 0.44 in LPS
treated cells; p=0.012).

Figure 22 A: MCP-5 ELISA Analysis with Wortmannin. AVF were pre-treated for 1 hour
with PGE2 (1 µM), the EP4 agonist (1 µM), or the PI3K inhibitor, wortmannin (1 µM)
followed by treatment with LPS (10 µg/ml) for 24 hours. All results were obtained as pg/ml
and corrected for the amount of protein in each well. Data is presented as fold of vehicle
treatment ± SEM. *p<0.05, *** p<0.005 vs. vehicle. + p<0.05, ++ p<0.01, +++ p< 0.005
vs. LPS. N=3.
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Figure 22 B: MCP-5 ELISA Analysis with wortmannin. AVF were pre-treated for 1 hour
with PGE2 (1 µM) or the PI3K inhibitor, wortmannin (1 µM) followed by treatment with LPS
(10 µg/ml) for 24 hours. All results were obtained as pg/ml and corrected for the amount
of protein in each well. Data are presented as fold of vehicle treatment ± SEM. ***
p<0.005 vs. vehicle. ++ p<0.01, +++ p< 0.005 vs. LPS. N=6.
To confirm our findings, we repeated this experiment using a separate PI3K
inhibitor, LY290042 (10 µM). Figure 22 C shows pre-treatment with LY290042 did not
affect the ability of PGE2 or the EP4 agonist to reduce LPS-stimulated MCP-5 (0.53 ±
0.09 in PGE2 treated vs. 2.33 ± 0.24 in LPS treated cells; p<0.005 and 0.59 ± 0.13 in EP4
agonist treated vs. 2.33 ± 0.24 in LPS treated cells; p<0.005). However, LY290042 pretreatment significantly reduced LPS-stimulated MCP-5 on its own (0.68 ± 0.13 vs. 2.33 ±
0.24 in LPS treated cells; p<0.005). To determine if PGE2 and/or the EP4 agonist is acting
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through the Akt pathway, we performed Western blot analysis of p-Akt. Figure 22 D
shows that treatment with PGE2 and the EP4 agonist had a significant reduction on LPS
stimulation of p-Akt after 15 mins (36.80 ± 4.5 % in PGE2 treated vs. 100 ± 0.0 % in LPS
treated cells; p<0.005 and 47.40 ± 6.5 in EP4 agonist treated vs. 100 ± 0.0 % in LPS
treated cells; p< 0.005 ). These data suggest that inhibition of the Akt pathway by PGE 2EP4 signaling is at least partly responsible for the reduction in LPS-stimulated MCP-5.

Figure 22 C: MCP-5 ELISA Analysis with LY290042. AVF were pre-treated for 1 hour
with PGE2 (1 µM), the EP4 agonist (1 µM), or the PI3K inhibitor, LY290042 (10 µM)
followed by treatment with LPS (10 µg/ml) for 24 hours. All results were obtained as pg/ml
and corrected for the amount of protein in each well. Data are presented as fold of vehicle
treatment ± SEM. *** p<0.005 vs. vehicle, +++ p< 0.005 vs. LPS. N=3.
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Figure 22 D: Representative AKT Western Blot Analysis. Top panel. Representative
western blot analysis using antibodies against phosphorylated Akt. AVF were pre-treated
with PGE2 (1 µM) and the EP4 agonist (1 µM) for 1 hour, followed by treatment with LPS
(10 µg/ml) for 15 and 30 minutes. Data obtained were corrected to total Akt. Bottom panel.
LPS stimulation at 15 mins was set to 100% and data was calculated as a percentage of
the LPS stimulation. ***p<0.005 vs. vehicle. N=3.
Discussion
The results of this study show, for the first time, that MCP-5 secretion induced by
treatment with LPS, can be inhibited by PGE2 and an EP4 receptor agonist in isolated
adult mouse cardiac fibroblasts. We have recently published that overexpression of the
EP4 receptor in the cardiomyocytes was protective in a model of myocardial infarction
[10]. In addition to the direct protective effects on cardiac function, we observed reduced
inflammation in the whole heart. We speculated that overexpression of EP4 in the
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cardiomyocytes may have paracrine effects mediated by the cardiac fibroblasts. Our lab
has data that show that the cardiac fibroblasts produce a much larger quantity of
chemokines than the cardiomyocytes (unpublished data). Therefore, this study may
provide some understanding of the anti-inflammatory effects we observed in the previous
publication. In the present study, we hypothesized that PGE2 inhibits LPS-induced MCP5 secretion in adult mouse cardiac fibroblasts via its EP4 receptor (summarized in
proposed scheme, Figure 23).
The results from our current study support our hypothesis, with significant
reductions in LPS-stimulated MCP-5 secretion after treatment with either PGE2 or an EP4
agonist. Treatment with an EP1, EP2 or an EP3 antagonist did not reverse the effect of
PGE2, suggesting that these receptors do not play a role in this process. Surprisingly,
treatment with the EP4 antagonist, GW627368X also did not fully reverse the effects of
PGE2, suggesting another mechanism may be involved. These unexpected data cannot
be due to sub-maximal blockade of EP4 as the EP4 antagonist reversed the effect of the
EP4 agonist and further studies are necessary to elucidate how PGE2 is acting, upstream
of p-Akt and NF-κB. Nevertheless, the fact that both PGE2 and an EP4 agonist reduce
LPS-stimulation of MCP-5 suggests some involvement of this receptor. PGE 2 has been
shown to have anti-inflammatory effects in cell types other than in the heart [11-15, 31]
and it was shown in mouse macrophages to be exclusively via EP4 signaling [32]. Ngoc
et al. examined PGE2-EP4 signaling in a rat model of experimental autoimmune
myocarditis (EAM) using an EP4 receptor agonist (EP4RAG). In vivo the authors
determined that treatment with the EP4RAG significantly reduced infiltration of CD4+, but
not CD8+ T cells in the left ventricle. Interestingly, the authors did not find a reduction in
cytokine mRNA expression in the left ventricles of EAM rats treated with the EP4RAG.
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They show however that in vitro, spleen cells treated with myosin to induce EAM exhibit
higher levels of MCP-1 in the supernatant, which is reduced with EP4RAG treatment [12].
Our study also supports an anti-inflammatory role for the EP4 receptor, in cardiac
fibroblasts, a novel finding. We also show that the transcription factor NF-κB plays an
important role in regulating MCP-5, at least in response to LPS in cardiac fibroblasts.
Furthermore, the inhibitory effect of both PGE2 and the EP4 receptor appears to be
through reduction of Akt signaling and inhibition of NF-κB translocation, determined by
reduced phosphorylation of IκBα.
The p38 and p44/42 MAPKs have been shown previously to become activated by
a wide variety of inflammatory signals [33]. Furthermore, it has been demonstrated that
LPS induces the phosphorylation of p38 in monocytes and macrophages [34, 35]. We
have been able to demonstrate in the current study that the endpoint of this signaling
cascade, NF-κB activation, is reduced with exogenous PGE 2 and EP4 agonist treatment
by using two separate and specific inhibitors of NF-κB activation (cardamonin, and IKK
inhibitor III). However, we find no evidence to support a role for either p38 or p44/42
phosphorylation in the inhibitory effects of PGE2 and the EP4 agonist on LPS-induced
MCP-5 secretion.
Evidence in the literature suggests that some chemokines and cytokines are
rapidly released upon stimulation from intracellular secretory compartments. Oynebraten
and colleagues showed that several chemokines, including MCP-1, were secreted in this
manner in human endothelial cells [36]. Additionally, Catalfamo et al. reported that the
chemokine RANTES is stored in intracellular vesicles and secreted rapidly from human
CD8+ T-cells [37]. To our knowledge, there has been no report of this mechanism in
cardiac fibroblasts. Furthermore, our data in this study would disagree with their findings.
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LPS stimulation only resulted in a significant increase in MCP-5 after 4 hours of treatment.
Moreover, we observed changes in MCP-5 mRNA after 1 hr. of LPS stimulation,
suggesting transcription is necessary. Evidence also suggests several cytokines are
regulated at the post transcriptional level [38, 39]. However, we have shown in this study
that the stability of the MCP-5 mRNA is not altered with exogenous PGE2 treatment
combined with LPS treatment. Together, these data would suggest that it is not a rapid
release of MCP-5 via secretory vesicles. Instead, the data suggest that transcription of
MCP-5 needs to take place.
cAMP is a well-known second messenger in the EP2 and EP4 signaling cascade
[29]. Largo et al. showed that in human synovial fibroblasts, PGE 2 reduces MCP-1
production after IL-1β stimulation via its EP4 receptor [15]. Importantly, they show that
this was due to production of cAMP, since the inhibitory effect on MCP-1 was reversed
using a cAMP inhibitor. This is in contrast to our current data, which show that treatment
with dibutyryl cAMP alone actually stimulated the production of MCP-5 significantly. Also,
pre-treatment of the AVF with butaprost, the EP2 agonist, had no effect on LPSstimulated MCP-5. Furthermore, the combination of LPS and dibutyryl cAMP had no
inhibitory effect on MCP-5 production. Another study conducted by Takayama et al.
utilized human macrophages and they showed that PGE2 inhibited the production of
chemokines via the EP4 receptor after LPS stimulation [14]. Furthermore, in agreement
with our data, they showed that this was independent of cAMP-PKA signaling, although
the exact mechanism was unclear. Therefore, our current study may shed light on the
mechanism by showing the involvement of reduced NF-κB activation. Minami and
colleagues [40] showed that in LPS stimulated RAW264.7 cells, forced expression of an
EP4 receptor-associated protein mitigated the pro-inflammatory response. Specifically,
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they showed that the EP4 receptor-associated protein resulted in reduced NF-κB
activation by directly interacting with the p105 subunit. This study differs from ours in that
we show treatment with exogenous PGE2 or EP4 agonist, reduces phosphorylated Akt
and IκBα.
Studies in tissues other than the heart have also implicated the PI3K-Akt signaling
pathway in playing an important role in regulating LPS-induced inflammation [41, 42]. Our
data agrees with the literature in that treatment with the PI3K inhibitors, wortmannin or
LY290042, reduced LPS-stimulated MCP-5. Furthermore, inhibition of the PI3K pathway
did not affect the ability of PGE2 or the EP4 agonist to reduce LPS-stimulated MCP-5, nor
was there an additional inhibitory effect, suggesting they are signaling through the same
pathway. Western blot analysis of p-Akt revealed that PGE2 and the EP4 agonist had a
significant reduction of LPS-stimulated p-Akt after 15 mins. In contrast, treatment with the
JNK inhibitor, SP600125, in combination with both PGE2 and the EP4 agonist resulted in
a further reduction in LPS-stimulated MCP-5. These data suggest that the JNK signaling
pathway plays some role in regulating MCP-5 production. However, the inhibitory effect
of PGE2 and the EP4 agonist is occurring via a different pathway, presumably through
Akt signaling.
Clinically, the use of an EP4 receptor agonist in the treatment of heart failure has
merit as being a potential therapy. The use of an EP4 agonist has been tested clinically
in healthy dogs [43, 44] and in humans [45] and was determined safe to use. However,
the use of an EP4 agonist in humans under heart failure conditions has not yet been
examined. We speculate that the use of an EP4 agonist in heart failure conditions may
prove beneficial due to its anti-inflammatory properties and ability to reduce
cytokines/chemokine production, potentially reducing chronic cardiac remodeling via
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effects on fibroblasts. The process of cardiac remodeling post MI is of critical importance
to the survival of patients clinically [46]. Cytokines and chemokines are produced rapidly
following myocardial ischemia [47, 48] and not only have direct effects on cardiac
contractility [49], but also have major effects chronically on extracellular matrix remodeling
[50], integrin expression [51], and angiogenesis [52]. Since cardiac fibroblasts are the
most abundant non-cardiomyocyte population in the heart, they contribute substantially
to the activation of the inflammation cascade following MI [53]. Evidence from clinical
studies suggest that patients with chronically elevated serum inflammatory biomarkers,
like MCP-1, have increased mortality even without new coronary events [54]. Therefore,
our study may help shed light on the mechanism of regulating chemokine production in
the cardiac fibroblasts via PGE2-EP4 signaling to mitigate adverse cardiac remodeling in
clinical situations.

Figure 23: Scheme Depicting the Proposed Pathway of PGE2 and EP4 Inhibition on LPSinduced MCP-5. Also shown are the various agonists and antagonists used in the study.
Filled lines indicated activation, dashed lines indicate inhibition, dashed/dotted lines
indicate inhibition via an unknown pathway.

98
CHAPTER 4 – CONDITIONED MEDIA FROM DAMAGED CARDIOMYOCYTES
PROMOTES MCP-5-DEPENDENT MACROPHAGE MIGRATION
Introduction
Our lab has previously published that mice lacking the EP4 receptor in the
cardiomyocytes (CM-EP4 KO) develop heart failure with a phenotype of dilated
cardiomyopathy, reduced cardiac function after MI, and increased cellular infiltrate. We
also reported that these mice have increased levels of cytokines/chemokines in their left
ventricles, including MCP-5 [73]. MCP-5 is a potent chemoattractor for monocytes and
macrophages. Although the increased cellular infiltrate in the CM-EP4 KO is of unknown
origin, we hypothesize that the increased MCP-5 among other cytokines and chemokines,
is responsible for this increase. In this chapter, we tested the hypothesis that MCP-5 is
responsible for increased macrophage migration in the CM-EP4 KO heart. This
hypothesis was tested in vitro using the Boyden migration assay.
Methods
Animal Use
Male C57BL/6, CM-EP4 KO, and EP4 WT mouse cardiomyocytes were isolated
as previously described [73]. All studies involving the use of animals were approved by
the animal care and use committee (IACUC) at Henry Ford Hospital, in accordance with
Federal Guidelines.
Cardiomyocyte Treatment
To generate conditioned media from the CM-EP4 KO mice, cardiomyocytes were
isolated from 31-36 wk. old mice, plated for 1 hour in MEM containing serum (10 % FBS)
and then starved in serum free media (MEM) for an additional hour. As a control,
cardiomyocytes from age-matched EP4 WT littermates were plated and incubated for the
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same amount of time. For all plates, media were collected after 1 hour of serum starvation,
snap frozen in liquid nitrogen, and stored at -80oC until future macrophage migration
assay analysis. In another set of treatments, cardiomyocytes were isolated from CM-EP4
KO and EP4 WT littermate mice and were then treated with or without 100 µM H2O2 for
90 minutes. The media were collected from all plates, snap frozen in liquid nitrogen, and
stored at -80oC until future macrophage migration assay analysis.
In a third set of experiments, cardiomyocytes were isolated from CM-EP4 KO mice
and plated for 1 hour in MEM containing serum, prior to being serum starved for 1 hour.
After 1 hour of serum starvation, media were collected and snap frozen in liquid nitrogen
and stored at -80oC. The media were thawed and incubated with either an IgG control, or
a neutralizing antibody to MCP-5 (R&D Systems, Cat No. MAB428) at a concentration of
17.5 ng/ml. This concentration is 25 times more concentrated than what is needed to
specifically neutralize MCP-5 at the amount secreted by cardiomyocytes. Anti MCP-5 or
the IgG control was incubated for 30 minutes at 37oC with the media samples. The media
were then used in a macrophage migration assay.
In a fourth set of experiments to address the effect of H2O2 alone, cardiomyocytes
were isolated from 10-12 wk. old C57BL/6 mice, plated for 1 hour, then serum starved for
an additional hour. As a control, media were placed in dishes in the absence of cells.
Next, all dishes were treated with or without 100 µM H2O2. After 90 minutes, media were
collected and snap frozen in liquid nitrogen and stored at -80oC until macrophage
migration assay was performed.
Macrophage Migration Assay
For macrophage migration experiments, the porous membrane of a Boyden
migration chamber (Figure 24) was first coated with 0.5 % BSA in PBS overnight. On the
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day of the experiment, BSA was removed and RAW 264.7 macrophages (0.3-0.6 x 106
cells) were plated on the membranes of a 24-well Boyden chamber plate. Next, either
conditioned or non-conditioned media were plated in the bottom of each well and the
macrophages were allowed to migrate for 4 hours at 37oC, 5 % CO2, before being stained
and imaged. Membranes were stained by first rinsing the wells with cold PBS and using
a sterile cotton tip to remove any non-migrating cells from the top of the membrane. Next,
the cells were fixed by adding methanol to the top and bottom chambers and incubating
at room temperature for 10 minutes. Membranes were then rinsed with water and stained
with hematoxylin for 6 minutes at room temperature. Membranes were once again rinsed
with water and then the chambers were filled with water and visualized on an inverted
light microscope under the 20X objective. The number of migrating macrophages from
four different fields per membrane was counted by an observer who was blind to the
treatment protocol.

Figure 24: Scheme Depicting the Boyden Macrophage Migration Plate Setup. The
Boyden chamber is inserted inside a well filled with conditioned or non-conditioned media.
RAW 264.7 macrophages are plated on top of the porous membrane containing 0.5 µm
pores and allowed to migrate for 4 hours. After, the membrane is rinsed, removed, and
stained with hematoxylin to visualize the migrating macrophages. Image adapted from
CliniSciences website [409].
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Results
Damaged Cardiomyocytes Promote Macrophage Migration
Since the CM-EP4 KO mice have increased cytokines/chemokines, like MCP-5, in
their left ventricles, we investigated the effect of media taken from these cardiomyocytes
under basal and damaged conditions on macrophage migration using the Boyden
migration assay. Figure 25 shows a representative image of the stained porous
membrane. Arrows indicate examples of cells that were migrating and included in

Figure 25: Representative Image of Migrated Macrophages. 20X image of a Boyden
migration membrane. Empty white circles are the 0.5 µm pores within the membrane.
The black arrows are a representation of some of the pores positive with hematoxylin
stain where macrophages are migrating through. The number of migrating macrophages
were counted by a blinded observer from four different fields per membrane and
averaged.
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analysis. Figure 26 shows that the conditioned media taken from EP4 WT cardiomyocytes
treated with H2O2 resulted in a significant increase in the number of macrophages that
migrated (162.7 ± 14.1 in EP4 WT vs. 240.2 ± 21.9 in EP4 WT + H 2O2; p<0.01).
Conditioned media taken from the CM-EP4 KO cardiomyocytes significantly increased
macrophage migration under baseline conditions suggesting that these cardiomyocytes
are already damaged/injured and releasing some factor(s) that promote the migration of
macrophages (162.7 ± 14.1 in EP4 WT vs. 204.8 ± 9.2 in CM-EP4 KO; p<0.05).
Interestingly, when these cells were treated with H2O2, the increase in macrophage
migration did not exceed that of the wild type mice (240.2 ± 21.9 in EP4 WT + H2O2 vs.
204.8 ± 9.2 in CM-EP4 KO; p=ns).

Figure 26: Macrophage Migration with CM-EP4 KO Cardiomyocytes. Macrophages were
plated on a Boyden migration chamber and allowed to migrate for 4 hours through the
porous membrane with either conditioned (media from H2O2 cells) or non-conditioned
media plated in the bottom of the chamber. The number of macrophages that migrated
were counted using a 20X objective on an inverted light microscope. * p<0.05, ** p<0.01
vs. EP4 WT. ++ p <0.01 vs. EP4 KO. N=4.
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Macrophage Migration Due to Damaged Cardiomyocytes Appears to Be MCP-5
Dependent
MCP-5 is a potent chemoattractor for monocytes and macrophages. Since MCP5 was significantly upregulated in the CM-EP4 KO mouse hearts, we investigated if MCP5 was responsible for the increase in macrophage migration that was observed under
basal conditions using CM-EP4 KO conditioned media. To test this, conditioned media
from CM-EP4 KO cardiomyocytes were incubated in the presence or absence of a
neutralizing antibody to MCP-5. These media were then used in a macrophage migration
experiment. Figure 27 shows that there was a substantial reduction in the number of
macrophages migrated when the media were treated with the neutralizing antibody (313.3
± 72.1 in IgG treated media vs. 187.2 ± 46.7 in anti MCP-5 treated media; p<0.05). These
data indicate that MCP-5 is an important factor released from the CM-EP4 KO

Figure 27: Macrophage Migration with
MCP-5
Neutralizing
Antibody.
Conditioned media were obtained
from CM-EP4 KO mice and incubated
with either IgG control or 17.5 ng/ml of
a neutralizing antibody to MCP-5 (anti
MCP-5). Macrophages were allowed
to migrate for 4 hours. The number of
macrophages that migrated were
counted using a 20X objective on an
inverted light microscope. * p<0.05 vs.
IgG control. N=5.
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H2O2 Alone Significantly Stimulates Macrophage Migration
As a control experiment, we investigated the chemoattractant effect of H2O2 alone
on macrophage migration. To test this, cardiomyocytes from C57BL/6 mice were treated
with or without H2O2 as already described (conditioned). As a control, cell culture dishes
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lacking any plated cells were treated with or without H2O2 (non-conditioned). The media
were then collected and used in a macrophage migration assay. Figure 28 shows that in
the non-conditioned media, treatment with H2O2 significantly increased macrophage
migration in the absence of any cellular stimuli (186.6 ± 11.8 in vehicle vs. 265.9 ± 4.0 in
H2O2 treated; p<0.005). However, this increase was less than the increase observed in
the conditioned media group, confirming a role for released cellular factors, like MCP-5

Figure 28: Macrophage migration
with H2O2 Treatment. Media taken
from cardiomyocytes treated with
or without H2O2 (conditioned
media), or media taken from media
alone treated with or without H2O2
were used in a macrophage
migration assay. Macrophages
were allowed to migrate for 4
hours.
The
number
of
macrophages that migrated was
counted using a 20X objective on
an inverted light microscope. ***
p<0.005 vs. respective vehicle
control. N=3.
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Discussion
MCP-1 has been shown to play a major role in inflammation in cardiovascular
diseases, by increasing in the myocardium during the early phase of MI for example [410,
411]. MCP-1 deletion or inhibition of MCP-1 prevents adverse post-MI remodeling [390]
and MCP-1 levels are increased in patients with HF [412].
The presence of oxidative stress in all phases of heart failure has been shown in
animals and humans [413-415]. Reactive oxygen species (ROS) like H2O2 can be
produced in the heart by several different sources: NADPH oxidases, xanthine oxidase,
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lipoxygenases, cyclooxygenases, peroxidase, mitochondrial respiration, cytochrome P450, nitric oxide synthase. ROS is detrimental by acting directly with lipids within
membranes, proteins, and nucleic acids, resulting in death via apoptosis and necrosis.
Additionally, ROS can trigger inflammation by acting as a signaling molecule.
MCP-5, the murine analogue of human MCP-1 is a potent chemoattractant for
monocytes and macrophages. We hypothesized that the increased expression of MCP5 in the CM-EP4 KO mouse heart was responsible for the increased interstitial cellular
infiltrate. Although the work in this chapter is in vitro, it highlights the importance of MCP5 as a chemoattractant molecule. Treatment with a neutralizing antibody to MCP-5
reduced macrophage migration by 40 % in CM-EP4 KO cells under baseline conditions.
This result was surprising, although reproducible. It was not expected that a neutralizing
antibody against one chemokine would have such a large effect. Nonetheless, the CMEP4 KO cardiomyocytes appear to be releasing a factor(s) that increase macrophage
migration even under basal conditions. Furthermore, treatment with H2O2 on these cells
only increased macrophage migration to the same magnitude as wild type, suggesting
the CM-EP4 KO cells are already damaged, potentially caused by oxidative stress.
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CHAPTER 5 – THE DELETERIOUS ROLE OF THE PROSTAGLANDIN E2 EP3
RECEPTOR IN ANG II HYPERTENSION
Introduction
Angiotensin II
Angiotensin II (Ang II) is the major effector peptide of the renin-angiotensin system
(RAS) [416]. Ang II plays an important role in both blood pressure regulation and
inflammation, along with other functions (i.e., regulating cell growth and apoptosis,
extracellular matrix deposition, cell migration, vascular motor tone.). As shown in Figures
3 and 4, Ang II is released from circulating hepatic-derived angiotensinogen via the
actions of renal-derived renin and ACE [38-40]. Ang II is a potent vasoconstrictor, causing
an increase in blood pressure, and vasculature remodeling in chronic hypertension (HTN)
[417]. Ang II also promotes increased vascular permeability leading to increased
inflammatory processes [305, 418, 419]. The various actions of Ang II are mediated by
specific intracellular signaling pathways downstream of Ang II binding to its surface
receptors. In mammals, Ang II binds to two G protein-coupled receptors; AT1 and AT2
[420, 421]. The AT1 receptor typically activates phospholipase C through the Gq protein.
AT1 is highly expressed in smooth muscle cells, while AT 2 receptors are present in the
kidneys, pancreas, heart, adrenals, brain, and vasculature [62, 63, 422]. Both receptors
signal via complex intracellular signaling cascades, although, it is the consensus that AT 2
antagonizes the effects of AT1 [55, 423].
Angiotensin II in Cardiovascular Disease
Ang II plays a critical role in cardiovascular disease [48]. It has been shown that
Ang II promotes pathological cardiac hypertrophy in both neonatal rat cardiomyocytes
[151, 424-426] and in adult cardiomyocytes [50, 427, 428]. Cardiomyocytes express both
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AT1 and AT2 receptors, although there is an abundance of evidence to support that Ang
II primarily signals through AT1 in the cardiomyocytes [429, 430]. Ang II can also act on
cardiac fibroblasts in the heart, increasing extracellular matrix proteins and collagen
deposition; an important factor in pathological left ventricle remodeling. This effect of Ang
II is also driven by activation of AT1 receptors, as AT2 receptors are undetectable in both
neonatal and adult rat cardiac fibroblasts [431, 432].
Inflammation and Oxidative Stress in ANG II HTN
In recent years, links between the immune system and hypertension have been
described [433, 434]. In various cell types and tissues, Ang II can directly activate immune
cells (i.e., chemotaxis and differentiation) [435], promote the transcription of proinflammatory mediators (i.e. chemokines and cytokines) [312, 418], and activate proinflammatory signaling pathways (i.e. NF-κB and MAPK) [321, 322]. It has been reported
that Ang II promotes the production of ROS through stimulation of NADPH oxidase, via
signaling through the AT1 receptor [436, 437]. This increase in oxidative stress promotes
further endothelial dysfunction and vascular inflammation and contributes to increased
activity of transcription factors like NF-κB combined with increases in chemokines,
cytokines, and adhesion molecules [52, 438].
Prostaglandin E2
Prostaglandin E2 (PGE2) is produced by three known prostaglandin E synthase
isoforms; a cytosolic form (cPGES) and two microsomal forms (mPGES-1 and mPGES2), which are membrane bound. PGE2 signals through 4 distinct G-protein coupled
receptor sub-types (EP1, EP2, EP3 and EP4) to produce a variety of physiological
and pathological effects. EP2 and EP4 increase cAMP levels in the cell via activation of
adenylate cyclase, whereas EP3 inhibits cAMP production, and EP1 increases
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Ca2+ levels in the cell. However, the cardiac effects of these receptors have not been fully
elucidated. We have previously published that mPGES-1 null mice were more susceptible
to the deleterious effects of chronic Ang II infusion on the heart [218], suggesting a
cardioprotective role for PGE2. Also, we previously published that PGE2 via its EP3
receptor could reduce contractility of isolated myocytes and in the whole heart by
mechanisms that appeared to involve decreased phospholamban phosphorylation [217].
Thus, we hypothesize that the relative abundance of EP3 and EP4 receptors is a crucial
determinant of end organ damage in the diseased heart. Furthermore, we hypothesize
that overexpression of EP3 is detrimental to cardiac function and promotes inflammation,
while inhibition of the EP3 receptor is protective in an Ang II HTN model.
Methods
Animal Use
For experimental protocols 1 and 3 (experimental protocol section below), male
10-12 wks. old C57Bl/6 mice were purchased from Jackson labs. For protocol 2, male
EP3 transgenic (Tg) and EP3 WT mice were kindly provided to the Harding Lab from Dr.
Hohlfield at the University of Dusseldorf in Germany. All animal experiments were
approved by the Henry Ford Health System Institutional Animal Care and Use Committee
in accordance with federal guidelines.
Experimental Protocol
1.

Effect of an EP3 agonist on Ang II HTN: Male 10-12 weeks old C57BL/6 were
treated with either vehicle (0.01 M acetic acid in 0.9 % NaCl) or Ang II (1.4 mg x
kg-1 x day-1) for a period of 2 weeks. Additionally, mice were treated with either
vehicle (ethanol diluted in 0.9 % NaCl) or an EP3 agonist (sulprostone; 80
µg/kg/day i.p.) daily. The dose of sulprostone was chosen based on Ki = 0.35 nM
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for human recombinant EP3.
2.

Effect of EP3 overexpression on Ang II HTN: Male 10-12 weeks old EP3 Tg mice
overexpressing EP3 in the cardiomyocytes and their wild type littermates (EP3
WT) were treated with either vehicle (0.01 M acetic acid in 0.9 % NaCl) or Ang II
(1.4 mg x kg-1 x day-1) for a period of 2 weeks.

3.

Effect of an EP3 antagonist on Ang II HTN and Isoproterenol model: Male 10-12
weeks old C57BL/6 mice were treated with either vehicle or Ang II (1.4 mg x kg-1
x day-1) for a period of 2 weeks. Additionally, mice were treated with either vehicle
(ethanol diluted in 0.9 % NaCl) or an EP3 antagonist (L798, 106; 40 µg/kg/day i.p.)
daily. The dose of L798, 106 was chosen based on Ki = 0.3 nM for EP3 and 916
nM for EP4. In separate experiments mice received 10 days of isoproterenol
infusion (30 mg x kg-1 x day-1) or vehicle (0.9 % NaCl). Mice were also treated with
either vehicle or an EP3 antagonist (L798, 106; 40 µg/kg/day i.p.) daily or the EP3
antagonist (L798, 106; 40 µg/kg/day).
For all experiments, echocardiography was performed on conscious animals

before surgery and at the end of the study. Blood pressure was monitored on a weekly
basis to ensure that all animals receiving Ang II exhibited the expected increase in systolic
blood pressure. At the end of the study, animals were anesthetized with pentobarbital
sodium (100 mg/kg i.p.), and the heart was injected with 15% potassium chloride, causing
arrest in diastole. The heart was excised and washed thoroughly in ice-cold Hanks
Buffered Salt Solution, followed by dissection of the atria and right ventricle. If hearts were
used for RNA isolation and PCR, they were stored in Trireagent (Molecular Research
Center, Cincinnati, OH) at −80°C. For histological analysis, hearts were frozen in OCT
media prechilled in isopentane and stored at −80°C. For protein extraction, pieces of heart
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were snap-frozen in liquid N2 and stored at −80°C.
Blood Pressure Measurements
Systolic blood pressure was measured on a weekly basis using the tail cuff
method. Pressure was obtained using a MC 4000 blood pressure analysis system for
mice (Hatteras Instruments, Cary, NC). Briefly, mice were trained for at least 1 week
before analysis. They were maintained at 38–40°C and subjected to 10 cycles of blood
pressure analysis. At least seven good readings in a cycle of 10 measurements were
needed to accept the measurements. In addition, a minimum systolic value of >75 mmHg
was implemented as an exclusion criterion.
Echocardiography
Echocardiography was performed on conscious animals before surgery and at 2
weeks post-infusion. The cardiac function of all mice was assessed by echocardiography
using an Acuson 256 system (Mountain View, CA) with a 15-MHz linear transducer, as
reported previously [219, 267]. All echocardiography assessment was performed on
conscious mice. Diastolic measurements were made at the maximum left ventricle cavity
dimension, whereas systolic parameters were measured during maximum anterior motion
of the posterior wall. All echocardiography was performed by the same investigator who
was blinded to the genotype. Additionally, all mice were trained for 2-3 days prior to
assessment.
Implantation of Osmotic Mini Pumps
Osmotic mini pumps contained Ang II, isoproterenol, or vehicle solution. Ang II was
dissolved in 0.01 M acetic acid diluted in 0.9 % NaCl saline and given at a dose of 1.4 mg
x kg-1 x day-1 s.c. [218]. Control mice for these experiments received vehicle (0.01 M
acetic acid diluted in physiological 0.9 % saline). Isoproterenol was dissolved in 0.9 %
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NaCl and administered at a dose of 30 mg x kg-1 x day-1 s.c. Control mice for the
isoproterenol experiments received 0.9 % NaCl. Mice at 10–12 weeks of age were
anesthetized with sodium pentobarbital (10 mg/kg), and osmotic minipumps were
implanted under the skin. Mice were allowed to recover on a heated pad followed by
administration of buprenorphine as an analgesic (0.05 mg/kg).
Histology
Mouse hearts were harvested and sectioned transversely into three slices from
apex to base (sections A–C). The sections were frozen in pre-chilled isopentane and
stored at −80°C for determination of interstitial collagen fraction and myocyte crosssectional area (MCSA). For MCSA, sections of the heart were double-stained with
fluorescein-labeled peanut agglutinin to delineate the myocytes and rhodamine-labeled
Griffonia simplicifolia lectin I to outline the capillaries. Four radially oriented microscope
fields were selected from each section and photographed under the 20 × objective. MCSA
was measured by computer-based planimetry (NIH Image J) and averaged across all four
fields of the sections. Photographs of five randomly chosen fields per section were taken
under the ×20 objective, and the percentage of collagen staining per field was measured
using Image J software. The mean percentage was then calculated for each animal. All
assessments were performed by observers that were blinded to animal identification and
treatment groups.
Myocyte Cross Sectional Area (MCSA)
This methodology is described in detail on pg. 38 of this dissertation. Briefly, frozen
left ventricle sections were stained with fluorescein-labeled peanut agglutinin to delineate
the myocytes. Four radially orientated microscopic fields were obtained under 20X
objective. The size of the myocytes was averaged across fields. All image analysis was
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performed by a blinded observer.
Immunohistochemistry of Macrophages and T Cells
The number of macrophages and T cells were assessed using CD68+ staining (rat
anti-CD68+ antibody, BioRad) and CD3+ staining (rabbit-anti CD3+ antibody, Abcam)
respectively, on frozen heart sections as we previously described [216]. Briefly, frozen
sections were fixed in acetone for 10 min, followed by incubation with fresh 0.3%
hydrogen peroxide for 30 min. Sections were then blocked in 5% centrifuged milk in TBS
and incubated with either anti-CD68+ or anti-CD3+ overnight at 4 °C. Biotinylated
secondary antibodies were placed onto sections for 1 h at room temperature. Sections
were then incubated with horseradish peroxidase reagent for 40 min at room temperature
and then visualized by AEC single solution (Vector laboratories; Burlingame, CA). Slides
were rinsed in tap water and then counterstained with Harris' hematoxylin solution for
1 min, then rinsed again in tap water and mounted onto slides using Aquamount (Lerner
laboratories). Negative controls consisted of sections incubated in the absence of primary
antibody. Photographs of four randomly-chosen fields per section were taken under the
multiple objectives and the number of positively-stained cells were counted by a blinded
observer. The number of cells per mm2 was measured by a blinded observer using Image
J software
Real time RT-PCR
Measurement of MCP-5 mRNA expression was performed by real-time RT-PCR
using a SYBR green method as follows. 2 µg of DNase I-treated RNA sample was reverse
transcribed using random primers and Omniscript reverse transcriptase kit (Qiagen). 2 µL
of the reverse transcription reaction was amplified in a Roche version 2.0 light cycler PCR
machine (Roche; Indianapolis, IN) using SYBR green dye and specific primers against
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MCP-5, IL-1β, TNF-α, IL-10, and Arg-1 were used. Primer sequences are in Table 4.
Table 4: Primer Sequences

Gene
Sense
Anti-Sense
MCP-5 5'-caagagratcaccagcagcagg-3ʹ
5ʹ- tgcttgaggtggttgtggaa-3ʹ
GAPDH
5ʹ-caaggtcatcccagagctg-3ʹ
5ʹ-tgtcatcatacttggcaggtt-3ʹ
Qiagen, NM_008361
IL-1β
Qiagen, NM_013693.3
TNF-α
IL-10
5ʹ-gctgcctgctcttactgact-3ʹ
5ʹ-ctgggaagtgggtgcagtta-3ʹ
5ʹ-gaacacggcagtggctttaac-3ʹ
5ʹ-tgcttagctctgtctgctttgc-3ʹ
Arg-1

.

Primers from Qiagen are proprietary and only the Refseq number is provided.

Western Blot Analysis
RhoA (1:1000), RhoB (1:1000), Nox2 (1:1000), and GAPDH (1:2000) were
measured by western blot using a method previously described by us [217]. All results
were corrected to GAPDH and expressed as fold of vehicle or EP3 WT. All antibodies
were from Cell Signaling (Danvers, MA).
Chemicals
EP3 agonist (Sulprostone) and prostaglandin E2 were from Cayman Chemical
(Ann Arbor, MI). EP3 antagonist (L798, 106) was from Tocris Bioscience (Minneapolis,
MN). Angiotensin II was from Bachem (Torrance, CA). Tri-reagent was from Molecular
Research Center. All other compounds were obtained from Sigma Aldrich.
Statistical Analysis
Statistical analysis was performed by a statistician in the Department of Public
Health Sciences of Henry Ford Hospital using the statistical package SAS Version 9.4.
For all tests, a two-sample Wilcoxon test with the Fligner-Policello correction for unequal
variances was used. We also used a Hochberg’s method for multiple testing. A p-value
<0.05 was considered as evidence of a statistically significant difference for experimental
data with the p values being two-sided.
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Results
Expression of the EP3 Receptor Increases after Ang II Infusion
We have previously shown that mRNA expression of the EP3 receptor increases
in the infarcted heart [217] and leads to reduced cardiac function. To determine
expression levels of the EP4 and EP3 receptors in the left ventricle and to examine
whether EP3 receptor expression increases in the Ang II HTN model, we implanted
osmotic mini-pumps containing either vehicle or Ang II for 2 weeks. Figure 29 shows the
expression of both receptors for both time points. Figure 29 shows that after 2 weeks, the
expression of EP3 increased 2.5-fold compared to vehicle infused animals (1.02 ± 0.13
in vehicle treated vs. 2.59 ± 0.63 in Ang II treated mice; p<0.05), while expression of the
EP4 receptor was unchanged (1.01 ± 0.10 in vehicle treated vs. 0.96 ± 0.11 in Ang II
infused mice; ns). In additional studies, we sought to examine whether the changes in
EP3 expression were occurring in cardiomyocytes or fibroblasts, the two major cell types
of the heart. We infused Ang II or vehicle control for 2 weeks and then isolated
cardiomyocytes (AVM) and fibroblasts (AVF) from each animal simultaneously. Real time
RT-PCR was used to determine EP3 and EP4 mRNA expression. Figure 29 shows that
EP3 mRNA expression increases approximately 5-fold in the AVM (5.14 ± 1.52 in Ang II
vs. 1.20 ± 0.46 in vehicle treated; p<0.05) while it increases only 25 % in the fibroblasts
(1.25 ± 0.05 in Ang II vs. 1.00 ± 0.07; p<0.05). There was no significant increase in EP4
in the AVM (2.08 ± 0.92 in Ang II vs. 1.08 ± 0.28 in vehicle treated; ns), however EP4
significantly increased in the fibroblasts in response to Ang II (1.80 ± 0.05 in Ang II vs.
1.01 ± 0.09 in vehicle; p<0.005).
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Figure 29: EP3 and EP4 Expression in AVM and AVF. Top: Real time RT-PCR analysis
of EP3 and EP4 mRNA expression in left ventricles after 2 weeks of vehicle (black bars)
or Ang II (blue bars) infusion (1.4 mg x kg-1 x day-1) via osmotic mini pumps. *p<0.05 vs.
Vehicle infused mice. N=3/group. Bottom: Real time RT-PCR analysis of EP3 (left) and
EP4 (right) mRNA expression in adult cardiomyocytes (AVM) or adult cardiac fibroblasts
(AVF) after 2 weeks of vehicle (white bars) or Ang II (black bars) infusion (1.4 mg x kg-1
x day-1).
EP3 Agonist Sulprostone Exacerbates Cardiac Dysfunction in Ang II Hypertension
Since EP3 receptor mRNA is increased in the left ventricle of mice with
hypertension, we hypothesized that treatment with the EP3 agonist sulprostone would
reduce cardiac function after Ang II infusion. The results in Figure 30 show that there
were significant differences in cardiac function measured by echocardiography in the
conscious mice after treatment with Ang II. There was no significant difference between
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vehicle
treated and Ang II treated mice on shortening fraction, a measure of contractility (56.54 ±
0.82 % in vehicle vs. 61.28 ± 1.82 % in Ang II infused mice; ns). However, there was a
reduction in shortening fraction when the mice received daily injections of sulprostone in
combination with Ang II infusion (56.71 ± 0.90 % in Ang II + sulprostone vs. 61.28 ± 1.82
% in Ang II infused mice; p<0.05). There was a trend for a reduction in ejection fraction,

Figure 30: Echocardiography with Sulprostone Treatment. Cardiac function assessed by
echocardiography in conscious mice 2 weeks after vehicle or Ang II (1.4 mg x kg-1 x day1) ± daily injections of Sulprostone (40 µg x kg-1 x day-1) or diluted ethanol vehicle. *p<0.05
vs. Ang II. N=4-5. LVDs - Left ventricular dimension at systole, LVDd-Left ventricular
dimension at diastole.
although this failed to reach statistical significance (71.75 ± 1.25 % in Ang II + sulprostone
vs. 75.27 ± 1.28 % in Ang II; p=0.093). Additionally, we observed an increase in left
ventricle dimension in systole with sulprostone treatment (1.05 ± 0.06 mm in Ang II +
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sulprostone vs. 0.84 ± 0.03 mm in Ang II infused mice; p<0.05). There was a tendency
for an increase in the left ventricle dimension in diastole, although this failed to reach
statistical significance (2.44 ±0.16 mm in Ang II + sulprostone vs. 2.19 ± 0.05 mm in Ang
II; ns). These data suggest that the addition of the EP3 agonist to Ang II hypertension
prompts a decline in cardiac function and increases left ventricle chamber dilatation.
Blood pressure was monitored throughout the study and Figure 31 shows that after 1
week of Ang II blood pressure was significantly increased (156 ± 15.4 in Ang II group vs.
111 ± 1.9 in vehicle; p<0.05). There was no difference between the group that received
Ang II + sulprostone treatment versus those that received Ang II alone (151 ± 17.6 in Ang
II + sulprostone vs. 156 ± 15.4 in Ang II group; p=ns). Similarly, after 2 weeks of Ang II,
there was no significant difference in the level of systolic blood pressure achieved in the
mice that received Ang II + sulprostone versus those that received Ang II alone (172 ±12.1

Systolic Blood Pressure (mmHg)

mmHg in the Ang II group vs. 153 ± 11.4 mmHg in the Ang II + sulprostone group; p=ns).
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Figure 31: Systolic Blood Pressure with sulprostone Treatment. Systolic blood pressure
measured by tail cuff plethysmography in conscious mice at baseline, 1 week, and 2
weeks after vehicle or Ang II (1.4 mg x kg-1 x day-1) ± daily injections of sulprostone (40
µg x kg-1 x day-1) or diluted ethanol vehicle. *p<0.05, ***p<0.005 vs. vehicle. N=4-5/group.
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EP3 Antagonist L798, 106 Improves Cardiac Function and Hypertrophy in Ang II
Hypertension
Since the addition of the EP3 agonist sulprostone worsened cardiac function in
Ang II hypertension, we hypothesized that antagonism of the EP3 receptor would reverse
the decline in cardiac function. Figure 32 shows that there was a modest, but significant
reduction in ejection fraction after 2 weeks of Ang II and this was attenuated when animals
were treated with an EP3 antagonist (77.26 ± 0.47 % in vehicle treated vs. 69.82 ± 1.01
% in Ang II treated, p<0.005; and 72.61 ± 0.51 % in Ang II + L798, 106 treated; p<0.05
vs. Ang II). Similarly, shortening fraction was reduced with Ang II and improved with L798,
106 treatment (51.61 ± 1.71 % in Ang II treated vs. 56.97 ± 1.01 % in Ang II + L798, 106
treated; p<0.05 vs. Ang II). Additionally, there were significant increases in posterior wall
thickness at systole after Ang II infusion, which was attenuated with an EP3 antagonist
(1.19 ± 0.02 mm in vehicle treated vs. 1.42 ± 0.02 mm in Ang II treated, p<0.01; and 1.30
± 0.03 mm in Ang II + L798, 106 treated; p<0.05 vs. Ang II). We did not observe any
change in cardiac output between the groups (14.43 ± 1.33 ml/min/10g in vehicle treated
vs. 12.38 ± 0.98 ml/min/10g in Ang II treated, p=ns; and 13.12 ± 1.10 ml/min/10g in Ang
II + L798, 106 treated; p=ns). These results suggest that the effect of L798, 106 on blood
pressure is not occurring via alterations in cardiac function.
Ang II infusion is known to produce cardiac hypertrophy [218]. We observed an
increase in heart weight to body ratio (Figure 33) with Ang II infusion (39.86 ± 1.08 in
vehicle treated vs. 45.31 ± 1.68 in Ang II treated; p<0.05). This increase was prevented
when animals were treated with L798, 106 (36.92 ± 1.74 in vehicle treated vs. 41.08 ±
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1.31 in Ang II + L798, 106; p=ns).

Figure 32: Echocardiography with L798, 106 Treatment. Cardiac function assessed by
echocardiography in conscious mice 2 weeks after vehicle or Ang II (1.4 mg x kg-1 x day1) ± daily injections of L798, 106 (40 µg x kg-1 x day-1) or diluted ethanol vehicle. ** p<0.05,
*** p<0.005 vs. Vehicle. + p<0.05, ++ p<0.01 vs. Ang II. N=11-13. LVDd-Left ventricular
dimension at diastole, PWTs-Posterior wall thickness at systole.
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Figure 33: Heart Weight (HW) to Body
Weight (BW) Ratio. Mice were anesthetized,
hearts were removed and weighed. Values
shown are means ± SEM in mg/10g BW.
*p<0.05 vs. vehicle.
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Treatment with L798, 106 Significantly Diminishes Pressor Response of Ang II
It has been shown in isolated mesenteric arteries lacking the EP3 receptor, that
the vasoconstrictive action of Ang II is ameliorated, suggesting an important role for EP3
in the control of blood pressure via the resistance vessels [439]. Indeed, daily
administration of the EP3 antagonist L798, 106 substantially reduced the hypertensive
effect of chronic Ang II treatment (Figure 34; 168 ± 5.0 mmHg in Ang II to 136 ± 9.7 in
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Ang II + L798, 106; p<0.05).
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Figure 34: Systolic Blood Pressure with L798, 106 Treatment. Systolic blood pressure
measured by tail cuff plethysmography in conscious mice at baseline, 1 week, or 2 weeks
after vehicle or Ang II (1.4 mg x kg-1 x day-1) ± daily injections of L798, 106 (80 µg x kg-1
x day-1) or diluted ethanol vehicle for 2 weeks. ***p<0.005 vs. Vehicle, + p<0.05 vs. Ang
II. N=11-13/group.
L798, 106 Treatment Has No Effect on AT1 mRNA Expression
It is known that upregulation of the AT 1 receptor plays an important role in
mediating the pathophysiology of increased blood pressure [440]. Therefore, we
examined if L798, 106 administrations is affecting mRNA levels of the Ang II AT1 receptor
in the left ventricles. Figure 35 shows that after Ang II infusion there was no change in
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AT1 mRNA levels (1.02 ± 0.09 in vehicle treated vs. 1.16 ± 0.13 in Ang II treated; p=ns).
Similarly, there was no significant change between mice that received Ang II infusion with
vehicle injection and those that received Ang II infusion with L798, 106 treatment (1.16 ±

AT1 mRNA Expression
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0.13 in Ang II treated vs. 0.86 ± 0.10 in Ang II + L798, 106 treated; p=ns).
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Figure 35: AT1 mRNA Expression with L798, 106 Treatment. AT1 mRNA expression in
left ventricle samples after 2 weeks of Ang II infusion ± L798, 106 (40 µg x kg -1 x day-1,
i.p.). Data presented are means ± SEM. N=6
Treatment with L798, 106 Significantly Prevents Ang II-Induced RhoB Expression
in Mesenteric Arteries
Changes in Rho-kinase signaling have been shown to contribute to increases in
total peripheral resistance in hypertension. This has been demonstrated in resistance
vessels such as the mesenteric arteries [441-443]. Western blot analysis using
mesenteric arteries from the mice revealed a significant increase in RhoB protein
expression after 2 weeks of Ang II infusion (Figure 36; 1.00 ± 0.14 in vehicle treated vs.
3.84 ± 1.39 in Ang II treated, p<0.005). This was dramatically attenuated when mice were
treated with L798, 106 (0.94 ± 0.32 in Ang II + L798, 106 vs. 3.84 ± 1.39 in Ang II treated,
p<0.005). These results suggest that Ang II increases RhoB expression, potentially
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increasing contraction in the vasculature. RhoB expression is reduced by L798, 106
treatment, possibly serving as a mechanism for the reduction in blood pressure we
observed. RhoB expression was undetectable in left ventricle homogenates 2 weeks after
Ang II infusion.

Figure 36: Quantification of RhoB Expression. Western Blot analysis for RhoB
expression in mouse mesenteric arteries with 2 weeks of vehicle or Ang II (1.4 mg/kg/day)
± L798, 106 (40 µg/kg/day). *** p<0.005, N=3-5/group.

Figure 37 shows that in contrast to RhoB, RhoA expression was unchanged in the
mesenteric arteries with infusion of Ang II (1.00 ± 0.20 in vehicle vs. 1.08 ± 0.40 in Ang
II; p=ns). Although expression of RhoB was undetectable in the LV, RhoA expression
was detectable in the LV homogenates. Interestingly, there was a small but significant
decrease in RhoA expression with Ang II infusion and this was unchanged with L798, 106
treatment. (Figure 37; 1.00 ± 0.03 in vehicle vs. 0.82 ± 0.04 in Ang II; p<0.05) and (0.82
± 0.04 in Ang II vs. 0.91 ± 0.14 in Ang II + L798, 106; p=ns).
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Figure 37: Quantification of RhoB Expression. Western Blot analysis for RhoA expression
in mouse mesenteric artery (top panel) and left ventricle (bottom panel) homogenates
with 2 weeks of vehicle or Ang II (1.4 mg-1 x kg-1 x day-1) ± L798, 106 (40 µg-1 x kg-1 x day1). * p<0.05 vs. vehicle group, N=3/group.
EP3 Transgenic Mice Overexpressing EP3 Have Normal Blood Pressure but
Reduced Cardiac Function
Since the increase in the EP3 receptor is occurring mainly in the cardiomyocytes,
we obtained mice that overexpress the porcine analogue of human EP3 in the
cardiomyocytes (EP3 Tg) and their wild type littermates (EP3 WT). To assess the effect
of EP3 overexpression in the cardiomyocytes on blood pressure, we measured systolic
blood pressure in EP3 Tg and their WT littermates under baseline conditions and after
infusion of Ang II for 2 weeks. Figure 38 shows that under baseline conditions, the EP3
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Tg mice have normal systolic blood pressure as measured by tail cuff and this increases
significantly after Ang II infusion, albeit to a similar extent to that observed in C57BL/6
mice (106 ± 2.01 mmHg at baseline vs. 152 ± 3.13 after Ang II infusion; p<0.05). These
data suggest that overexpression of EP3 in the cardiomyocytes has no direct effect on
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Figure 38: Systolic Blood Pressure in EP3
Tg. Systolic blood pressure measured by
tail cuff plethysmography in conscious EP3
Tg mice 2 weeks after vehicle or Ang II (1.4
mg x kg-1 x day-1). *** p<0.005 vs. vehicle.
N=4-5/group
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Figure 39 shows that as early as 10-12 weeks of age, EP3 Tg mice have reduced
ejection fraction (56.93 ± 4.94 % in EP3 Tg vs. 76.18 ± 1.25 % in EP3 WT; p<0.05) and
reduced shortening fraction at baseline (38.49 ± 3.46 % in EP3 Tg vs. 61.69 ± 2.93 % in
Figure
39:
Baseline
Echocardiography in EP3 WT
and EP3 Tg. Cardiac function
assessed by echocardiography
in conscious male EP3 Tg or EP3
WT mice at 10-12 weeks of age
under baseline conditions. LVDd
- Left ventricular dimension at
diastole, PWTs-Posterior wall
thickness at systole. **p<0.01,
vs. EP3 WT. N=3 EP3 WT and
N=5 EP3 Tg.

125
EP3 WT; p<0.01). Additionally, the hearts display robust dilatation as shown by the left
ventricular dimensions in diastole (3.55 ± 0.23 mm in EP3 Tg vs. 2.62 ± 0.01 mm in EP3
WT; p<0.01). The posterior wall thickness is unchanged between EP3 Tg and EP3 WT,
thus the data suggest that the hearts display a phenotype of eccentric hypertrophy (1.13
± 0.02 mm in EP3 Tg vs. 1.21 ± 0.01 in EP3 WT; ns).
To measure the hypertrophy of the EP3 Tg hearts at baseline, we performed
myocyte cross sectional area staining on frozen sections of LV at baseline. Figure 40
shows that the average myocyte area is increased in EP3 Tg compared to the WT
littermates (191.4 ± 2.6 in EP3 WT vs. 218.9 ± 2.8 in EP3 Tg;p<0.005). These data
suggest that the EP3 Tg hearts are hypertrophied under baseline conditions and confirm
the echocardiography data showing ventricle dilatation.
Figure 40: Myocyte Cross
Sectional Area Analysis EP3
WT vs. EP3 Tg. Myocyte cross
sectional area (MCSA) analysis
using NIH Image J software.
Values shown are means ±
SEM. *** p<0.005. N=5

We hypothesized that the decline in cardiac function is exacerbated in Ang II
hypertension. Figure 41 shows that in response to Ang II, the hearts of EP3 WT mice are
well compensated and maintain ejection fraction (76.49 ± 0.70 % in vehicle vs. 75.30 ±
0.80 % in Ang II; ns) and shortening fraction (63.19 ± 0.98 % in vehicle vs. 63.21 ± 1.37
% in Ang II; ns). In contrast, the transgenic mice have reduced ejection fraction and
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Figure 41: Echocardiography in EP3 WT and EP3 Tg After 2 Wks. Ang II. Cardiac
function assessed by echocardiography in conscious male EP3 Tg or EP3 WT mice at
10-12 weeks of age after 2 weeks of vehicle or Ang II infusion (1.4 mg x kg-1 x day-1). N=3
EP3 WT and N=5 EP3 Tg. EF – Ejection fraction, SF-Shortening fraction, LVDs – Left
ventricular dimension in systole, LVDd – Left ventricle dimension in diastole. *p<0.05,
**p<0.01, ***p<0.005. N=3-5.
shortening fraction at baseline and there is a greater response to Ang II (ejection fraction:
75.30 ± 0.83 % in WT + Ang II vs. 45.92 ± 9.63 % in EP3 Tg + Ang II; p<0.01) and
(Shortening fraction: 63.21 ± 1.37 % in WT + Ang II vs. 34.77 ± 7.33 % in Tg + Ang II).
Similarly, there was an exacerbated increase in left ventricle dimensions at systole and
diastole (0.88 ± 0.04 in WT + Ang II vs. 2.40 ± 0.54 in Tg + Ang II; p<0.005) and (2.42 ±
0.05 in WT + Ang II vs. 3.50 ± 0.42 in Tg + Ang II; p<0.005) respectively.
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EP3 Tg Mice Have Increased Markers of Inflammation in their Left Ventricle
We hypothesized that the depressed cardiac function observed in EP3 Tg mice
correlates with an increase in inflammation. We performed real time RT-PCR for several
pro-inflammatory cytokines and chemokines using left ventricles from EP3 Tg and their
WT littermates under baseline conditions. Figure 42 shows that there was a significant
increase in TNF-α mRNA levels in EP3 Tg mice, (1.01 ± 0.08 in EP3 WT vs. 1.45 ± 0.22
in EP3 Tg; p<0.05). Additionally, we observed an increase in IL-1β (1.04 ± 0.21 in EP3
WT vs. 1.87 ± 0.46 in EP3 Tg; p<0.05). Interestingly, the mRNA levels of the chemokine

Figure 42: Real Time RT-PCR of Cytokines. Real time RT-PCR analysis of several
cytokines in the left ventricles of EP3 WT and EP3 Tg mice under baseline conditions.
* p<0.05 vs. EP3 WT. N=3/group.
MCP-5 were unchanged between the two groups (1.02 ± 0.15 in EP3 WT vs. 1.10 ± 0.06
in EP3 Tg). We also observed a significant reduction in the anti-inflammatory cytokine IL10 and a reduction in the anti-inflammatory M2 macrophage marker arginase-1, although
this failed to reach statistical significance (IL-10: 1.01 ± 0.11 in EP3 WT vs. 0.71 ± 0.02
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in EP3 Tg; p<0.05. Arginase-1: 1.02 ± 0.13 in EP3 WT vs. 0.80 ± 0.07 in EP3 Tg; p=0.26).
Together these data suggest that the EP3 Tg mice have increased pro-inflammatory
signaling in their left ventricles by upregulating pro-inflammatory genes and down
regulating anti-inflammatory genes. To confirm our PCR results, we examined the protein
expression of several cytokines and chemokines using a multiplex ELISA array. Figure
43 shows that there was a reduction in IL-10, confirming our real time RT-PCR results
(0.04 ± 0.01 A.U. in EP3 WT vs. 0.02 ± 0.01 A.U. in EP3 Tg; p<0.05). There was also a
significant reduction in IL-4 in the EP3 Tg mice (0.03 ± 0.01 A.U. in EP3 WT vs. 0.02 ±
0.0 A.U. in EP3 Tg; p<0.005). Unfortunately, levels of other cytokines were below the kit’s
limit of detection.

Figure 43: Multiplex ELISA Analysis. Multiplex ELISA array analysis of cytokines in the
left ventricles of EP3 WT and EP3 Tg mice under baseline conditions. Absorbance was
obtained at 570 nm, corrected for the absorbance at 450 nm and then corrected for the
total µg of protein per well. * p<0.05, *** p<0.005 vs. EP3 WT. N=3/group.

EP3 Tg Mice Have Increased T Cells but Not Macrophages in their Left Ventricle
Since the EP3 Tg mice have increased markers of inflammation with a reduction
in anti-inflammatory markers, we hypothesized that they would have increased infiltration
of immune cells. In this study, we investigated the presence of CD68+ macrophages and
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CD3+ T cells in the left ventricles of EP3 WT and EP3 Tg mice under baseline conditions
by immunohistochemistry. Figure 44 shows that there was no change in the number of

Figure 44: CD68+ Staining. Top. Representative immunohistochemistry for macrophages
(CD68+). Bottom. Quantitative CD68+ analysis. Images were taken under 20X objective
and analyzed using Image J software. The number of positive cells were counted by a
blinded observer and corrected to mm 2 of tissue. Data are presented as means ± SEM.
N=5 in EP3 WT, N=10 in EP3 Tg.
macrophages in the left ventricle of EP3 Tg mice compared to EP3 WT littermates (170.8
± 7.6 cells/mm2 in EP3 WT vs. 150.4 ± 4.5 cells/mm2 in EP3 Tg; p=ns). However, Figure
45 shows that when we analyzed T cells, there was a significantly higher number of CD3 +
cells in EP3 Tg left ventricles (32.3 ± 2.4 cells/mm2 in EP3 WT vs. 62.9 ± 5.6 cells/mm2
in EP3 Tg; p<0.005). These data confirm our findings with the cytokines/chemokine
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mRNA levels as a lack of chemokines specific for macrophages like MCP-5, correlates
with a lack of increased macrophages. Similarly, the increase in IL-1β could attribute to
the increase in T cells.

Figure 45: CD3+ Staining. Top. Representative immunohistochemistry for T cells (CD3+).
Bottom. Quantitative CD3+ analysis. Images were taken under 20X objective and
analyzed using Image J software. The number of positive cells were counted by a blinded
observer and corrected to mm2 of tissue. Data are presented as means ± SEM.
***p<0.005 vs. EP3 WT. N=5 in EP3 WT, N=10 in EP3 Tg.
EP3 Tg Mice Have Increased Expression of the Reactive Oxygen Species Generator
NADPH Oxidase 2 (Nox2)
Left ventricle hypertrophy and heart failure have been associated with increased
reactive oxygen species (ROS) in various models [444, 445]. To determine if the EP3 Tg
mice have increased ROS in their left ventricles, we performed western blot for Nox2, a
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major enzyme responsible for ROS production. Figure 46 shows that compared to EP3
WT, EP3 Tg mice have a 2-fold increase in Nox2 expression in their left ventricles (1.00
± 0.19 in EP3 WT vs. 2.02 ± 0.42 in EP3 Tg; p<0.05). Although ROS generation was not
measured per se, increased Nox2 expression suggests there is increased oxidative stress
in the EP3 Tg mice.
Figure 46: Western Blot Analysis of Nox2
Expression. Western blot analysis for Nox2 in
left ventricles of EP3 WT and EP3 Tg mice.
Nox2 was corrected for protein loading by
GAPDH and the results are presented as means
± SEM, fold of EP3 WT. * p<0.05. N=3.

The Effects of L798, 106 on Blood Pressure and Cardiac Function are Unique to the
Ang II Model
Infusion of the β-adrenergic receptor agonist, isoproterenol, is another nonischemic model that has been used to induce heart failure in rodents [446-449]. Figure
47 shows that when mice received isoproterenol infusion for 10 days, there was a

Figure 47: Systolic Blood Pressure and Heart Rate in Isoproterenol Infusion. Systolic
blood pressure (left panel) or heart rate (right panel) measured by tail cuff
plethysmography in conscious mice throughout the infusion protocol of vehicle or
isoproterenol (30 mg x kg-1 x day-1) ± daily injections of L798, 106 (80 µg x kg -1 x day-1)
or diluted ethanol vehicle. * p<0.05, *** p<0.005 vs. Vehicle. N=4-6/group.
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significant increase in heart rate, as expected (594 ± 24.0 bpm in vehicle treated vs. 739
± 33.6 bpm in isoproterenol treated; p<0.005). This was evident as early as 4 days after
treatment. Treatment with an EP3 antagonist had no effect on this increase (670 ± 37.5
bpm in isoproterenol + L798, 106 group vs. 739 ± 33.6 bpm in isoproterenol group; ns).
Isoproterenol infusion also resulted in a significant, but modest increase in systolic blood
pressure compared with vehicle infused mice (122 ± 2.8 mmHg in isoproterenol vs. 108
± 4.4 mmHg in vehicle; p<0.05). EP3 antagonist treatment did not reduce this increase in
blood pressure (114 ± 7.3 mmHg in isoproterenol + L798, 106 vs. 122 ± 2.8 mmHg in
isoproterenol; ns). Cardiac function was assessed in these mice by echocardiography.
Figure 48 shows that there was a modest but significant reduction in shortening fraction

Figure 48: Echocardiography after Isoproterenol Infusion. Cardiac function assessed by
echocardiography in conscious mice at 10-12 weeks of age 10 days after vehicle or
isoproterenol (ISO) infusion (30 mg x kg-1 x day-1). Ejection fraction (top left), shortening
fraction (top right), and left ventricle diameter in systole (LVDs; bottom left). The left
ventricle to body weight ratio (bottom right) was obtained using weights at sacrifice. Data
presented as means ± SEM. ** p < 0.01, *** p< 0.005 vs. vehicle. N=7-8.
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(55.16 ± 1.3 % in isoproterenol vs. 61.81 ± 1.0 % in vehicle; p<0.005). However, this
reduction was not altered when mice were treated with L798, 106 (53.87 ± 1.2 % in
isoproterenol + L798, 106 vs. 55.16 ± 1.3 % in isoproterenol; ns). Figure 48 also shows
a significant increase in left ventricular dimension at systole, and a corresponding
increase in left ventricle mass as measured by echocardiography. Neither of these
parameters of hypertrophy were attenuated when mice received L798, 106 treatment.
Altogether, these data suggest the protective effects of EP3 antagonism are selective to
the Ang II model and are not promiscuous for other non-ischemic models of heart failure.
Discussion
The results of this study show, for the first time, that administration of an EP3
agonist, sulprostone, reduces cardiac function after 2 weeks of Ang II infusion, although
it has no effect on systolic blood pressure. In contrast, administration of an EP3
antagonist, L798, 106 prevented a reduction in cardiac function with Ang II infusion and
substantially attenuates the increase in blood pressure. Furthermore, we report that mice
overexpressing EP3 in the cardiomyocytes have reduced cardiac function at baseline, an
exacerbated decline in cardiac function in response to Ang II and increased inflammatory
cytokines/chemokines in their left ventricles.
Previous studies have documented the role of the EP3 receptor in hypertension by
performing studies on vascular reactivity [439]. Using global EP3 knockout mice, Chen et
al. showed that the mice display reduced systolic blood pressure at baseline and a
reduced pressor response to Ang II [439]. Our current study is novel in that utilizes
systemic administration of the EP3 agonist and antagonist and employs the
cardiomyocyte-specific EP3 overexpressing mice. Our data suggests that the EP3
receptor may act synergistically with Ang II to increase blood pressure.
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The Rho/Rho-kinase cascade has been shown to play an important role in
regulating cardiovascular function [251, 281, 282, 284, 450, 451]. For example, Guan et
al. have shown in rats with transverse aortic constriction pressure overload, cardiac
function was improved when the rats were treated with the Rho-kinase inhibitor fasudil
[452]. Moreover, they showed this was due to a reduction in reactive oxygen species.
Similar cardioprotective effects were observed in a mouse model of autoimmune
myocarditis when mice were treated with fasudil [453]. Interestingly, in the
aforementioned study, Dai et al. found a shift in the cardiac T cell population from Th17
to Treg, suggesting Rho-kinase may directly affect the T cell population and IL-17
production. In our current study, we observed an increase in RhoB expression in the
mesenteric arteries in response to Ang II, and this was reduced with L798, 106 treatment.
There was no change in RhoA expression in the mesenteric arteries. We speculate that
because RhoA is the constitutively expressed isoform, it would be necessary to measure
RhoA activity rather than the expression. These experiments were not performed in this
study. In the left ventricle, RhoB expression was completely undetectable, while RhoA
was robustly detected. This agrees with the literature showing only the RhoA isoform is
expressed in cardiomyocytes [454]. Interestingly, when animals received Ang II infusion
for 2 weeks, there was a significant decrease in RhoA expression in the LV. It is possible
that 2 weeks of Ang II infusion may cause a down-regulation of RhoA, as RhoA is typically
shown to be fast-acting in response to Ang II, however this is purely speculation.
Furthermore, the RhoA/Rho kinase signaling cascade in response to Ang II treatment has
been studied in depth [278-282, 454, 455]. However, little is known about the role of RhoB
in Ang II HTN, therefore making our results a novel finding. RhoB could play a role in
promoting inflammation in Ang II HTN as it has been shown that RhoB, but not RhoA, is
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a mediator of Rho-Kinase-induced NF-κB activation [456]. Inflammation in the mesenteric
arteries in response to increased RhoB expression was not studied in this dissertation.
Although the response to L798, 106 in Ang II hypertension in the kidneys and/or
central nervous system was not studied in this dissertation, It is known that renal AT1
receptors play a role in Ang II hypertension [457]. It was also shown that EP3 receptor
activation in the rostral ventrolateral medulla mediates the pressor effects of PGE 2 [458].
Surprisingly, the EP3 agonist sulprostone had no effect on blood pressure in the Ang II
hypertension model. It was previously reported that sulprostone invokes contraction of
guinea-pig aorta and induces Ca2+ influx [459]. Other studies have confirmed the ability
of EP3 receptor activation to mobilize Ca2+ [460-462]. Unlike these studies performed in
vitro or on isolated artery preparations, our current study utilized systemic injections of
the EP3 agonist. The calcium dynamics of EP3 antagonism was not studied in this
dissertation, however, and this could serve as a future project.
We repeated the L798, 106 experiment using isoproterenol infusion, another
model of non-ischemic heart failure. We observed a robust increase in heart rate, as
expected with β-adrenergic stimulation, and a modest, but significant increase in systolic
blood pressure after 10 days of isoproterenol infusion. However, there was no effect of
L798, 106 on heart rate, blood pressure, or cardiac function. These data suggest that the
effects of EP3 receptor antagonism are unique to the Ang II signaling pathway.
To study the effects of EP3 in the heart specifically, we obtained transgenic mice
that overexpress EP3 in the cardiomyocytes. The EP3 Tg mice were a gift from the
University of Dusseldorf. They previously reported that the hearts of these mice are
markedly hypertrophied, which is obvious as early as 5-6 weeks of age and that they have
reduced ejection fraction at baseline [463]. They also reported that overexpression of EP3
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is protective in a mouse ischemia-reperfusion model due to the reduced contractility of
the left ventricle, which would normally result in depletion of ATP [268, 463]. However,
we are the first to show that these mice have an exacerbated response to Ang II infusion
as well as increased inflammation in their left ventricles as evidenced by increased TNFα and IL-1β, two cytokines associated with heart failure [384, 464, 465]. There was also
reduction of anti-inflammatory cytokines IL-10 and IL-4. Interestingly, it was also observed
that mRNA levels of the chemokine MCP-5 were unchanged between EP3 WT and EP3
Tg mice. MCP-5 is a potent chemoattractant molecule for monocytes and macrophages
and we speculate that this could account for the lack of increased macrophages in the
EP3 Tg heart, as determined by immunohistochemistry. However, the EP3 Tg mouse
hearts did show a significant increase in the number of infiltrating T cells.
The work in this chapter has resulted in a manuscript that is in preparation. The
results showing the importance of the EP3 in hypertension could lead to the development
of new drugs targeting both the Angiotensin II receptors as well as EP3 for example.
Furthermore, it is important to understand the deleterious effects of EP3 in the heart
during hypertension as well as the detrimental effects of EP3 independent of blood
pressure.
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CHAPTER 6 – DEVELOPMENTAL METHODOLOGY
Importance of a Cardiomyocyte Specific EP3 KO Mouse
We published that treatment of adult mouse cardiomyocytes with the EP1/EP3
agonist sulprostone and/or PGE2 resulted in reduced departure velocity, a measure of
contractility. We verified this using a Langendorff preparation and in vivo using pressurevolume loops and showed reduced +dp/dt and –dp/dt. PGE2 and sulprostone both
decreased +dp/dt, while the EP4 agonist increased +dp/dt [217]. Therefore, we concluded
that the deleterious effects of PGE2 are likely mediated via the EP3 receptor. Furthermore,
we have reported that expression of the EP3 receptor increases in the mouse heart in
response to injury (MI and/or Ang II infusion). Therefore, we overexpressed EP4 in the
cardiomyocytes (Chapter 2) and observed significant improvements in parameters of
cardiac function, a reduction in infiltrating macrophages and T cells, reduced MMP
expression and fibrosis, and a reduction of the pro-inflammatory chemokine MCP-1 [216].
We concluded that overexpression of EP4 helps tip the balance towards activation of the
EP4 receptor.

Based on these previous studies, we sought to generate the

cardiomyocyte specific EP3 knockout and hypothesized that lack of EP3 in the
cardiomyocyte would improve cardiac function after injury.
Generation of a Conditional Cardiomyocyte Specific EP3 Knockout Mouse
The use of recombinases such as Cre recombinase to generate tissue specific
knockouts has become a very common research tool. In general, the gene of interest to
be knocked out is flanked by loxP sites. If two loxP sites are placed in the same orientation
in sequence, the floxed gene will be excised by the activity of Cre [466].
Our cardiomyocyte specific EP3 knockout mouse (EP3 KO) utilizes this technology
to generate a conditional knockout model. The model is conditional since the EP3 gene
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is only knocked out once the mice are treated with tamoxifen. Once tamoxifen is
administered, a conformation change in the ER ligand-binding domain induces nuclear
translocation and activation of the Cre recombinase. This results in excision of the loxPflanked gene sequence [467]. Verification of our mouse genotype is performed by a
company called Transnetyx®. This company is a non-biased automated genotyping
service. Ear biopsies of the mice are sent to their lab and they detect the presence or
absence of MerCreMer (indicated by a + or – symbol) and the presence or absence of
the EP3 floxed gene (Figure 49). We have confirmed the presence of MerCreMer in the
heart by western blot analysis (Figure 50).

Figure 49: Representative Transnetyx® Genotyping Results. Left: Representative
genotyping results from Transnetyx® (not all results are shown). 3 probes are used to
genotype the mice. Esr-Cre detects the presence of the MerCreMer, Ptger3-4 FL detects
the presence of EP3 floxed by LoxP sites in exon 1, while Ptger3-4 WT detects the
presence of unfloxed, wild type EP3. The results indicate that all mice are positive for
floxed EP3 and negative for wild type. Right: Representative ‘raw data’ file from
Transnetyx® demonstrating the results for MerCreMer. Note the very low signals for
34945, 34947, 34948, and 34950, all of which were negative (-) for MerCreMer
expression. Also note there is varying signal strength for MerCreMer positive (+) mice,
most likely a difference between heterozygote and homozygote mice.
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Figure 50: Western Blot Analysis of MerCreMer and Cre Recombinase. Representative
western blot from left ventricle tissue of EP3 floxed (EP3 FL/FL) mice showing constitutive
expression of the MerCreMer protein. As a control, we loaded equal amounts of two EP4
KO left ventricle samples which express the Cre recombinase protein. Thus, our EP3 KO
mice express only MerCreMer.

The EP3 floxed mice were acquired from cryopreservation from Jackson
Laboratories. To generate the EP3 floxed mice, a vector containing the Ptger3 (EP3)
sequence and neomycin/kanamycin resistance genes was used. 70 bp upstream of the
start codon for exon 1, a loxP site was inserted. Another loxP site was inserted 408 bp
downstream of exon 1. This construct was electroporated into 129S4/SVJ derived J1
embryonic stem cells. Correct embryonic stem cells were then transfected with a plasmid
to remove the marker cassette. The cells that now only retained the loxP-flanked exon 1
were injected into C57BL/6 blastocysts resulting in chimeric male animals. These mice
were then back crossed to 129X1/SVJ mice (Stock No. 000691). The resulting mice were
crossed to generate homozygotes and then back crossed one time to C57 BL/6J mice.
Once we obtained the EP3 floxed mice from Jackson Labs, we began establishing
breeder pairs to maintain the EP3 floxed gene. At the same time, we established breeding
with another line of mouse, the αMHC-MerCreMer mouse.
The αMHC-MerCreMer mouse line expresses Cre recombinase fused to mutated
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estrogen receptor (ER) ligand-binding domains (MerCreMer) only in the cardiomyocytes.
This MerCreMer protein is under control of the alpha myosin heavy chain promoter
(αMHC). There are two myosin heavy chain genes that are expressed in the mammalian
heart; αMHC and βMHC [468]. The alpha myosin heavy chain gene encodes a cardiacspecific protein involved in muscle force generation and has been widely used in
transgenic models to drive the expression of proteins of interest in the cardiac muscle
specifically. Therefore, the αMHC drives the expression of Cre specifically in the
cardiomyocytes. The Cre-ER proteins are sensitive to tamoxifen but insensitive to
estrogen. Also, the fusion proteins are sequestered in the cytoplasm in an inactive state
in the absence of a ligand (tamoxifen).
Treatment with tamoxifen has well known cardiac toxicity in the mouse model,
although the mechanism is unknown [469-472]. Consistent with published data, injection
of tamoxifen in our mice resulted in substantial left ventricle dilatation and reduction of
cardiac function. This condition improved however after allowing the mice to rest for at
least 1 week following tamoxifen treatment. In fact, ventricle size and function is
completely back to normal by 2 weeks (Table 5). We determined that the optimal time
and dose of tamoxifen was daily intraperitoneal injections of 30 µg x g-1 x day-1 for 7 days
followed by at least 7 days of rest. This resulted in approximately 80 % knockdown of EP3
using real time RT-PCR primers targeting only exon 1.

141
Table 5: Echocardiography Data of EP3 KO Mice
7 days Tamoxifen - No Rest
Cardiac Parameter
Ejection Fraction (%)
Shortening Fraction (%)
Left Ventricle Dimension in Systole (mm)
Left Ventricle Dimension in Diastole (mm)
Posterior Wall Thickness in Systole (mm)
2

Area in Systole (mm )
Area in Diastole (mm2)
Sample Number (N)
7 days Tamoxifen - 2 Weeks Rest
Cardiac Parameter
Ejection Fraction (%)
Shortening Fraction (%)
Left Ventricle Dimension in Systole (mm)
Left Ventricle Dimension in Diastole (mm)
Posterior Wall Thickness in Systole (mm)
Area in Systole (mm2)

Treatment Group
-1

Vehicle (Corn oil) 30 µg x g x day
73.88 ± 0.39
69.91 ± 5.56
61.03 ± 1.52
56.87 ± 2.73
1.00 ± 0.07
1.18 ± 0.14
2.58 ± 0.16
2.70 ± 0.13
1.28 ± 0.01
1.23 ± 0.02
0.97 ± 0.18
1.39 ± 0.56
3.68 ± 0.62
3.70 ± 0.70
4
6

-1

-1

-1

-1

-1

60 µg x g x day
67.37 ± 3.13
54.81 ± 3.56
1.33 ± 0.16
2.92 ± 0.16
1.25 ± 0.01
1.59 ± 0.39
4.64 ± 0.67
5

Treatment Group
-1

Vehicle (Corn oil) 30 µg x g x day
73.88 ± 1.18
72.15 ± 0.64
64.35 ± 0.97
59.38 ± 0.53
0.91 ± 0.04
1.04 ± 0.05
2.57 ± 0.09
2.58 ± 0.10
1.28 ± 0.04
1.25 ± 0.01
0.88 ± 0.15
0.83 ± 0.04

-1

60 µg x g x day
70.34 ± 0.45
64.04 ± 1.60
0.94 ± 0.06
2.63 ± 0.13
1.26 ± 0.05
0.88 ± 0.06

2
3.23 ± 0.42
2.98 ± 0.10
2.98 ± 0.15
Area in Diastole (mm )
Sample Number (N)
4
6
5
Cardiac parameters assessed in conscious mice by echocardiography immediately following tamoxifen
injections (top-no rest) or 2 weeks after tamoxifen (bottom-2 weeks rest). Mice received either corn oil
vehicle or tamoxifen at 30 µg x g-1 x day-1 or 60 µg x g-1 x day-1 for 7 days.

Troubleshooting the Generation of the EP3 KO Mouse
Initial tests of the mice resulted in zero knockdown of EP3 with the treatment of
tamoxifen. We used various different doses of tamoxifen and different rest times. All initial
attempts resulted in inconsistent results, although no consistent knockdown of EP3. The
first attempts utilized intraperitoneal injections of tamoxifen at 40 µg x g-1 x day-1 or corn
oil vehicle for 6 days followed by 2 weeks recovery time. Using real time RT-PCR and
EP3 primers designed by Qiagen (Cat No. 330001 PPM04249A) we did not generate any
knockdown of EP3 (Figure 51). Next, it was investigated if the length of time for tamoxifen
administration was the limiting factor. We administered tamoxifen for 2 weeks at 30 µg x
g-1 x day-1 I.P. Again, there was no reduction of EP3 mRNA expression with tamoxifen
treatment (Figure 52).
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Figure 51: EP3 mRNA Expression to
Test Knockdown. Real time RT-PCR
analysis of EP3 using primers from
Qiagen that recognize exon 2 of the
EP3 transcript and detect all three
splice variants of EP3. N=2 in vehicle
group and N=3 in tamoxifen group.

2.0
1.5
1.0
0.5
0.0
Vehicle

Tamoxifen

Figure 52: EP3 mRNA Expression to Test
Knockdown. Real time RT-PCR analysis of
EP3 mRNA using primers that recognize
exon 2 of the EP3 transcript and detect all
three splice variants of EP3. Mice received
tamoxifen at 30 µg x g-1 x day-1 for 2 weeks.
N=4 in vehicle group and N=6 in tamoxifen
group.
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After several months of administering different doses, for various lengths of time,
and varying the recovery time, it was decided to re-analyze the detection method for EP3
mRNA knockdown. The primers being used detected exon 2 of the EP3 gene. Since exon
1 is the floxed region in the EP3 KO model, we requested that the company TIB MolBiol
design three different sets of primers that are only in exon 1 (Figure 53). We then repeated
the tamoxifen protocol, administering 30 µg x g-1 x day-1 or 60 µg x g-1 x day-1 for 7 days
followed by rest. After 2 weeks, there was knockdown of EP3 mRNA with both doses
(Figure 54). Since cardiac function was worse with the higher 60 µg x g-1 x day-1 dose, it
was determined that 30 µg x g-1 x day-1 is the optimal dose.
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Figure 53: Exon 1 Primer Design. (Primer design from TIB MolBiol). Top panel shows the
different sequences, ascension number used for sequence identification, and the melting
temperature (Tm) for each primer. Bottom scheme shows the location of each primer set
within exon 1 of the EP3 gene.
Lastly, tamoxifen was administered daily to mice in their chow. We purchased food
containing 40 µg x g-1 x day-1 tamoxifen (Teklad, Cat no. 130856). This dose assumes
that the mice are consuming three-four grams of chow daily. Food consumption was
simply monitored by weighing the food daily to be sure that the mice were consuming the
chow. It took at least one week for the mice to acclimate to the new chow and begin
consuming the recommended amount to achieve the advertised dose. We then left the
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mice on this diet for 6 weeks. There was an approximate 57 % decrease in EP3 mRNA
compared with mice that received normal chow, unfortunately these data did not reach
statistical significance (1.09 ± 0.20 in normal chow vs. 0.43 ± 0.15 in tamoxifen chow
mice; p = 0.146, N=6). We concluded that administering tamoxifen via the diet would not
be a practical method to obtain EP3 knockdown as it took 6 weeks to achieve only 57 %
knockdown.

EP3 / GAPDH
(Fold of Vehicle)

2.0

Figure
54:
EP3
mRNA
Expression to Test Knockdown.
Real time RT-PCR analysis of
EP3 using primers from TIB
MolBiol that recognize exon 1 of
EP3 (primer design pair F3/R3).
Mice received tamoxifen at 30 µg
x g-1 x day-1 or 60 µg x g-1 x day-1
for 7 days, followed by 2 weeks
rest. N=3

1.5
1.0
0.5
0.0

Vehicle
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Flow Cytometry for the Characterization of the EP3 Transgenic Mouse
In order to confirm our immunohistochemistry results showing increased T cell
infiltration in the EP3 Tg mouse heart under basal conditions, we sought to perform flow
cytometry analysis from EP3 WT and EP3 Tg mouse hearts for F4/80+ macrophages and
CD3+ T cells. Flow cytometry is a sensitive and quantitative method to rapidly count cells
in any tissue of interest on a much larger scale than possible by normal
immunohistochemistry or immunofluorescence.
Flow Cytometry Methods
Hearts were excised from 10-12 wk. old C57Bl/6 mice and immediately immersed
in ice-cold HBSS to wash out red blood cells. Washes were repeated until buffer was
clear. The hearts were then transferred to a beaker containing ice-cold HBSS and
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mechanically minced using scissors. Hearts were then allowed to pellet via gravity on ice.
The HBSS was then aspirated off and the minced pellet was resuspended in 2.5 ml of
digestion buffer (200 U/ml collagenase + 100 µg/ml DNase II). This solution was then
stirred on low power at room temperature until the hearts were fully digested. After
digestion, the solution was pipetted twice through an 80 µm sieve to remove undigested
tissue and cardiomyocytes. This was followed by a wash with Dulbecco’s PBS (dPBS) by
centrifuging at 1500 rpm for 10 minutes. This was repeated once more. On the last wash,
the supernatant was aspirated and the pellet resuspended in 1 % paraformaldehyde
solution and fixed overnight at 4oC. The following day, samples were washed with wash
buffer (2% heat-inactivated FBS in dPBS) and then each heart was sub divided into
aliquots for staining. Nonspecific reactivity was blocked for 1 hour at room temperature
with 2 % heat-inactivated FBS as a blocking buffer. Fluorochrome-conjugated antibodies
against the T cell surface marker CD3 (anti-CD3 PE, BD Biosciences), anti-F4/80 FITC
(BD Biosciences) for detection of the macrophage marker F4/80, and anti-CD45 (CD45PerCP, BD Biosciences) were added in a 1:10 dilution to the staining aliquots.
Fluorochrome-matched isotype controls were used in each assay to adjust for nonspecific
staining. Cells were stained for 30 minutes at room temperature, followed by a wash step.
Samples were stored at 4oC and flow cytometry was performed within 1-2 hours of
staining. Flow cytometry analysis was performed using a LSR II flow cytometer (BD
Biosciences) and the data was analyzed using BD FACSDiva TM v8.0.1 software. Cells
were gated based on forward and side scatter and a minimum of 20,000 gated events
were acquired.
In one experiment, spleens were removed to serve as a control to test specificity
of the antibodies. Spleens were handled and stained in the same manner as described
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above for the hearts.
Flow Cytometry Troubleshooting
The first attempt at performing flow cytometry and optimizing the protocol to detect
macrophages and T cells was with using the left ventricle from an EP3 WT mouse.
Working with an expert immunologist in the flow cytometry core at Henry Ford Hospital,
we obtained protocols to begin a trial experiment. This initial attempt involved an
additional step in the methods using a Ficoll-paque gradient centrifugation to concentrate
the leukocytes from the heart digest. The major issue that occurred was the small number
of cells that we obtained. Figure 55 shows a representative forward/side scatter plot from
an unstained control sample with the gating set to obtain live cell events and a chart
displaying the total number of events. The resulting number of events was small (1,254
events). It was later determined that the Ficoll-paque reagent used would not work for
mouse samples, as mouse leukocytes have a higher density than human leukocytes. In
subsequent experiments, hearts were digested, washed, and fixed without the Ficollpaque centrifugation step.

Figure 55: Flow Cytometry Side/Forward Scatter Plot. The plot on the left shows the
forward and side scatter from an unstained control sample to demonstrate the gating
technique used to obtain live cell events. The table on the right shows the quantified
number of live events.
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In the next experiment, the number of gated live cells improved dramatically by
skipping the Ficoll-paque protocol. However, there was an issue of antibody signal
acquisition as the F4/80-FITC signal was weaker than its isotype control (Figure 56)
making it difficult to determine if the F4/80-FITC signal was truly macrophage specific (4.2
% in the FITC isotype vs. 2.0 % in F4/80-FITC). Likewise, Figure 57 shows the
background isotype signal for the CD3-PE antibody signal was just as strong as the CD3PE signal itself (5.0 % in the PE isotype vs. 5.3 % in CD3-PE). As a positive control for
the antibody specificity, the spleen was collected since it is known to contain a large
amount of leukocytes. Figure 59 shows that the antibody signal / isotype signal for the
CD3 T cells was much higher than in the heart, suggesting the antibody used is in fact
specific (0.7 % in the PE isotype vs. 28.0 % in CD3-PE). For the F4/80 macrophages
however, the F4/80-FITC signal was identical to the FITC isotype (Figure 58; 2.5 % in
FITC isotype vs. 2.6 % in F4/80-FITC). Thus, the antibody signal / isotype signal
improved, although it is still not optimal.

Figure 56: Flow Cytometry F4/80-FITC Results in LV. Left panel shows the unstained
portion of the heart as a control to set the live cell gating. The middle panel represents
the portion of the heart that was stained with the isotype-FITC control antibody. Note the
% parent = 4.2 % for the control antibody. The right panel represents the portion of the
heart that was stained with F4/80-FITC. Note the % parent is less than the isotype control
= 2.0 %. N=1 mouse heart.
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Figure 57: Flow Cytometry CD3-PE Results in LV. Left panel shows the unstained portion
of the heart as a control to set the live cell gating. The middle panel represents the portion
of the heart that was stained with the isotype-PE control antibody. Note the % parent =
5.0 % for the control antibody. The right panel represents the portion of the heart that was
stained with CD3-PE. Note the % parent is only 5.3 % compared to the control. N=1
mouse heart.

Figure 58: Flow Cytometry F4/80-FITC Results in Spleen. Left panel shows the unstained
portion of the spleen as a control to set the live cell gating. The middle panel represents
the portion of the spleen that was stained with the isotype-FITC control antibody. Note
the % parent = 2.5 % for the control antibody. The right panel represents the portion of
the spleen that was stained with F4/80-FITC. Note the % parent is 2.6 % compared to the
control. N=1 mouse spleen.
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Figure 59: Flow Cytometry CD3-PE Results in Spleen. Left panel shows the unstained
portion of the spleen as a control to set the live cell gating. The middle panel represents
the portion of the spleen that was stained with the isotype-PE control antibody. Note the
% parent = 0.7 % for the control antibody. The right panel represents the portion of the
spleen that was stained with CD3-PE. Note the % parent is 28.0 % compared to the
control. N=1 mouse spleen.
Since all cells of hematopoietic origin express the surface marker CD45+, we have
also tried to first gate the cells based on CD45+ expression and then acquire the
subsequent CD3+ and F4/80+ cells. Figure 60 demonstrates our ability to gate the cells
based on CD45+ cells. The cells in this population were CD3 - and F4/80-, as expected
when the gate was specific for CD45+ cells. Surprisingly, when the cells were stained for
CD3+ and F4/80+, there was no F4/80+ cells within the CD45+ population. CD3+ cells
comprised 24.0 % of that same CD45+ population (Figure 61).
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Figure 60: Flow Cytometry CD45 Gating Strategy (Control). Top left panel shows the
portion of the heart used as a control to set the live cell gating based on the CD45-PerCP+
population. Note the gate is much smaller than in previous figures, and only surrounds
the lymphocyte/monocyte population. The top middle panel represents the portion of the
heart that was F4/80-FITC positive (0.0 %). The top right panel represents the portion of
the heart that was CD3-PE+ (0.0 %). N=1 mouse heart.

Figure 61: Flow Cytometry CD45 Gating Strategy (F4/80+ and CD3+ Cocktail). Top left
panel shows the live cell gating based on the CD45-PerCP+ population. The top middle
panel represents the portion of the heart that was F4/80-FITC positive (0.0 %). The top
right panel represents the portion of the heart that was CD3-PE+ (24.0 %). N=1 mouse
heart.
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Flow Cytometry Conclusion
Further optimization of the protocol is necessary in order to accurately determine
the number of macrophages and T cells present in the heart. Once the ideal protocol is
determined, flow cytometry will be a very useful tool for the lab to analyze any cell type of
interest in the heart at baseline or in the disease state (Ang II hypertension, MI, etc.). One
potential issue with the current protocol could be the isotype controls being used.
Consistently we obtain higher signal with the isotype control, although the isotype is the
same IgG and of the same host species as the primary antibody. One possible solution
is to try isotypes from alternative companies. Additionally, to circumvent the low number
of macrophages at baseline, we could first use a model like MI, whereby there is a known
increase in macrophages and T cells. This would confirm that the antibodies are specific
and that the dilutions of antibody are appropriately titrated. Lastly, we think the initial gate
on CD45+ cells (Figures 60 and 61) is ideal to obtain the highest yield of macrophages
and T cells.
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CHAPTER 7 – OVERALL DISCUSSION
In this thesis, we sought to determine the role of PGE2 in heart failure and cardiac
remodeling in MI and the Ang II hypertension models. Building on our previously
published work, we hypothesized in the initial study that overexpression of the EP4
receptor is cardioprotective in a mouse model of MI by antagonizing the deleterious
effects of EP3. Our results support our hypothesis and show, for the first time, that delivery
of the EP4 receptor via an AAV9 viral package is sufficient to improve cardiac function in
mice with MI. After administration of AAV9-EP4 there were significant improvements in
ejection fraction, shortening fraction, and left ventricular dimensions. There was also
reduced fibrosis determined by picrosirius red staining and reduced hypertrophy,
determined by real time RT-PCR for BNP and β-MHC as well as myocyte cross sectional
area analysis. With regard to inflammation, administration of AAV9-EP4 prevented an
increase in TNF-α mRNA after MI, reduced MCP-1 protein levels, and increased levels of
IL-10, thus promoting an anti-inflammatory environment. The mechanism of how EP4
overexpression affects production of these chemokines/cytokines is unclear and was not
addressed in the present study but lays a solid foundation for future projects. However,
we speculate that due to the close proximity of cardiomyocytes and cardiac fibroblasts
and/or their direct interactions within the heart, perhaps there are paracrine effects
resulting in altered fibroblast/myofibroblast activity. It is also possible that the reduced
macrophage and T cell infiltration that occurred with EP4 overexpression is responsible
for the reduced pro-inflammatory signaling. Characterizing the cell infiltrate post-MI with
EP4 overexpression using flow cytometry would be a useful and novel project for future
studies with important therapeutic implications. Additionally, we showed reduced
expression of iNOS, a M1 macrophage marker, in the left ventricles of these mice,
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although we never delineated which cell type this was occurring in. Furthermore,
additional markers of the M1 phenotype would be needed to draw this conclusion. Future
studies could use the flow cytometry to analyze the M1/M2 macrophage populations in
the heart.
In the course of these studies, I also gained invaluable experience in generating a
novel mouse strain. This dissertation has led to the generation of a conditional
cardiomyocyte-specific EP3 knockout mice in which EP3 is deleted in the cardiomyocyte
upon administration of Tamoxifen (see Chapter 6). Preliminary data indicate that these
mice have normal cardiac function at baseline, but we hypothesize will be protected from
the deleterious effects of MI and Ang II hypertension and that these effects will be similar
to those observed after EP4 overexpression. These hypotheses will be tested in future
work.
To investigate how EP4 receptor signaling affects chemokine production (MCP-5
specifically) within the cardiac fibroblasts, we performed in-vitro experiments that are
presented in this dissertation (chapter 3). The cardiac fibroblasts are known to express
both TLR-2 and TLR-4 and thus respond to stimuli such as lipopolysaccharide. We
therefore utilized LPS treatment to induce production of the pro-inflammatory chemokine
MCP-5 and investigate the role of PGE2 and its EP4 receptor on MCP-5 regulation. Little
is known about the regulation of MCP-5 but we showed that a neutralizing antibody to
MCP-5 prevents macrophage migration in vitro after mouse cardiomyocytes are damaged
with hydrogen peroxide. Therefore, MCP-5 seems to be a key chemoattractant in mice
for monocytes/macrophages. We hypothesized that PGE2 inhibits LPS-induced MCP-5
secretion in mouse cardiac fibroblasts via its EP4 receptor. Our results show that both
PGE2 and an EP4 receptor agonist (CAY10598) reduce LPS-stimulated MCP-5 secretion.
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This was shown to be due to reduced AKT phosphorylation and subsequent NF-κB
activation. It remains to be determined however, whether MCP-5 has NF-κB binding
domains in its promoter region, as review of the literature and promoter analysis software
show little evidence for that fact. However, our data strongly suggests a role for NF-κB in
the regulation of MCP-5 under LPS-stimulated conditions. Also, it has been shown that
the close human analogue to MCP-5, MCP-1, does have NF-κB binding domains in its
promoter and is largely regulated by NF-κB [473], thus supporting our results.
Surprisingly, blockade of the EP4 receptor using a specific antagonist did not reverse the
effects of PGE2 suggesting another mechanism is involved. However, the fact that both
PGE2 and its EP4 receptor agonist both antagonize LPS-stimulated MCP-5 production,
suggest some involvement of this receptor. Although these in vitro studies with cardiac
fibroblasts do not represent the full complexity of the in vivo situation, they are useful to
discern signaling pathways utilized by activation of the EP4 receptor. Indeed, the
inhibition of MCP-5 production by an EP4 agonist in cultured cardiac fibroblasts is in
complete agreement with a reduction in cytokine production in vivo after overexpression
of the EP4 receptor.
Similar to the MI model, we have shown here that Ang II hypertension results in an
increase in EP3 expression in the heart, particularly in the cardiomyocytes. Systemic
administration of an EP3 agonist, sulprostone, had no effect on blood pressure neither
under baseline conditions nor after 2 weeks of Ang II infusion. The combination of
sulprostone and Ang II did have deleterious effects on cardiac function by significantly
reducing ejection fraction and shortening fraction, although these reductions were modest
and still within normal physiological limits. Future studies with the transgenic EP3 mice
that overexpress EP3 only in the cardiomyocytes, and the cardiomyocyte specific
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conditional EP3 KO mice would be able to compare and contrast systemic EP3 activation
versus the specific effects of EP3 in the heart. Surprisingly, antagonism of the EP3
receptor using L798, 106 substantially attenuated the increase in blood pressure with Ang
II infusion by approximately 30 mmHg. We speculate that the Ang II receptor (AT1) and
the EP3 receptor may share common downstream signaling. sulprostone treatment in
combination with Ang II did not exacerbate the increase in systolic blood pressure but
antagonism of the EP3 receptor reduced blood pressure, suggesting commonality
between these two pathways and that the EP3 receptor may be necessary for the effects
of Ang II. It also cannot be ruled out that there is a dimerization events between EP3 and
AT1, or other G-protein coupled receptors, as this is not known and should be investigated
in future studies. Ang II infusion along with L798, 106 administration did not affect cardiac
output, measured by echocardiography, thus the effects on blood pressure are likely not
occurring at the level of the heart. Interestingly, we found that RhoB, but not RhoA,
expression increased significantly in the mesenteric artery, a resistance vessel. This
increase in RhoB was significantly attenuated with L798, 106 treatment. RhoA expression
decreased in the left ventricle in response to Ang II, however, we speculate that this small,
but significant effect is not physiologically relevant. Activity assays for RhoA would need
to be performed to truly determine if RhoA signaling was reduced in response to Ang II.
Nonetheless, our data with RhoB suggests the effects on blood pressure with L798, 106
are occurring at the level of the vasculature and via changes in total peripheral resistance.
Little is known about RhoB and its role in hypertension, therefore these data is novel in
suggesting that EP3 signaling may modulate its expression. However, we cannot exclude
the possibility that EP3 antagonism in the kidneys or the central nervous system may play
a key role in regulating blood pressure and those studies were beyond the scope of this
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research. In contrast to sulprostone, L798, 106 treatment prevented a decline in cardiac
function after 2 weeks of Ang II; specifically, by improving ejection fraction, shortening
fraction, and posterior wall thickness. One limitation of these studies is that both
sulprostone and L798, 106 were administered via systemic injection and the
concentration of compound reaching the heart was not determined. Additionally, studying
the effects of the compound on the heart specifically poses challenges.
To circumvent this, the EP3 Tg mouse model was used, whereby EP3 is
overexpressed specifically in the cardiomyocytes. In chapter 4 of this dissertation, we
confirm the previously published findings using echocardiography, showing the EP3 Tg
mice have reduced cardiac function at baseline [268, 463]. Importantly, we are the first to
show that the left ventricles of these mice have increased expression of TNF-⍺ and IL-1β
mRNA, with reductions in IL-10 and the M2 macrophage marker, arginase-1. We also
show that the protein levels of IL-10 and IL-4 are reduced by ELISA. The cytokine levels
were coupled with an increase in CD3+ T cells in the left ventricle of EP3 Tg hearts. The
inflammatory profile of these mice has not been previously determined and therefore
provides important insight into the deleterious effects of EP3 activation independent of
changes in blood pressure. Since cardiac function is already reduced at baseline, we
hypothesized this decline would be exacerbated in hypertension. There was a propensity
for a further reduction in ejection fraction and shortening fraction with Ang II infusion,
although more mice are needed to confirm this hypothesis in future studies.
There is increasing evidence for the beneficial effects of EP4 receptor activation in
various models [244, 257-259, 372, 393, 394, 474]. Very recently, it was reported that
mPGES-1 reduces ischemia/reperfusion injury via activation of endothelial EP4 and
improvements in microcirculation [475]. An EP4 receptor agonist has also been tested
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clinically, with positive potential, although it has not been tested in heart failure conditions
as of yet [476]. Altogether, the results of this dissertation support a role for the use of an
EP4 receptor agonist in human heart failure conditions, both ischemic and non-ischemic,
to offset the deleterious actions of the EP3 receptor by improving cardiac function and
reducing persistent myocardial inflammation. Finally, it is expected that future studies
derived from the results of these studies will indicate whether use of EP3 antagonists
have a role in the treatment of heart failure.
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According to the center for disease control about 610,000 people die every year in
the United States from heart disease, of which, coronary heart disease is the most
common form. One major risk factor for heart attack is hypertension, which affects nearly
half of all Americans [472, 473]. PGE2 plays an important role in regulating cardiovascular
function and mediating inflammation, both of which contribute to the development of
hypertension and/or heart disease. Prostaglandin E2 can act as a vasodilator or
vasoconstrictor depending on which of its receptor subtypes are activated.
In general, activation of the EP1 and EP3 receptors is vasoconstrictive while
EP2/EP4 activation promotes vasodilation [13]. Treatment with an EP4 agonist has been
shown to protect the heart during reperfusion after ischemia, while antagonizing EP4
reduced cardiac function and exacerbated cardiac remodeling [267, 394]. We have
published that mice lacking the EP4 receptor in cardiomyocytes develop heart failure and
have worsened cardiac function after MI [73, 268]. With regard to the EP3 receptor, we
have published that its activation reduces contractility in isolated cardiomyocyte
preparations and in the ex-vivo Langedorff system [219].
In this dissertation, we have been the first to show in both the MI and the Ang II

215
hypertension model, that EP3 expression increases significantly, whereby the expression
of EP4 does not change or increases slightly. Thus, we hypothesize that the deleterious
effects of PGE2 are via the EP3 receptor. Furthermore, we have presented here that
overexpression of the EP4 receptor in the cardiomyocytes is protective in a mouse model
of MI by improving cardiac function, and reducing fibrosis and inflammation [218]. We
postulated that the mechanism of reduced inflammation may be mediated by the cardiac
fibroblasts. We therefore show in isolated adult mouse cardiac fibroblasts, that PGE 2 and
an EP4 receptor agonist reduce LPS-stimulated MCP-5 production. Lastly, we report that
activation of the EP3 receptor is deleterious in Ang II hypertension and that systemic
administration of an EP3 antagonist can reduce blood pressure after Ang II infusion.
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